



National Comprehensive
Cancer Network®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Management of Immunotherapy-Related Toxicities

Version 2.2019 — April 8, 2019

[NCCN.org](https://www.nccn.org)

[Continue](#)



*John A. Thompson, MD/Chair † ‡ ≡
Fred Hutchinson Cancer Research Center/
Seattle Cancer Care Alliance

*Bryan J. Schneider, MD/Vice-Chair † ≡
University of Michigan Rogel Cancer Center

*Julie Brahmer, MD/Vice-Chair † ≡
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Stephanie Andrews, MS, ANP-BC ‡
Moffitt Cancer Center

Philippe Armand, MD, PhD ‡
Dana-Farber/Brigham and Women's
Cancer Center

Shailender Bhatia, MD †
Fred Hutchinson Cancer Research Center/
Seattle Cancer Care Alliance

Lihua E. Budde, MD, PhD ‡
City of Hope National Medical Center

Luciano Costa, MD, PhD ‡
University of Alabama at Birmingham
Comprehensive Cancer Center

Marianne Davies, MSN, DNP † #
Yale Cancer Center/Smilow Cancer Hospital

David Dunnington, MA
Patient Advocate

Marc S. Ernstoff, MD † ≡
Roswell Park Cancer Institute

Matthew Frigault, MD †
Massachusetts General Hospital Cancer
Center

Brianna Hoffner, MSN † #
University of Colorado Cancer Center

Christopher J. Hoimes, MD †
Case Comprehensive Center/
University Hospitals Seidman Cancer
Center and Cleveland Clinic Taussig
Cancer Institute

Mario Lacouture, MD ☞
Memorial Sloan Kettering Cancer Center

Frederick Locke, MD †
Moffitt Cancer Center

Matthew Lunning, DO † ☐
Fred & Pamela Buffett Cancer Center

Nisha A. Mohindra, MD †
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Jarushka Naidoo, MD †
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Anthony J. Olszanski, MD, RPh †
Fox Chase Cancer Center

Olalekan Oluwole, MD ‡
Vanderbilt-Ingram Cancer Center

Sandip P. Patel, MD † ‡ ☐
UC San Diego Moores Cancer Center

Sunil Reddy, MD †
Stanford Cancer Institute

Mabel Ryder, MD ø
Mayo Clinic Cancer Center

Bianca Santomaso, MD, PhD Ψ
Memorial Sloan Kettering Cancer Center

Scott Shofer, MD, PhD ≡
Duke Cancer Institute

Jeffrey A. Sosman, MD ‡
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Momen Wahidi, MD ≡
Duke Cancer Institute

Yinghong Wang, MD, PhD ☐ ≡
The University of Texas
MD Anderson Cancer Center

NCCN
Alyse Johnson-Chilla, MS
Jillian Scavone, PhD

NCCN wishes to acknowledge the contributions of ASCO in supporting advisory committees for the development of these NCCN Guidelines.

[NCCN Guidelines Panel Disclosures](#)

Continue

† Medical oncology	Ψ Neurology/Neuro-oncology
‡ Hematology/Hematology oncology	≡ Pulmonary medicine
# Nursing	☐ Gastroenterology
☞ Dermatology	≡ ASCO committee member
☐ Internal medicine	* Discussion Section Writing Committee
ø Endocrinology	



[NCCN Management of Immunotherapy-Related Toxicities Panel Members](#)
[Summary of the Guidelines Updates](#)

Immune Checkpoint Inhibitor-Related Toxicities

- [Principles of Routine Monitoring \(IMMUNO-1\)](#)
- [Infusion/Related Reactions \(ICI_INF-1\)](#)
- Dermatologic Toxicity
 - ▶ [Maculopapular Rash \(ICI_DERM-1\)](#)
 - ▶ [Pruritis \(ICI_DERM-2\)](#)
 - ▶ [Blistering Disorder \(ICI_DERM-3\)](#)
- Gastrointestinal Toxicity
 - ▶ [Diarrhea/Colitis \(ICI_GI-1\)](#)
 - ▶ [Hepatic Toxicity \(ICI_GI-2\)](#)
 - ▶ [Elevation in Amylase/Lipase \(ICI_GI-4\)](#)
 - ▶ [Acute Pancreatitis \(ICI_GI-5\)](#)
- Endocrine Toxicity
 - ▶ [Hyperglycemia/Diabetes Mellitus \(ICI_ENDO-1\)](#)
 - ▶ [Thyroid \(ICI_ENDO-2\)](#)
 - ▶ [Adrenal \(ICI_ENDO-3\)](#)
 - ▶ [Hypophysitis \(ICI_ENDO-4\)](#)
- [Pulmonary Toxicity \(ICI_PULM-1\)](#)
- [Renal Toxicity \(ICI-RENAL-1\)](#)
- [Ocular Toxicity \(ICI_EYE-1\)](#)
- Nervous System Toxicity
 - ▶ [Myasthenia Gravis \(ICI_NEURO-1\)](#)
 - ▶ [Guillain-Barré Syndrome \(ICI_NEURO-2\)](#)
 - ▶ [Peripheral Neuropathy \(ICI_NEURO-3\)](#)
 - ▶ [Aseptic Meningitis \(ICI_NEURO-4\)](#)
 - ▶ [Encephalitis \(ICI_NEURO-4\)](#)
 - ▶ [Transverse Myelitis \(ICI_NEURO-5\)](#)

- [Cardiovascular Toxicity \(ICI_CARDIO-1\)](#)
- Musculoskeletal Toxicity
 - ▶ [Inflammatory Arthritis \(ICI_MS-1\)](#)
 - ▶ [Myalgias/Myositis \(ICI_MS-2\)](#)
- [Principles of Immunosuppression \(IMMUNO-A\)](#)
- [Principles of Immunotherapy Patient Education \(IMMUNO-B\)](#)
- [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#)

CAR T-Cell-Related Toxicities

- [Principles of Patient Monitoring \(CART-1\)](#)
- [Overview of CAR T-Cell Therapy-Related Toxicities \(CART-2\)](#)
- [Cytokine Release Syndrome \(CART-3\)](#)
- [CAR T-Cell-Related Neurotoxicity \(CART-4\)](#)

Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, [click here: nccn.org/clinical_trials/clinicians.aspx](#).

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2019.



Updates in Version 2.2019 of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities from Version 1.2019 include:

[CART-2](#)

- Neurologic toxicity: Typical time to onset was updated from “4-6 days” to “4-10 days”

[CART-3](#)

- This page was extensively revised to align with the new American Society for Transplantation and Cellular Therapy (ASTCT, formerly ASBMT) grading criteria.

[CART-4](#)

- This page is new and contains updated grading criteria for CAR T-cell-related neurotoxicity.

[CART-5](#)

- Grading criteria for neurotoxicity have been removed from this page and are now on CART-4.
- Grade 3, no concurrent CRS: First bullet was updated, “*Consider ICU care is recommended.*”

Updates in Version 1.2019 of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities from Version 2.2018 include:

[Global Changes](#)

- A new section on the Management of CAR T-Cell-Related Toxicities was added.
- The discussion has been updated to reflect the changes in the Immune Checkpoint-Inhibitor algorithm.
- The Principles of Patient Monitoring was moved from an attachment page to IMMUNO-1.

[IMMUNO-1](#)

- Pancreatic: “Baseline amylase/lipase” was removed from Baseline Assessment column.
- Adrenal/Pituitary
 - ▶ “Adrenocorticotrophic hormone (ACTH)” was moved from the Baseline Assessment column to Evaluation for Abnormal Findings/Symptoms.
 - ▶ “Serum” was added to cortisol in Baseline Assessment column.
 - ▶ “Total T3” was removed from the Pituitary Baseline Assessment column.
- Pulmonary: 2nd bullet under Baseline Assessment updated, “Pulmonary function tests (PFTs) for high-risk patients”

[IMMUNO-1 \(continued\)](#)

- Cardiovascular
 - ▶ Baseline Assessment:
 - ◇ “ECG and total CK” and “Cardiac biomarkers (ie, troponin I or T) if risk factors present” were removed.
 - ◇ “Individualized assessment in consultation with cardiology as indicated” was added.
 - ▶ Evaluation for Abnormal Findings/Symptoms updated: “Brain natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-pro-BNP) Individualized follow-up in consultation with cardiology as indicated”
- Musculoskeletal Evaluation for Abnormal Findings/Symptoms updated, “~~NA~~ Consider rheumatology referral.”

[ICI_INF-1](#)

- Management of Mild or Moderate Infusion-Related Reactions: the last bullet is new.
- Footnote c: Acetaminophen was added.

[ICI_DERM-1](#)

- “to affected areas” was added to topical steroid bullets.
- Management of Severe Maculopapular Rash
 - ▶ “up to 2 mg/kg/day” added to 3rd bullet.
 - ▶ “Consider inpatient care” was added.

[Continued](#)



Updates in Version 1.2019 of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities from Version 2.2018 include:

ICI_DERM-2

- Grade 4 was removed
- Oral antihistamines were added to the Management of Mild and Severe
- Management of Mild Pruritus
 - ▶ The third bullet was updated: “Treatment with high moderate potency topical steroids to affected areas.”
- Management of Moderate Pruritus
 - ▶ “Consider holding immunotherapy until \leq G1” was changed to “Continue immunotherapy with intensified antipruritic therapy” with corresponding footnote l.
 - ▶ Ceterizine and hydroxyzine were removed.
- Management of Severe Pruritus
 - ▶ 4th bullet updated: “Consider GABA agonists...”
 - ▶ 5th bullet updated: “Consider aprepitant or omalizumab for refractory cases”
 - ▶ “Consider omalizumab was removed.

ICI_DERM-3

- Assessment/Grading: “for skin biopsy” was removed.
- Management of Mild Bullous dermatitis
 - ▶ 2nd bullet updated: “High potency topical steroids to affected areas.”
- Management of Severe and Life-Threatening pathways were combined.
 - ▶ Urology consultation was added.

ICI_GI-1

- Assessment/Grading
 - ▶ 1st bullet, 2nd sub-bullet was updated: “Nucleic amplification tests (NAATs) for GI pathogens/bacterial culture.”
 - ▶ “molecular testing for *Giardia* and *Cryptosporidium* spp and *E. histolytica*; consider microsporidia, *Cyclospora/isospora* spp” added to Ova & parasites.
 - ▶ “Viral pathogens testing when available” is new.
 - ▶ “Consider” was added to abdominal/pelvic CT with contrast.
 - ▶ “Consider” was added to GI consultation
 - ◇ “or flexible sigmoidoscopy” was added to last sub-bullet.
- Management of Mild Diarrhea/Colitis
 - ▶ 2nd bullet was updated: “Loperamide or diphenoxylate/atropine”
- Management of Moderate Diarrhea/Colitis

ICI_GI-1 (continued)

- ▶ 2nd bullet was updated: “Prednisone/IV-methylprednisolone...”
- ▶ 3rd bullet, 2nd subbullet updated: “Consider adding infliximab”
- ▶ “If infliximab-refractory, consider vedolizumab” was removed.
- Management of Severe Diarrhea/Colitis
 - ▶ 2nd bullet: “agent responsible for toxicity” was added.
 - ▶ Infliximab bullet was updated: “Continue steroids, consider adding infliximab.”
- Footnote a was updated: “Symptoms include: watery diarrhea, cramping, urgency, abdominal pain, blood and mucus in the stool, fever. Blood in the stools and/or fever should prompt a more thorough workup for infection and for other causes of GI bleeding, including peptic ulcer disease (PUD) and malignant bleeding.”
- Footnote k: “(See Principles of Immunosuppression [IMMUNO-A] regarding TB testing)” was added.

ICI_GI-2

- Assessment/Grading
 - ▶ Ultrasound and its sub-bullet are new.
 - ▶ “(assess acetaminophen, dietary supplement, and alcohol use)” was added to the last bullet.
- Management of Mild Transaminitis:
 - ▶ “consider holding immunotherapy for concerning lab value trend” was added to the first bullet.
- Management of Moderate Transaminitis
 - ▶ Last bullet was updated: “If LFTs worsen, Consider prednisone 0.5–1 mg/kg/day.”
- Management of Severe Transaminitis
 - ▶ 6th bullet was updated: “If steroid refractory or no improvement after 3 days, consider adding mycophenolate.” (also for Life-Threatening and ICI_GI-3)
- Management of Life-Threatening Transaminitis
 - ▶ “Liver biopsy if no contraindications” is new.
 - ▶ 7th bullet updated: “...consider adding mycophenolate.”
- Footnote m was updated: “continue to taper over at least 1 month with frequent follow-up to guide taper duration...”

ICI_GI-3

- Assessment: “(assess acetaminophen, dietary supplements, and alcohol use)” was added to the last bullet.
- Management: 6th bullet updated, “...consider adding mycophenolate.”

Continued
UPDATES



Updates in Version 1.2019 of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities from Version 2.2018 include:

[ICI GI-4](#)

- “medications, alcohol” was added to footnote p.

[ICI GI-5](#)

- Footnote r was updated: “*Provide standard medical care for signs and symptoms of acute pancreatitis, including hospital admission, aggressive fluid resuscitation, and pain control. Management and follow-up of Once pancreatitis is diagnosed, management and monitoring should be directed by gastroenterology/pancreatic subspecialists.*”
- The footnote “Additional immunosuppression with mycophenolate mofetil may be considered” was removed.

[ICI ENDO-2](#)

- Assessment for Thyrotoxicosis: the last bullet is new.
- Management of Thyrotoxicosis
 - ▶ “if asymptomatic” added to the first bullet.
 - ▶ The fourth bullet is new: “Thyrotoxicosis often evolves to hypothyroidism.”

[ICI ENDO-4](#)

- Management of Central Hypothyroidism: The first bullet was updated, “*Continue Consider holding immunotherapy until no longer symptomatic.*”
- Management of Hypophysitis: “If symptomatic” added to third bullet.
- “Visual field cuts, or severe fatigue” added to footnote t.

[ICI PULM-1](#)

- Management of Mild Pneumonitis
 - ▶ First bullet was updated: “*Consider holding immunotherapy.*”
 - ▶ Third bullet was updated: “*Consider chest imaging (chest CT with contrast (preferred) or chest x-ray).*”
 - ◇ Footnote g is new, also for Moderate Pneumonitis.
 - ◇ Last sub-bullet was updated: “*Consider repeat chest CT imaging in 3–4 weeks or as clinically indicated for worsening symptoms.*”
- Management of Moderate Pneumonitis
 - ▶ “Pulmonary consultation” is new.
 - ▶ 5th bullet was updated: “*Consider chest imaging (chest CT with contrast [preferred] or baseline chest x-ray)*”
 - ◇ Sub-bullet was updated: “*Repeat chest CT in 3–4 weeks*”

[ICI PULM-2](#)

- “consider PFTs” added to 4th bullet.
- 7th bullet was updated: “*Methylprednisolone 1–2 mg/kg/day. Assess response within 48 hours and plan taper until symptoms improve to Grade ≤1 then taper over ≥6 weeks*”
- Dosing for IVIG was moved to a new footnote i.

[ICI RENAL-1](#)

- Management of Severe or Life-Threatening: last bullet was updated, “*Consider adding one of the following if >G2 after 1 week of steroids...*”

[ICI EYE-1](#)

- Footnote f is new.

[ICI NEURO-1](#)

- Assessment/Grading
 - ▶ “(not needed for diagnosis)” was added to the first bullet.
 - ▶ The 4th bullet is new.
- Management of Moderate Myasthenia Gravis
 - ▶ 2nd bullet was updated: “*Pyridostigmine 30 mg TID and gradually increase to maximum of 120 mg orally four times a day as tolerated and based on symptoms, wean based on symptom improvement*”
 - ▶ 3rd bullet was updated: “*Consider low-dose oral prednisone 20 mg daily. Increase by 5 mg every 3–5 days to a target dose of 1 mg/kg/day but not more than 100 mg daily methylprednisolone 1–2 mg/kg/day (steroid taper based on symptom improvement)*”
- Management of Severe Myasthenia Gravis
 - ▶ Neurology consultation was removed.
 - ▶ “(may need intensive care unit [ICU] level monitoring)” was added to the 2nd bullet.
 - ▶ Dosing for IVIG was moved to a new footnote f. (Also ICI_NEURO-2, ICI_NEURO-4, ICI_NEURO-5)
- “Myasthenia Gravis Foundation of America (MGFA) severity class I (ocular symptoms and findings only) and MGFA severity class II (mild generalized weakness)” added to footnote b.
- “or MGFA severity class III-IV moderate to severe generalized weakness to myasthenic crisis” added to footnote c.

[Continued](#)



Updates in Version 1.2019 of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities from Version 2.2018 include:

ICI NEURO-2

- Management
 - ▶ 2nd bullet is new.
 - ▶ “Methylprednisolone 2–4 mg/kg/day” was removed.
 - ▶ 4th bullet was updated: “~~If no improvement, Start IVIG 0.4 g/ kg/day for 5 days or plasmapheresis in addition to pulse-dose methylprednisolone 1 gram daily for 5 days in addition to IVIG 0.4 g/kg/day for 5 days or plasmapheresis (slow steroid taper)~~”
 - ▶ 6th and 7th bullets are new.
- “in addition to IVIG or plasmapheresis” was added to footnote l.

ICI NEURO-3

- Management of Moderate Peripheral Neuropathy
 - ▶ 2nd bullet was updated: “*Initial observation or initiate prednisone 0.5–1 mg/kg orally (if progressing from mild)*”
 - ▶ 3rd bullet was updated: “~~If progression, prednisone~~ initiate methylprednisolone ~~0.5–1~~ 2–4 mg/kg/day and see Guillain-Barré Syndrome (ICI_NEURO-2).”
- Footnote n is new.
- “Severe peripheral neuropathy is not necessarily GBS but the management can be similar.” was added to footnote q.

ICI NEURO-4

- Aseptic meningitis
 - ▶ “Consider neurology consultation” was added to Assessment
 - ▶ Management: 4th bullet updated, “~~Consider IV acyclovir until GSF results~~ polymerase chain reaction (PCR) results obtained.”
- Encephalitis
 - ▶ Assessment: last bullet was updated, “Autoimmune encephalopathy and paraneoplastic panel *in CSF and serum.*”
 - ▶ Management: last bullet was updated, “If positive for autoimmune encephalopathy antibody and or limited or no improvement after 7–14 days, consider rituximab.”

ICI NEURO-5

- Assessment: “paraneoplastic panel for anti-Hu and anti-CRMP5/ CV2” added to 4th bullet.
- Grading was removed.
- Management: 3rd bullet was updated, “Methylprednisolone 2 mg/kg/ day ~~Strongly consider pulse dosing 1 g/day for 3–5 days~~”

ICI NEURO-5 (continued)

- The following footnotes were removed:
 - ▶ “Limiting self-care and aids warranted.”
 - ▶ “Treat until symptoms improve to Grade ≤1 then taper over 4-6 weeks.”

ICI CARDIO-1

- Management of Severe: 2nd bullet was updated, “*Consider prednisone/methylprednisolone pulse dosing 1 g/day for 3–5 days 1–2 mg/kg/day*”
- Management of Life-Threatening
 - ▶ “Prednisone/methylprednisolone 1–2 mg/kg/day” was removed.
 - ▶ “...for 3–5 days” added to 2nd bullet.
 - ▶ The 3rd bullet was updated: “*If no improvement within 24 hours on steroids, consider anti-thymocyte globulin (ATG). May also consider adding infliximab.*”
- “Myasthenia gravis” was added to footnote a.

ICI MS-1

- Management of Severe: The following bullets were combined into the sub-bullet:
 - ▶ “Consider infliximab or tocilizumab for refractory/severe arthritis not responding to steroids and anti-inflammatory agents”
 - ▶ “If no improvement by week 2, rheumatology consultation for consideration of additional disease-modifying antirheumatic drugs (sulfasalazine, methotrexate, leflunomide)”
- Footnote b and h are new.
- Footnote c was updated: “Limits ADLs, *presence of joint erosions. with or without irreversible joint damage.*”
- Footnote i was updated: “Consider ESR, CRP to monitor response if *elevated at the onset of therapy.*”

ICI MS-2

- “(muscle weakness)” added after “Myositis”
- “Comprehensive metabolic panel” added to Assessment.
- Management of Moderate, Severe, or Life-Threatening
 - ▶ The 2nd bullet is new.
 - ▶ 4th bullet: “Consider concomitant myasthenia gravis.” was added.
 - ▶ The last bullet is new.
- “...and/or weakness...” was added to footnote j.
- “...or elevated CK or aldolase...” was added to footnote k.

[Continued](#)



Updates in Version 1.2019 of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities from Version 2.2018 include:

[IMMUNO-A \(1 of 2\)](#)

- 3rd bullet
 - ▶ 2nd sub-bullet: sub sub-bullet was updated, *“In the absence of specific indications such as prior infusion reaction or concurrent chemotherapy, routine premedication with corticosteroids in the prophylactic setting is not recommended given the potential mitigation of immunotherapeutic effectiveness.”*
 - ▶ 7th sub-bullet is new.
 - ▶ “cardiac” was added to 10th sub-bullet.

[IMMUNO-A \(2 of 2\)](#)

- 1st bullet, 3rd sub-bullet, 1st sub sub-bullet is new.
- 2nd bullet, 3rd sub-bullet was updated: “Graft failure while on cancer immunotherapy has been reported, and potential transplant organ loss...”
 - ▶ Sub sub-bullet was updated: “Patients with solid organ transplantation *who have viable option for alternative therapy if graft rejection (eg, kidney) may be candidates...*”
- Last bullet was updated: “Vaccines that are inactivated or killed preparations are permissible during a course of immunotherapy. ~~There is less clarity regarding live vaccine use and there should be an educated discussion with the patient prior to the administration of~~ *Due to the lack of clarity regarding live vaccine use, it is not recommended during ICI therapy.*”

[IMMUNO-B \(1 of 2\)](#)

- Prior to starting immunotherapy, 4th bullet: the sub-bullet is new.
- Under “Instruct patients to notify the oncology care team if”: 4th bullet updated to be consistent with IMMUNO-A (2 of 2)
- Toxicity Management: The first bullet is new.

[IMMUNO-B \(2 of 2\)](#)

- Side effects: “irAE rebound during steroid taper can also occur.” added to the 3rd bullet.
- Monitoring and treatment response: the second bullet is new.

[IMMUNO-C \(1 of 2\)](#)

- 1st bullet, 2nd sub-bullet is new.
- GI
 - ▶ 1st bullet was updated: “...immunotherapy may be resumed while patient is still on ≤ 10 mg steroid *prednisone equivalent* daily.”
 - ▶ 2nd bullet was updated: “CTLA-4 agents: ~~permanently~~ *discontinue if irAE is serious or life-threatening. Do not make up doses missed due to irAE and/or required steroid treatment.*”
- Liver: “prednisone equivalent” added to first bullet.
- Pancreas: “Symptomatic” added to first bullet.

[IMMUNO-C \(2 of 2\)](#)

- Endocrine: 4th bullet was updated, “consider resumption of immunotherapy after symptoms *related to mass effect are resolved.* ~~are controlled on < 10 mg daily steroid dose.~~”
- Lung: “and patient is off steroids” added to 2nd bullet.



PRINCIPLES OF ROUTINE MONITORING

Baseline Assessment ^a	Monitoring Frequency ^b	Evaluation for Abnormal Findings/Symptoms
Clinical <ul style="list-style-type: none"> Physical examination Comprehensive patient history of any autoimmune/organ-specific disease, endocrinopathy, or infectious disease Neurologic examination Bowel habits (typical frequency/consistency) 	Clinical exam at each visit with adverse event (AE) symptom assessment	Follow-up testing based on findings, symptoms
Imaging <ul style="list-style-type: none"> CT imaging Brain MRI if indicated 	Periodic imaging as indicated	Follow-up testing as indicated based on imaging findings
General bloodwork <ul style="list-style-type: none"> CBC with differential Comprehensive metabolic panel Infectious disease screening as indicated 	Repeat every 2–3 weeks during immunotherapy, then in 6–12 weeks or as indicated	HbA1c for elevated glucose
Dermatologic (ICI_DERM-1) <ul style="list-style-type: none"> Examination of skin and mucosa if history of immune-related skin disorder 	Conduct/repeat as needed based on symptoms	Monitor affected BSA and lesion type; photographic documentation. Skin biopsy if indicated.
Pancreatic (ICI_ENDO-1) <ul style="list-style-type: none"> Baseline testing is not required. 	No routine monitoring needed if asymptomatic	Amylase, lipase, and consider abdominal imaging for suspected pancreatitis.
Thyroid (ICI_ENDO-2) <ul style="list-style-type: none"> Thyroid-stimulating hormone (TSH), free thyroxine (T4) 	Every 4–6 weeks during immunotherapy, then follow-up every 12 weeks as indicated	Total T3 if abnormal thyroid function suspected. TPO antibodies if TSH is high, TRAbs if TSH is low.
Adrenal/Pituitary (ICI_ENDO-3) <ul style="list-style-type: none"> Adrenal: Serum cortisol Pituitary: TSH, free T4 	Every 2–3 weeks during immunotherapy, then follow-up every 6–12 weeks	Luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, adrenocorticotropic hormone (ACTH)
Pulmonary (ICI_PULM-1) <ul style="list-style-type: none"> Oxygen saturation (resting and with ambulation) Pulmonary function tests (PFTs) for high-risk patients 	Repeat oxygen saturation tests based on symptoms	Chest CT to evaluate for pneumonitis, biopsy if needed to exclude other causes.
Cardiovascular (ICI_CARDIO-1) <ul style="list-style-type: none"> Individualized assessment in consultation with cardiology as indicated 	Consider periodic testing for those with abnormal baseline or symptoms	Individualized follow-up in consultation with cardiology as indicated
Musculoskeletal (ICI_MS-1) <ul style="list-style-type: none"> Joint examination/functional assessment as needed for patients with pre-existing disease 	No routine monitoring needed if asymptomatic	Consider rheumatology referral.

^a Prior to initiating treatment, counsel patients on the warning signs and symptoms of immune-related adverse events (irAEs).

^b Closer monitoring may be required for patients with combination immunotherapy regimens. Refer to prescribing information for each individual immunotherapy agent for monitoring recommendations.

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



ADVERSE EVENT(S)

ASSESSMENT/GRADING

MANAGEMENT



^a Symptoms include: Fever/chills/rigors, urticaria/pruritus, angioedema, flushing/headache, hypertension, hypotension, shortness of breath, cough/wheezing, hypoxemia, dizziness/syncope, sweating, and arthralgia/myalgia. Refer to prescribing information for each individual immunotherapy agent for recommendations for premedication to prevent infusion reactions.


^b Mild transient reaction; infusion interruption not indicated. Intervention not indicated.

^c Therapy or infusion interruption indicated but responds promptly to symptomatic treatment (eg, antihistamines, acetaminophen, NSAIDs, narcotics, intravenous [IV] fluids); prophylactic medications indicated for less than or equal to 24 hours.

^d Prolonged (eg, not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement. Hospitalization indicated; life-threatening consequences; urgent intervention.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



^a Characterized by the presence of macules (flat) and papules (elevated). Also known as morbilliform rash, it is one of the most common cutaneous adverse events (AEs), frequently affecting the upper trunk, spreading centripetally and may be associated with pruritus.

^b Macules/papules covering <10% body surface area (BSA) with or without symptoms (eg, pruritus, burning, tightness).

^c Macules/papules covering 10%–30% BSA with or without symptoms (eg, pruritus, burning, tightness); limiting instrumental activities of daily living (IADLs).


^d Macules/papules covering >30% BSA with or without associated symptoms; limiting self-care activities of daily living (ADLs).

^e See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^f See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^g Treat until symptoms improve to Grade ≤1 then taper over 4–6 weeks.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



^e See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^f See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^g Treat until symptoms improve to Grade ≤1 then taper over 4–6 weeks.

^h Characterized by an intense itching sensation.


ⁱ Mild or localized.

^j Intense or widespread; intermittent; skin changes from scratching (eg, edema, papulation, excoriations, lichenification, oozing/crusts); limiting iADLs.

^k Intense or widespread; constant; limiting self-care ADLs or sleep. Assess serum IgE and histamine; consider oral antihistamines for increased histamine and omalizumab for increased IgE.

^l Consider holding in select cases.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



^e See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^f See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^g Treat until symptoms improve to Grade ≤1 then taper over 4–6 weeks.

^j Intense or widespread; intermittent; skin changes from scratching (eg, edema, papulation, excoriations, lichenification, oozing/crusts); limiting iADLs.

^m Characterized by inflammation of the skin and the presence of bullae, which are filled with fluid.

ⁿ Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) should be treated as grade 3–4 bullous dermatitis. SJS, overlapping SJS/TEN, and TEN are characterized by separation of the dermis involving <10%, 10%–30%, and >30% BSA, respectively. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.

^o Asymptomatic; blisters covering <10% BSA.


^p Blisters covering 10%–30% BSA; painful blisters; limiting iADLs.

^q Blisters covering >30% BSA; limiting self-care ADLs.

^r Blisters covering >30% BSA; associated with fluid or electrolyte abnormalities; intensive care unit (ICU) care or burn unit indicated.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



^a Symptoms include: watery diarrhea, cramping, urgency, abdominal pain, blood and mucus in the stool, fever. Blood in the stools and/or fever should prompt a more thorough workup for infection and for other causes of GI bleeding, including peptic ulcer disease (PUD) and malignant bleeding.

^b Fewer than 4 bowel movements above baseline per day and no colitis symptoms.

^c 4–6 bowel movements above baseline per day, colitis symptoms, not interfering with ADLs.

^d More than 6 bowel movements above baseline per day, colitis symptoms, interfering with ADLs, hemodynamic instability, hospitalization, other serious complications (eg, ischemic bowel, perforation, toxic mega-colon).

^e It is not necessary to wait for test results before providing therapy to manage immune-related adverse events (irAEs).

^f See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^g See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^h If progressive, consider stool evaluation to rule out infectious etiology.


ⁱ Convert to prednisone when appropriate.

^j Treat until symptoms improve to Grade ≤1 then taper over 4–6 weeks.

^k Duration of therapy with tumor necrosis factor alpha (TNF-alpha) blockers is not clearly defined, but is usually a single dose. Repeat endoscopy may be helpful, but optional for the guidance of treatment. (See [Principles of Immunosuppression \[IMMUNO-A\]](#) regarding TB testing.)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



^f See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^g See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^l Elevated alanine transaminase (ALT) and aspartate transaminase (AST).

^m When liver enzymes show sustained improvement or return to ≤ G1, initiate steroid tapering and continue to taper over at least 1 month with frequent follow-up to guide taper duration. Re-escalate as needed.

ⁿ Mycophenolate mofetil treatment (0.5–1 g every 12 hours) can be considered in patients who have persistent severe hepatitis despite high-dose corticosteroids.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



**HEPATIC
ADVERSE
EVENT(S)**

ASSESSMENT

MANAGEMENT^f

Grade >1 transaminitis^l
with bilirubin >1.5 x ULN
(unless Gilbert's syndrome)

- Rule out viral etiology, disease-related hepatic dysfunction, other drug-induced transaminase elevations
- Consider GI evaluation
- Limit/discontinue hepatotoxic medications (assess acetaminophen, dietary supplements, and alcohol use)

- Permanently discontinue immunotherapy^g
- Initiate prednisone/methylprednisolone 2 mg/kg/day^m
- Inpatient care
- Monitor liver enzymes daily
- Hepatology consultation
- If steroid refractory or no improvement after 3 days, consider adding mycophenolateⁿ
- Infliximab should not be used for hepatitis

^f See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^g See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^l Elevated ALT and AST.

^m When liver enzymes show sustained improvement or return to ≤ G1, initiate steroid tapering and continue to taper over at least 1 month. Re-escalate as needed.

ⁿ Mycophenolate mofetil treatment (0.5–1 g every 12 hours) can be considered in patients who have persistent severe hepatitis despite high-dose corticosteroids.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.


PANCREATIC ADVERSE EVENT(S)	ASSESSMENT/GRADING	MANAGEMENT
Elevation in amylase/lipase (asymptomatic)	<ul style="list-style-type: none"> Assess for signs/symptoms of pancreatitis If clinical concern for pancreatitis, see ICI_GI-5 	
	<p>Mild ≤3 x ULN amylase and/or ≤3 x ULN lipase</p>	<ul style="list-style-type: none"> If isolated elevation of enzymes without evidence of pancreatitis, continue immunotherapy Evaluate for pancreatitis <ul style="list-style-type: none"> Clinical assessment^o Consider abdominal CT with contrast Consider MRCP If evidence of pancreatitis, manage according to pancreatitis algorithm (ICI_GI-5) Consider other causes for elevated amylase/lipase^p
	<p>Moderate >3–5 x ULN amylase and/or >3–5 x ULN lipase</p>	<ul style="list-style-type: none"> If isolated elevation of enzymes without evidence of pancreatitis, consider continuing immunotherapy^g Evaluate for pancreatitis <ul style="list-style-type: none"> Clinical assessment^o If persistent moderate to severe amylase and/or lipase elevation, abdominal CT with contrast or MRCP Consider other causes for elevated amylase/lipase^p If evidence of pancreatitis, manage according to pancreatitis algorithm (ICI_GI-5)
	<p>Severe >5 x ULN amylase and/or >5 x ULN lipase</p>	<ul style="list-style-type: none"> If isolated elevation of enzymes without evidence of pancreatitis, consider continuing immunotherapy^g Evaluate for pancreatitis <ul style="list-style-type: none"> Clinical assessment^o If persistent moderate to severe amylase and/or lipase elevation, abdominal CT with contrast or MRCP Consider other causes for elevated amylase/lipase^p If evidence of pancreatitis, manage according to pancreatitis algorithm (ICI_GI-5)

^g See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^o Routine amylase/lipase assessments do not have to be performed outside of clinical suspicion of possible pancreatitis. See [Principles of Routine Monitoring \(IMMUNO-1\)](#).

^p Inflammatory bowel disease, irritable bowel syndrome, bowel obstruction, gastroparesis, nausea/vomiting, medications, alcohol, and/or diabetes mellitus (DM).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



^f See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^g See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^j Treat until symptoms improve to Grade ≤1 then taper over 4–6 weeks.

^q No requirement for routine monitoring of potential pancreatitis with imaging.

^r Provide standard medical care for signs and symptoms of acute pancreatitis, including hospital admission, aggressive fluid resuscitation, and pain control.

Management and follow-up of pancreatitis should be directed by gastroenterology/pancreatic subspecialists.

^s Any one of the following features present: elevation of amylase/lipase >3 x ULN or radiologic findings on CT or clinical findings concerning for pancreatitis.


^t Two of three of the following features present: elevation of amylase/lipase >3 x ULN ± radiologic findings on CT ± clinical findings concerning for pancreatitis.

^u Elevation of amylase/lipase ± radiologic findings ± severe abdominal pain or vomiting and hemodynamically unstable.

^v Evaluate for signs/symptoms of pancreatic exocrine insufficiency and/or DM, and supplement if needed.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



^a High-dose corticosteroids may induce or exacerbate hyperglycemia. Consider endocrinology referral and appropriate management if symptomatic and/or persistently uncontrolled.

^b Symptoms of diabetic ketoacidosis (DKA) may include excessive thirst, frequent urination, general weakness, vomiting, confusion, abdominal pain, dry skin, dry mouth, increased heart rate, and fruity odor on the breath.

^c The development of type I DM is rare (1%–2%) but can be life-threatening if insulin therapy is not provided. Once new type I DM is diagnosed, management and monitoring should be directed by endocrinology team.

^d Evaluate for signs/symptoms of pancreatic exocrine insufficiency, and supplement if needed.


^e Insufficient evidence to suggest corticosteroids may reverse type I DM induced by immunotherapy, and may complicate glycemic control.

^f See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^g Institutional guidelines may include but are not limited to: IV fluids +/- potassium supplementation, IV insulin, hourly glucose, serum ketones, blood pH, and anion gap.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



^h Elevated TSH with normal free T4.

ⁱ Generally, elevated TSH (>10) with low free T4, clinical symptoms.

^j Defined as suppressed TSH that may be: a) subclinical if free T4 normal, b) clinical if high free T4. The majority of suppressed TSH (<0.01) are due to transient or progressive painless thyroiditis.

^k For patients without baseline thyroid function abnormalities or who are asymptomatic, can increase thyroid function testing interval to every 12–18 weeks as indicated.

^l Levothyroxine oral daily ~1.6 mcg/kg with goal of getting TSH to reference range or age-appropriate range; reduce dose by 10% to avoid hyperthyroidism in patient populations that may be sensitive to thyroid supplementation (eg, elderly populations or patients with comorbidities).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**ENDOCRINE
ADVERSE EVENT(S)**

ASSESSMENT/GRADING

MANAGEMENT^{n,o}

Primary adrenal insufficiency^m

- Evaluate cortisol level (AM)
- Comprehensive metabolic panel (Na, K, CO₂, glucose), renin level

- Endocrine consultation
 - ▶ Endocrine evaluation prior to surgery or any procedure
- Hold immunotherapy^f
- Start corticosteroid first before other hormone replacement to avoid adrenal crisis
- Steroid replacement^{p,q}
 - ▶ Hydrocortisone 20 mg in AM, 10 mg in PM, then slowly titrating doses down according to symptoms^r
 - OR
 - ▶ Prednisone 7.5 mg or 10 mg starting dose, then reduce to 5 mg daily as appropriate
 - AND
 - ▶ Fludrocortisone can be started 0.1 mg every other day; then titrated up or down based on blood pressure, symptoms, lower-extremity edema, and labs
- If hemodynamically unstable, inpatient care and initiate high-dose/stress-dose steroids
- Patients with severe symptoms (hypotension) may require additional fluids (eg, normal saline often >2 L required)
- Patient education regarding stress doses of hydrocortisone for infection, trauma, etc.
 - ▶ Alert bracelet is recommended

^f See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^m Low morning cortisol (<5) with high ACTH (> reference range) with or without abnormal electrolytes and symptoms. Other criteria: 30- or 60-minute cortisol <18 after ACTH stimulation in the setting of low morning cortisol and high ACTH. Other abnormalities: hypotension, orthostatic hypotension, low Na, and high K.

ⁿ See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^o If severe acute symptoms (eg, headache/nausea/emesis, fevers), high-dose steroids as indicated until symptoms resolve (1–2 weeks) then rapid taper to physiologic replacement.

^p If acutely ill, double or triple these doses for 24–48 hours (ie, sick day rules for fever >101, nausea/emesis, surgeries).

^q Will require physiologic replacement steroids indefinitely.

^r The goal for physiologic steroid replacement is to identify the lowest steroid dose needed to prevent symptoms of adrenal insufficiency. For many patients, this may be, for example, 10 mg in AM and 5 mg in PM, if tolerated.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



ENDOCRINE ADVERSE EVENT(S)	ASSESSMENT	MANAGEMENT ⁿ
Central hypothyroidism ^s	<ul style="list-style-type: none"> • Evaluate cortisol (AM), FSH, LH, TSH, free T4, DHEA-S • Estradiol testing in women • Testosterone testing in men • Consider MRI of pituitary if confirmed central thyroid/adrenal insufficiency 	<ul style="list-style-type: none"> • Consider holding immunotherapy until no longer symptomatic^f • Treat as hypophysitis (below)
Hypophysitis ^t	<ul style="list-style-type: none"> • Evaluate cortisol (AM), FSH, LH, TSH, free T4, testosterone in men, estrogen in premenopausal women • MRI brain ± contrast with pituitary/sellar cuts, if symptomatic 	<ul style="list-style-type: none"> • Consider endocrine consultation • Hold immunotherapy until acute symptoms resolve^{f,t} • If symptomatic, prednisone/methylprednisolone 1–2 mg/kg/day^o • Hormone replacement as indicated^u • Patient education regarding stress doses of hydrocortisone for infection, trauma, etc. <ul style="list-style-type: none"> ▶ Alert bracelet is recommended

^f See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

ⁿ See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^o If severe acute symptoms (eg, headache/nausea/emesis, fevers), high-dose steroids as indicated until symptoms resolve (1–2 weeks) then rapid taper to physiologic replacement.


^s Low or suppressed TSH with inappropriately low free T4 may represent sequela of hypophysitis; for which other pituitary axes may be affected. Follow free T4 for thyroid replacement in the setting of hypophysitis–induced loss of TSH production.

^t Hypophysitis may present with acute symptoms such as headache, photophobia, dizziness, nausea/emesis, fevers, anorexia, visual field cuts, or severe fatigue. Tests may show low ACTH, low AM cortisol, low Na, low K, low testosterone, and DHEA-S. Non-acute symptoms may include fatigue and possible weight loss.

^u Hormone replacement for pituitary damage should include steroid replacement (hydrocortisone 20 mg PO every AM, 10 mg PO every PM); it may also include levothyroxine for central hypothyroidism and testosterone supplementation in males. Patients may require physiologic replacement hormones indefinitely.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



^a Focal or diffuse inflammation of the lung parenchyma (typically identified on CT imaging as ground-glass opacities).

^b Asymptomatic; confined to one lobe of the lung or <25% of lung parenchyma; clinical or diagnostic observations only.

^c Presence of new/worsening symptoms including: shortness of breath, cough, chest pain, fever, and increased oxygen requirement.

^d G3-severe symptoms involve all lung lobes or >50% of lung parenchyma, limiting self-care ADLs; G4-life-threatening respiratory compromise.

^e See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^f See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^g CT with contrast to rule out other etiologies if not contraindicated.

^h Treat until symptoms improve to Grade ≤1 then taper over 4–6 weeks.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**ASSESSMENT/
GRADING**

MANAGEMENT^e

Severe (G3–4)^d
pneumonitis^a



- Permanently discontinue immunotherapy^f
- Inpatient care
- Infectious workup:
 - ▶ Consider that patient may be immunocompromised
 - ▶ Nasal swab for potential viral pathogens
 - ▶ Sputum culture, blood culture, and urine culture
- Pulmonary and infectious disease consultation, consider PFTs
- Bronchoscopy with BAL to rule out infection and malignant lung infiltration
- Consider empiric antibiotics if infection has not yet been fully excluded
- Methylprednisolone 1–2 mg/kg/day. Assess response within 48 hours and plan taper over ≥6 weeks
- Consider adding any of the following if no improvement after 48 hours:
 - ▶ Infliximab 5 mg/kg IV, a second dose may be repeated 14 days later at the discretion of the treating provider
 - ▶ Mycophenolate mofetil 1–1.5g BID then taper in consultation with pulmonary service
 - ▶ Intravenous immunoglobulin (IVIG)ⁱ

^a Focal or diffuse inflammation of the lung parenchyma (typically identified on CT imaging as ground-glass opacities).

^d G3-severe symptoms involve all lung lobes or >50% of lung parenchyma; limiting self-care ADL; G4–life-threatening respiratory compromise.


^e See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^f See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

ⁱ Total dosing should be 2 g/kg, administered in divided doses per package insert.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



^a Azotemia, creatinine elevation, inability to maintain acid/base or electrolyte balance, and urine output change.

^b General medical review and testing as warranted for prerenal and postrenal causes. Include medication review for nephrotoxic agents such as NSAIDs, and consider obstruction, cardiomyopathy/heart failure, pulmonary hypertension, diuretics, hypovolemia due to primary GI cause, stones, and infection.

^c Distinguish cell infiltrate vs. immune-complex-mediated renal injury.

^d For proteinuria >3 g/24-hour, check ANA, RF, ANCA, anti-dsDNA, and serum C3, C4, and CH50.


^e See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^f See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^g Treat until symptoms improve to Grade ≤1 then taper over 4–6 weeks.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



^a Patients experiencing ocular adverse events (AEs) may present with any of the following symptoms: blurred/distorted vision, blind spots, change in color vision, photophobia, tenderness/pain, eyelid swelling, proptosis. Episcleritis can be associated with red or purple discoloration of the eye. Uveitis can be associated with eye redness.

^b Treat blepharitis per the episcleritis algorithm.

^c See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^d See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^e Treat until symptoms improve to Grade ≤1 then taper over 4–6 weeks.

^f If refractory to high-dose systemic steroids, consider adding infliximab or antimetabolites (eg methotrexate) for pan-uveitis.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**NERVOUS
SYSTEM
ADVERSE
EVENT(S)**

ASSESSMENT/GRADING

MANAGEMENT^d

Myasthenia
gravis^a →

- Acetylcholine receptor (AChR) antibodies and anti-muscle-specific tyrosine kinase antibodies in blood (not needed for diagnosis)
- Pulmonary function assessment with negative inspiratory force (NIF) and vital capacity (VC)
- Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), creatinine phosphokinase (CPK), aldolase for possible superimposed myositis
- If respiratory insufficiency or elevated CPK, perform cardiac exam, EKG, troponin, and TTE for possible concomitant myocarditis
- Electromyography (EMG) with repetitive stimulation and nerve conduction study (NCS)
- Neurology consultation
- Consider MRI brain and/or spine depending on symptoms to rule out CNS involvement by disease

Moderate
(G2)^b

Severe
(G3–4)^c

- Hold immunotherapy^e
- Pyridostigmine 30 mg TID and gradually increase to maximum of 120 mg orally four times a day as tolerated and based on symptoms
- Consider low-dose oral prednisone 20 mg daily. Increase by 5 mg every 3–5 days to a target dose of 1 mg/kg/day but not more than 100 mg daily (steroid taper based on symptom improvement)

- Permanently discontinue immunotherapy^e
- Inpatient care (may need intensive care unit [ICU]-level monitoring)
- Methylprednisolone 1–2 mg/kg/day (steroid taper based on symptom improvement)
- Initiate plasmapheresis or IVIG^f if no improvement/worsening on steroids or severe symptoms
- Frequent pulmonary function assessment
- Daily neurologic evaluation
- Avoid medications that can worsen myasthenia^g

^a Progressive or fluctuating muscle weakness, generally proximal to distal. May have bulbar involvement (ie, ptosis, extraocular movement abnormalities resulting in double vision, dysphagia, facial muscle weakness) and/or respiratory muscle weakness. May occur with myositis and myocarditis. Respiratory symptoms may require evaluation to rule out pneumonitis. Miller Fisher variant of Guillain-Barré syndrome (GBS) has overlapping symptoms (ophthalmoplegia and ascending weakness).

^b Some symptoms interfering with ADLs. Myasthenia Gravis Foundation of America (MGFA) severity class I (ocular symptoms and findings only) and MGFA severity class II (mild generalized weakness).

^c Limiting self-care and aids warranted, weakness limiting walking, any dysphagia, facial weakness, respiratory muscle weakness, or rapidly progressive symptoms or MGFA severity class III-IV moderate to severe generalized weakness to myasthenic crisis.

^d See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^e See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^f Total dosing should be 2 g/kg, administered in divided doses per package insert.

^g Beta-blockers, ciprofloxacin, and IV magnesium.

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



**NERVOUS
SYSTEM
ADVERSE
EVENT(S)**

ASSESSMENT/GRADING

MANAGEMENT^d



^d See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^f Total dosing should be 2 g/kg, administered in divided doses per package insert.

^h Progressive, most often symmetrical muscle weakness with absent or reduced deep tendon reflexes. May involve extremities, facial, respiratory, and bulbar & oculomotor nerves. May have dysregulation of autonomic nerves. Often starts with pain in lower back and thighs.

ⁱ Cerebrospinal fluid (CSF) typically has elevated protein and often elevated white blood cell (WBC) count; even though this is not typically seen in classical GBS, cytology should be sent with any CSF sample.


^j Some interference with ADLs, symptoms concerning to patient.

^k Limiting self-care and aids warranted, weakness limiting walking, any dysphagia, facial weakness, respiratory muscle weakness, or rapidly progressive symptoms.

^l Steroids are not usually recommended for idiopathic GBS; however, in immunotherapy-related forms, a trial is reasonable in addition to IVIG or plasmapheresis.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



^d See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^e See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^m Can present as asymmetric or symmetric sensory-motor deficit. Sensory deficit may be painful or painless paresthesias or potentially life-threatening autonomic (eg, myenteric plexus) dysfunction. Hypo- or areflexia. Isolated sensory deficit or sensory plus lower motor neuron deficit.

ⁿ GI tract paresis due to myenteric neuritis is a rare toxicity associated with ICI therapy. The presentation may be fulminant with profound ileus. Early institution of high-dose steroids in concert with multidisciplinary management is recommended.

^o No interference with function and symptoms not concerning to patient. Note: any cranial nerve problem should be managed as moderate.

^p Some interference with ADLs, symptoms concerning to patient (ie, pain but no weakness or gait limitation).

^q Limiting self-care and aids warranted, weakness limiting walking or respiratory problems (ie, leg weakness, foot drop, rapidly ascending sensory changes). Severe peripheral neuropathy is not necessarily GBS but the management can be similar.

^r There is a low threshold to hold immune checkpoint inhibitors in mild cases of peripheral neuropathy.

^s Specifically monitor for new interference with iADLs from either pain or weakness, gait difficulty, ataxia, or autonomic changes.

^t Treat until symptoms improve to Grade ≤1 then taper over 4–6 weeks.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NERVOUS SYSTEM ADVERSE EVENT(S)	ASSESSMENT	MANAGEMENT ^d
Aseptic meningitis ^{u,v}	<ul style="list-style-type: none"> • MRI brain with and without contrast + pituitary protocol • AM cortisol, to rule out adrenal insufficiency • Consider lumbar puncture^x • Consider neurology consultation 	<ul style="list-style-type: none"> • Hold immunotherapy^e if mild/moderate • Permanently discontinue immunotherapy if severe • Inpatient care (G3–4^{aa}) • Consider IV acyclovir until polymerase chain reaction (PCR) results obtained • Rule out bacterial and viral infection, then may closely monitor off steroids or consider prednisone 0.5–1 mg/kg/day or methylprednisolone 1–2 mg/kg/day if moderate/severe symptoms^{bb}
Encephalitis ^{v,w}	<ul style="list-style-type: none"> • Neurology consultation • MRI brain with and without contrast^y • Lumbar puncture^z • EEG to evaluate for subclinical seizures • Comprehensive metabolic panel, CBC, ESR, CRP, antineutrophil cytoplasmic antibody (ANCA) (if vasculitic process suspected), thyroid panel including TPO and thyroglobulin • Autoimmune encephalopathy and paraneoplastic panel in CSF and serum 	<ul style="list-style-type: none"> • Hold immunotherapy^e if mild • Permanently discontinue immunotherapy if moderate/severe • Inpatient care (G3–4^{aa}) • Consider IV acyclovir until PCR results obtained • Trial of methylprednisolone 1–2 mg/kg/day^{bb} • If severe or progressing symptoms or oligoclonal bands present, consider pulse steroids methylprednisolone 1 g IV daily for 3–5 days plus IVIG^f • If positive for autoimmune encephalopathy antibody or limited or no improvement after 7–14 days, consider rituximab

^d See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^e See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^f Total dosing should be 2 g/kg, administered in divided doses per package insert.

^t Treat until symptoms improve to Grade ≤1 then taper over 4–6 weeks.

^u May present with headache, photophobia, and neck stiffness, often afebrile but may be febrile. There may be nausea/vomiting. Mental status should be normal (distinguishes from encephalitis).

^v Exclude infectious causes, especially viral (ie, HSV).

^w Confusion, altered behavior, headaches, seizures, short-term memory loss, depressed level of consciousness, focal weakness, and speech abnormality.

^x Measure opening pressure and check cell count, protein glucose, gram stain, culture, PCR for HSV and other viral PCRs depending on suspicion and cytology. May see elevated WBC with normal glucose, normal culture, and gram stain. May see reactive lymphocytes or histiocytes on cytology.

^y May reveal T2/FLAIR changes typical of what is seen in autoimmune encephalopathies or limbic encephalitis or may be normal.

^z Check cell count, protein glucose, gram stain, culture, PCR for HSV, and other viral PCRs depending on suspicion, cytology, oligoclonal bands, and autoimmune encephalopathy panel. May see elevated WBC with lymphocytic predominance and/or elevated protein.

^{aa} Limiting self-care and aids warranted.

^{bb} Taper steroids rapidly once symptoms resolve.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**NERVOUS SYSTEM
 ADVERSE EVENT(S)**

ASSESSMENT

MANAGEMENT^d

Transverse myelitis^{cc}



- Neurology consultation
- MRI of spine and brain
- Lumbar puncture^{dd}
- B₁₂, HIV, rapid plasma reagin (RPR), ANA, anti-Ro/La antibodies, TSH, aquaporin-4 IgG, paraneoplastic panel for anti-Hu and anti-CRMP5/CV2
- Evaluation for urinary retention, constipation



- Permanently discontinue immunotherapy^e
- Inpatient care
- Methylprednisolone pulse dosing 1 g/day for 3–5 days
- Strongly consider IVIG^f or plasmapheresis

^d See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^e See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^f Total dosing should be 2 g/kg, administered in divided doses per package insert.

^{cc} Acute or subacute weakness or sensory changes bilaterally, often with increased deep tendon reflexes.

^{dd} Cell count, protein, glucose, oligoclonal bands, viral PCRs, cytology, and onconeural antibodies.

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



**CARDIOVASCULAR
ADVERSE EVENT(S)**

ASSESSMENT/GRADING

MANAGEMENT^e



^a Myocarditis symptoms are nonspecific. It is rare, but potentially severe, not viral in etiology, associated with myositis/myasthenia gravis, and is more common with combination therapy. In fatal cases, conduction abnormalities were mode of death and ejection fraction was preserved.

^b No evidence specific to immunotherapy-related myocarditis; recommendations drawn from other causes of myocarditis.

^c Arrhythmia, significant echo findings without hypotension, cardiac markers >ULN.

^d Arrhythmia, hemodynamic (hypotension/cardiomyopathy) >3xULN.

^e See [Principles of Immunosuppression \(IMMUNO-A\)](#).


^f See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

MUSCULOSKELETAL ASSESSMENT/GRADING
ADVERSE EVENT(S)

MANAGEMENT^d



^a Clinical symptoms: joint pain, joint swelling; inflammatory symptoms: stiffness after inactivity, improvement with heat.

^b Mild in severity or only 1 joint involved.

^c Limits ADLs, presence of joint erosions.

^d See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^e See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^f Treat until symptoms improve to Grade ≤1 then taper over 4–6 weeks.


^g Consider discontinuing immunotherapy if arthritis worsens, with repeated dosing, to the point where daily activities are limited or patient's quality of life is severely impaired.

^h Consider co-existence of other irAEs in which choice of immunosuppression may be relevant.

ⁱ Consider ESR, CRP to monitor response if elevated at the onset of therapy.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



^c See [Principles of Immunosuppression \(IMMUNO-A\)](#).

^d See [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#).

^e Treat until symptoms improve to Grade ≤1 then taper over 4–6 weeks.

ⁱ Myalgia is a disorder characterized by marked discomfort sensation originating from a muscle or group of muscles.

^j Myositis is a disorder characterized by inflammation and/or weakness involving the skeletal muscles.

^k Moderate pain associated with weakness or elevated CK or aldolase; limiting self-care ADLs.

^l For myalgias, moderate pain associated with weakness; pain limiting iADLs. In myositis, pain associated with severe weakness; limiting self-care ADLs.

^m Only applies to myositis; urgent intervention indicated.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

PRINCIPLES OF IMMUNOSUPPRESSION

- These immunosuppression recommendations are for patients receiving immune checkpoint inhibitor immunotherapy.
- Close consultation with disease-specific subspecialties is encouraged.
 - ▶ Referral to a tertiary care center may be required for management of complex cases or multi-system irAEs.
- Corticosteroids are the mainstay of treatment of most irAEs related to immunotherapy.
 - ▶ Early intervention with corticosteroids is a key goal in general management of immune-related toxicity.
 - ▶ Use of corticosteroids to treat irAEs has NOT been shown to reduce anti-tumor efficacy.
 - ◊ In the absence of specific indications such as prior infusion reaction or concurrent chemotherapy, routine premedication with corticosteroids is not recommended given the potential mitigation of immunotherapeutic effectiveness in the prophylactic setting.
 - ▶ Longer steroid tapers (>4 weeks, sometimes 6–8 weeks or longer) may be required to prevent recurrent irAE events, particularly pneumonitis and hepatitis.
 - ▶ See individual toxicity pages for specific recommendations on steroid dose by grade. Where immunotherapy rechallenge is indicated, see the [Principles of Immunotherapy Rechallenge \(IMMUNO-C\)](#) for guidance by organ site.
 - ▶ Prophylaxis against pneumocystis jiroveci pneumonia (PJP) can be considered in patients receiving a prednisone equivalent of 20 mg or more daily for 4 or more weeks.
 - ▶ Prophylaxis against fungal infections (eg, fluconazole) can be considered in patients receiving a prednisone equivalent of 20 mg or more daily for 6–8 or more weeks.
 - ▶ Prophylaxis against herpes zoster reactivation can be considered.
 - ▶ Proton pump inhibitor therapy or H2 blockers can be considered for patients at higher risk of gastritis (eg, NSAID use, anticoagulation) for the duration of corticosteroid therapy.
 - ▶ Higher potency (eg, Class 2 or 3) topical corticosteroids are preferred for short-term use for immune-related dermatitis, compared to longer term use of lower potency steroids.
 - ▶ For neurologic, cardiac, or grade 3 or 4 irAEs, higher dose steroids (eg, methylprednisolone or prednisone 1–2 mg/kg/day) should be given.
 - ▶ If patients need to be on long-term steroids, they are at risk for developing osteoporosis. Vitamin D and calcium supplementation should be provided to prevent osteoporosis.
- Selected irAEs including hypothyroidism and other endocrine irAEs may be treated with hormonal supplementation, without the need for corticosteroid therapy. [See Endocrine Toxicities section.](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

IMMUNO-A
1 OF 2

PRINCIPLES OF IMMUNOSUPPRESSION

- **Anti-TNF α agents (eg, infliximab) are particularly effective in management of immune-related colitis and inflammatory arthritis.**
 - ▶ **There is a risk for hepatitis B virus reactivation with infliximab. Test for viral hepatitis B and hepatitis C prior to TNF inhibition and monitor HBV/HCV carriers during and for several months after therapy.**
 - ▶ **There is a risk for tuberculosis (TB) activation. Test for latent/active TB prior to TNF inhibition. TB testing should not delay initiation of anti-TNF α agents for the management of irAEs.**
 - ◊ **Results of TB testing need not be finalized prior to dosing anti-TNF α agents in the acute setting.**
 - ◊ **Interferon-gamma release assays for TB testing are preferred.**
 - ▶ **For patients with severe irAEs not responsive to steroids within 48–72 hours, early (~72 h) initiation of anti-TNF α therapy (eg, infliximab 5 mg/kg) may be warranted in consultation with the relevant medical specialist.**
 - ◊ **Close monitoring and follow-up of patients on steroids and infliximab is required to assess for response.**
 - ◊ **A second dose of anti-TNF α therapy may be required, and can be administered 2 weeks after initial dose of infliximab.**
 - ▶ **Anti-TNF α agents should be avoided in patients with immune-related hepatitis.**
 - ◊ **Alpha-4 beta-7 integrin inhibitors (eg, vedolizumab) may be considered in these cases for management of concomitant hepatitis and immune-related colitis.**
 - ◊ **Other immunosuppressive agents may be of use in certain irAEs; see individual toxicity pages.**
- **Patients with pre-existing autoimmune conditions or organ transplant recipients may be candidates for immune checkpoint blockade.**
 - ▶ **Anti-CTLA-4–based therapy has a higher incidence of exacerbating baseline autoimmune conditions relative to anti-PD-1/PD-L1–based approaches.**
 - ▶ **Optimization of immunosuppression for pre-existing autoimmune conditions, including close follow-up with pertinent subspecialists, is recommended.**
 - ◊ **Goal of immunosuppressive regimen allowing for dose of prednisone <10 mg daily or equivalent prior to initiating cancer immunotherapy.**
 - ▶ **Graft failure while on cancer immunotherapy has been reported. Transplant organ loss may be an outcome of treatment with cancer immunotherapy and should be discussed with patient and organ transplant team.**
 - ◊ **Patients with solid organ transplantation who have viable option for alternative therapy if graft rejection (eg, kidney) may be candidates for immunotherapy, particularly if no prior evidence of graft rejection and if on maintenance immunosuppression.**
 - ▶ **Patients with autoimmune neurologic conditions or life-threatening autoimmune disorders, particularly if not controlled with immunosuppressive medications or requiring high doses of immunosuppression, are unlikely to be suitable candidates for cancer immunotherapy.**
 - ▶ **Patients with prior allogeneic stem cell transplant may be candidates for immunotherapy.**
 - ◊ **There is an increased risk of transplant-related complications, including potentially fatal graft-versus-host disease (GVHD).**
 - ◊ **Careful discussion with patient and stem cell transplant physicians should precede initiation of immunotherapy.**
- **Patients with history of HIV or viral hepatitis may be candidates for immunotherapy.**
- **Vaccines that are inactivated or killed preparations are permissible during a course of immunotherapy. Due to the lack of clarity regarding live vaccine use, it is not recommended during ICI therapy.**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF IMMUNOTHERAPY PATIENT EDUCATION
HEALTH CARE PROVIDER (HCP) INFORMATION**

Prior to starting immunotherapy:

- Document any underlying medical conditions affecting any organ system (eg, pulmonary, cardiac, neurologic, musculoskeletal).
- It is important to take a history of any autoimmune diseases.
- Record all medications, including over-the-counter medications and herbal supplements.
- Patients of reproductive age should be advised to use effective birth control during and for at least 5 months after the final dose of immunotherapy.
 - ▶ The effect of immunotherapy on human reproductive function is unknown. Consider fertility preservation and reproductive endocrinology referral for all patients starting therapy who have not yet completed family planning.
- Breastfeeding is contraindicated during and for at least 5 months after the final dose of immunotherapy.
- Provide patients with and instruct them to carry a wallet card that outlines the type of immunotherapy they are receiving, potential irAEs, and contact numbers for their oncology health care team.

Instruct patients to notify the oncology health care team if:

- Any new signs or symptoms develop, including severe fatigue, headache, rash, cough, shortness of breath, chest pain, abdominal bloating, change in bowel pattern, weight loss, vision changes or eye pain, severe muscle weakness, severe muscle or joint pains, and/or mood changes.
 - ▶ irAEs can occur after completion of therapy. Patients should monitor symptoms for at least 1 year following the conclusion of immunotherapy.
- Patient is evaluated by other HCPs or admitted to the hospital.
- Any new medications are prescribed, or prior to receiving any immunizations or vaccinations.
 - ▶ Vaccines that are inactivated or killed preparations are permissible during a course of immunotherapy. Due to the lack of clarity regarding live vaccine use, it is not recommended during ICI therapy.

Toxicity management:

- Review patient medications for potential drug interactions (eg, QT prolongation) when administering agents to manage ICI-related toxicity.
- Mild to moderate adverse events (AEs):
 - ▶ Provide symptomatic management.
 - ▶ Delay in immunotherapy may be required until AEs resolve to grade 1 or pre-treatment baseline.
 - ▶ Corticosteroids may be required if AE does not improve. If hormone replacement is required, it is usually for lifetime and may continue beyond the completion of therapy with immune checkpoint inhibitors.
- Severe AEs:
 - ▶ Discontinue immunotherapy.
 - ▶ Initiate corticosteroid therapy immediately. IV methylprednisolone should be considered until there is evidence of improvement in toxicity.
 - ▶ Additional immunosuppressant therapy may be required for steroid-refractory AEs.
 - ▶ Inpatient care and additional supportive care may be required.
- Supportive care during immunosuppressant therapy may include the following:
 - ▶ Monitoring of blood glucose levels
 - ▶ Proton pump inhibitors or H2 blockers to prevent gastritis
 - ▶ Antimicrobial and antifungal prophylaxis to prevent opportunistic infections
 - ▶ Vitamin D and calcium supplementation to prevent osteoporosis

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

IMMUNO-B
1 OF 2

PRINCIPLES OF IMMUNOTHERAPY PATIENT EDUCATION

PATIENT EDUCATION CONCEPTS

Immunotherapy background:

- One of the functions of the immune system is to distinguish healthy cells from abnormal cells. Tumor cells have proteins on their surface that bind to immune cells, blocking the ability of the immune cell to recognize them as foreign.
- Immunotherapy is a type of therapy that works to boost the body's natural defenses to fight cancer. Immune checkpoint inhibitors are a class of medications that prevent tumors from “hiding” or “evading” the body's natural immune system.

Side effects (AEs):

- AEs from immunotherapy differ from those of other types of cancer treatment and can affect one or several different organ systems.
- Amplifying the immune system can cause T cells to attack healthy cells in the body, causing inflammatory conditions that mimic a range of autoimmune conditions, some of which can be serious. These are known as irAEs.
- irAEs can occur at any time during treatment or after treatment is completed. irAE rebound during steroid taper can also occur.
- The severity of AEs can range from asymptomatic to severe or life-threatening. They may be cumulative over the course of therapy.
- Combination therapy may increase the severity of AEs. This can occur when immunotherapy is combined with chemotherapy, targeted agents, radiation therapy, or other types of immunotherapy.

Monitoring and treatment response:

- Therapy with immune checkpoint inhibitor requires close communications between patient/family and the treating center. Symptoms that patients may think are unrelated (for instance, diarrhea or nausea) are often signs of immune checkpoint inhibitor toxicity.
- Educate patients to notify all HCPs (especially primary care providers) that they are receiving/have received immunotherapy.
- Regular monitoring will be conducted to detect any potential irAEs and to assess treatment response.
- Laboratory tests will be obtained at regular intervals.
- Physical exams will include monitoring of organ function and weight.
- Treatment response time differs from standard cancer therapy; it may take longer to see a response than with other types of cancer therapy.
- Most irAEs can be managed effectively if detected and treated early.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

PRINCIPLES OF IMMUNOTHERAPY RECHALLENGE

General Principles

- Exercise caution when considering resumption of immunotherapy after significant irAEs. Close follow-up should be performed when resuming immunotherapy to monitor for recurrent symptoms.
 - ▶ If re-challenged and toxicity returns, permanently discontinue class of immunotherapy.
 - ▶ Assess patient's tumor status prior to rechallenge. If an objective response (complete or partial) to ICI therapy was achieved, resumption of immunotherapy may not be advisable due to risk of toxicity recurrence. Discuss the risks/benefits of restarting immunotherapy with the patient.
- Permanent discontinuation of a given class of immunotherapy is typically warranted in the setting of severe irAEs induced by that class of immunotherapy and may be warranted in the setting of moderate irAEs. For example, if a patient experiences grade 3 or 4 toxicity from an ipilimumab-containing regimen, consideration may be given to later therapy with a PD-1 or PD-L1 monotherapy after resolution of the earlier toxicity.
- With some exceptions, resumption of immunotherapy following grade 2 irAEs can be considered upon resolution to ≤ grade 1.
- Consult with organ-specific specialists prior to resumption of immunotherapy as appropriate following an immunotherapy hold due to irAEs.

Organ-Specific Considerations for Immunotherapy Rechallenge After a Hold

Skin	<ul style="list-style-type: none"> • Maculopapular rash and/or pruritus: Consider resuming after symptoms have resolved to ≤ grade 1 (ie, once skin condition is mild/localized with only topical intervention indicated). • Permanent discontinuation of immunotherapy in the setting of severe or life-threatening bullous disease (grade 3–4), including all cases of SJS and TEN.
GI	<ul style="list-style-type: none"> • PD-1/PD-L1 agents: After grade 2–3 colitis, consider resumption of immunotherapy after symptoms have resolved to ≤ grade 1. In rare circumstances in which the patient cannot completely taper off steroids, immunotherapy may be resumed while patient is still on ≤10 mg prednisone equivalent daily. • CTLA-4 agents: Discontinue if irAE is serious or life-threatening. Do not make up doses missed due to irAE and/or required steroid treatment.
Liver	<ul style="list-style-type: none"> • Transaminitis without elevated bilirubin: following a grade 2 irAE, consider resumption of immunotherapy after ALT/AST return to baseline and steroids, if used, have been tapered to ≤10 mg prednisone equivalent daily. • Permanent discontinuation is warranted in the setting of severe or life-threatening (grade 3–4) hepatitis.
Pancreas	<ul style="list-style-type: none"> • Symptomatic grade 2 pancreatitis: Consider resumption of immunotherapy if no clinical/radiologic evidence of pancreatitis ± improvement in amylase/lipase. Consider consultation with relevant pancreatic specialist regarding resumption. • Permanent discontinuation is warranted for severe (grade 3–4) pancreatitis.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

PRINCIPLES OF IMMUNOTHERAPY RECHALLENGE

Organ-Specific Considerations for Immunotherapy Rechallenge After a Hold

Endocrine	<ul style="list-style-type: none"> • Thyroid: No discontinuation required for hypothyroidism. For symptomatic hyperthyroidism resembling Graves-like disease, consider holding immunotherapy and resuming after workup is complete and there is evidence for improvement in symptoms and TFTs. • Primary adrenal insufficiency: After appropriate replacement endocrine therapy is instituted, immunotherapy may continue. • Hypophysitis manifested by deficiency of TSH and/or gonad-stimulating hormones, but without symptomatic pituitary swelling: Immunotherapy may continue while replacement endocrine therapy is regulated. • Hypophysitis accompanied by symptoms of pituitary swelling (eg, headache, vision disturbance, and/or neurologic dysfunction): Hold immunotherapy until resolution of symptoms after steroid therapy; consider resumption of immunotherapy after symptoms related to mass effect are resolved. • T1DM with DKA: Consider resuming once DKA has been corrected and glucose level has stabilized.
Lung	<ul style="list-style-type: none"> • Progressive grade 1 pneumonitis requiring a hold: Consider resuming upon radiographic evidence of improvement. • Grade 2: Resume once pneumonitis has resolved to ≤ grade 1 and patient is off steroids. • Permanent discontinuation is warranted in the setting of severe (grade 3–4) pneumonitis.
Kidney	<ul style="list-style-type: none"> • Grade 1–2 renal irAE: Hold immunotherapy per guidelines; upon resolution to ≤ grade 1, consider resuming concomitant with steroid if creatinine is stable. • Permanent discontinuation is warranted in the setting of severe (grade 3–4) proteinuria.
Eye	<ul style="list-style-type: none"> • Grade 2 irAE: Hold immunotherapy per guideline; consider resumption of immunotherapy in consultation with ophthalmology upon resolution to ≤ grade 1. • Permanent discontinuation of immunotherapy is warranted in the setting of severe (grade 3–4) uveitis or episcleritis.
Nervous System	<ul style="list-style-type: none"> • Myasthenia gravis: Consider resuming immunotherapy after moderate (grade 2) AE based on steroid responsiveness. Permanently discontinue immunotherapy after grade 3–4 AE. • GBS: Permanently discontinue immunotherapy for any grade GBS. • Peripheral neuropathy: Following hold for grade 1–2 AE, consider resuming if symptoms resolve to ≤ grade 1 or if patient has well-controlled isolated painful sensory neuropathy. • Aseptic meningitis: Consider resuming following mild to moderate AE if symptoms resolve to grade 0. • Encephalitis: Permanent discontinuation is warranted in the setting of moderate to severe encephalitis (grade 2–4). • Transverse myelitis: Discontinuation of immunotherapy following any-grade transverse myelitis.
Cardiovascular	<ul style="list-style-type: none"> • Grade 1 myocarditis: Consider resuming upon resolution of symptoms. • Permanent discontinuation is warranted in the setting of grade 2–4 myocarditis.
Musculoskeletal	<ul style="list-style-type: none"> • Inflammatory arthritis (moderate to severe irAE requiring hold): Resume upon stabilization or adequate management of symptoms. Permanent discontinuation may be warranted for severe inflammatory arthritis that significantly impairs ADLs and quality of life.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF PATIENT MONITORING

Before and During CAR T-Cell Infusion

- Perform central venous access, preferably with double or triple lumen catheter, for IV fluid and other infusions in case of toxicities.
- Perform cardiac monitoring at least at the onset of grade 2 cytokine release syndrome (CRS) until resolution to \leq grade 1, and additionally as clinically indicated.
- Tumor lysis precautions are recommended for patients with large tumor burden and aggressive histologies, as per standard institutional guidelines.
- Start seizure prophylaxis on the day of infusion for CAR T-cell therapies known to cause CAR T-cell-related neurotoxicity (eg, levetiracetam 500–750 mg orally every 12 h for 30 days).
- Consider baseline brain MRI.

Post-CAR T-Cell Infusion

- Hospitalization or extremely close outpatient monitoring at centers with transplant or prior outpatient CAR T-cell transplant experience. Close monitoring in the hospital is preferable with current products used for adults; however, extremely close outpatient monitoring may be possible at centers with outpatient transplant experience.
- Hospitalization for patients with CRS is warranted.
- Monitor CBC, complete metabolic panel (including magnesium and phosphorus), and coagulation profile.
- Baseline CRP and ferritin; recheck at least 3 times per week for 2 weeks post-infusion. Consider daily checks during CRS. CRP can normalize prior to the onset of neurotoxicity.
- Assessment for CRS should be done at least twice daily, or when the patient's status changes, during the peak window of CRS risk.
- Neurotoxicity assessment should be done at least twice daily or when the patient's status changes, during the peak window of neurotoxicity risk. If neurologic concern develops, assess at a minimum of every 8 hours to include cognitive assessment and motor weakness.

[Overview of CAR T-Cell Therapy-Related Toxicities \(CART-2\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

OVERVIEW OF CAR T-CELL THERAPY-RELATED TOXICITIES

	Axicabtagene ciloleucel ^a and tisagenlecleucel ^b
CRS (CART-3)	<ul style="list-style-type: none"> • Typical time to onset: 2–3 days • Typical duration: 7–8 days • Manifestation may include fever, hypotension, tachycardia, hypoxia, and chills. CRS may be associated with cardiac, hepatic, and/or renal dysfunction. • Serious events may include atrial fibrillation and ventricular tachycardia, cardiac arrest, cardiac failure, renal insufficiency, capillary leak syndrome, hypotension, hypoxia, and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).
Neurologic Toxicity (CART-4)	<ul style="list-style-type: none"> • Typical time to onset: 4–10 days • Typical duration: 14–17 days • The most common neurologic toxicities include encephalopathy, headache, tremor, dizziness, aphasia, delirium, insomnia, anxiety, and autonomic neuropathy. Agitation, hyperactivity, or signs of psychosis can also occur. • Serious events including seizures, as well as fatal and serious cases of cerebral edema, have occurred.
Hemophagocytic Lymphohistiocytosis/Macrophage-Activation Syndrome (HLH/MAS) During CRS (CART-3)	<ul style="list-style-type: none"> • Criteria for considering HLH/MAS: <ul style="list-style-type: none"> ▶ Rapidly rising and high ferritin (>5,000 ng/mL) with cytopenias in the context of CRS, especially if accompanied by <i>any of the following</i>: <ul style="list-style-type: none"> ◊ Grade ≥ 3 increase in serum bilirubin, AST, ALT ◊ Grade ≥ 3 oliguria or increase in serum creatinine ◊ Grade ≥ 3 pulmonary edema ▶ Presence of hemophagocytosis in bone marrow or organs based on histopathologic assessment of cell morphology and/or CD68 IHC.
Miscellaneous	<ul style="list-style-type: none"> • Patients may exhibit cytopenias for weeks to months following lymphodepleting chemotherapy and CAR T-cell therapy infusion. • Long-term B-cell aplasia and hypogammaglobulinemia can occur in patients with a complete remission after CAR T-cell therapy infusion.

^a Axicabtagene ciloleucel: Median time to CRS onset of 2 days (range: 1–12 days), median duration of 7 days (range: 2–58 days). Median time to neurotoxicity onset of 4 days (range: 1–43 days), median duration of 17 days.

^b Tisagenlecleucel: Median time to CRS onset of 3 days (range: 1–51 days), median duration of 8 days (range: 1–36 days). Median time to neurotoxicity onset of 6 days (range: 1–359 days); median duration of 14 days.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

CYTOKINE RELEASE SYNDROME (CRS)^{c,d}

- Prompt and urgent intervention to prevent progression of CRS is required; however, other causes of systemic inflammatory response should be ruled out, including infection and malignancy progression. Empiric treatment for infection is warranted in the neutropenic patient. Organ toxicities associated with CRS may be graded according to CTCAE v5.0 but they do not influence CRS grading.^e
- Fever is defined as temperature >38°C not attributable to any other cause. In patients who have CRS then receive antipyretics or anticytokine therapy such as tocilizumab or steroids, fever is no longer required to grade subsequent CRS severity. In this case, CRS grading is driven by hypotension and/or hypoxia.

CRS Grade	Anti-IL-6 Therapy	Corticosteroids ^{h,i}	Additional Supportive Care
Grade 1 Fever (≥ 38°C)	For prolonged CRS (>3 days) in patients with significant symptoms and/or comorbidities, consider tocilizumab as per Grade 2	N/A	<ul style="list-style-type: none"> • Empiric broad-spectrum antibiotics, consider granulocyte colony-stimulating factor (G-CSF) if neutropenic • Maintenance IV fluids for hydration • Symptomatic management of organ toxicities
Grade 2 Fever with hypotension not requiring vasopressors and/or hypoxia ^f requiring low-flow nasal cannula ^g or blow-by	Tocilizumab 8 mg/kg IV over 1 hour (not to exceed 800 mg/dose) ^h . Repeat in 8 hours if no improvement; no more than 3 doses in 24 hours, with a maximum of 4 doses total	For persistent refractory hypotension after 1–2 doses of anti-IL-6 therapy: Dexamethasone 10 mg IV every 6 hours (or equivalent) ^j	<ul style="list-style-type: none"> • IV fluid bolus as needed • For persistent refractory hypotension after two fluid boluses and anti-IL-6 therapy: Start vasopressors, consider transfer to intensive care unit (ICU), consider echocardiogram, and initiate other methods of hemodynamic monitoring • Manage per Grade 3 if no improvement within 24 hours after starting anti-IL-6 therapy • Symptomatic management of organ toxicities
Grade 3 Fever with hypotension requiring a vasopressor with or without vasopressin and/or hypoxia requiring high-flow cannula ^g , face mask, nonrebreather mask, or Venturi mask.	Anti-IL-6 therapy as per Grade 2 ^h if maximum dose not reached within 24-hour period	Dexamethasone 10 mg IV every 6 hours (or equivalent) ^j . If refractory, manage as grade 4	<ul style="list-style-type: none"> • Transfer to ICU, obtain echocardiogram, and perform hemodynamic monitoring • Supplemental oxygen • IV fluid bolus and vasopressors as needed. • Symptomatic management of organ toxicities
Grade 4 Fever with hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive pressure (eg, CPAP, BiPAP, intubation and mechanical ventilation).	Anti-IL-6 therapy as per Grade 2 ^h if maximum dose not reached within 24-hour period	Dexamethasone 10 mg IV every 6 hours (or equivalent) ^j . If refractory, consider methylprednisolone 1000 mg/day IV ^k	<ul style="list-style-type: none"> • ICU care and hemodynamic monitoring • Mechanical ventilation as needed • IV fluid bolus and vasopressors as needed • Symptomatic management of organ toxicities

[See Footnotes on next page](#)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



FOOTNOTES

- ^c For HLH/MAS during CRS, treat as per CRS with addition of steroids. If symptoms do not improve within 48 hours, consider etoposide and intrathecal cytarabine for neurotoxicity.
- ^d With permission from Elsevier: Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biol Blood Marrow Transplant*. 2018;18:31691-4. DOI: <https://doi.org/10.1016/j.bbmt.2018.12.758>. This article is published under the terms of the [Creative Commons Attribution-NonCommercial-No Derivatives License \(CC BY NC ND\)](#).
- ^e Organ toxicities should receive a thorough workup and appropriate management.
- ^f CRS grade is determined by the more severe event: hypotension or hypoxia not attributable to any other cause. For example, a patient with temperature of 39.5°C, hypotension requiring 1 vasopressor, and hypoxia requiring low-flow nasal cannula is classified as grade 3 CRS.
- ^g Low-flow nasal cannula is defined as oxygen delivered at ≤6 L/minute. Low flow also includes blow-by oxygen delivery, sometimes used in pediatrics. High-flow nasal cannula is defined as oxygen delivered at >6 L/minute.
- ^h After each dose, assess need for subsequent dosing.
- ⁱ Antifungal prophylaxis should be strongly considered in patients receiving steroids for the treatment of CRS and/or neurotoxicity.
- ^j Alternative steroids at an equivalent dose may be considered.
- ^k For example, methylprednisolone IV 1000 mg/day for 3 days, followed by rapid taper at 250 mg every 12 h for 2 days, 125 mg every 12 h for 2 days, and 60 mg every 12 h for 2 days.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

CAR T-CELL-RELATED NEUROTOXICITY GRADING

Immune Effector Cell-Associated Encephalopathy (ICE) Assessment Tool^d

- **Orientation:** orientation to year, month, city, hospital: 4 points
- **Naming:** ability to name 3 objects (eg, point to clock, pen, button): 3 points
- **Following commands:** ability to follow simple commands (eg, “Show me 2 fingers” or “Close your eyes and stick out your tongue”): 1 point
- **Writing:** ability to write a standard sentence (eg, “Our national bird is the bald eagle”): 1 point
- **Attention:** ability to count backwards from 100 by 10: 1 point

ICE Scoring
• 7-9, grade 1
• 3-6, grade 2
• 0-2, grade 3
• 0 due to patient unarousable and unable to perform ICE assessment, grade 4

ASBMT Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Consensus Grading for Adults^d

ICANS grade is determined by the most severe event (ICE score, level of consciousness, seizure, motor findings, raised ICP/cerebral edema) not attributable to any other cause; for example, a patient with an ICE score of 3 who has a generalized seizure is classified as grade 3 ICANS.

Neurotoxicity Domain ^l	Grade 1	Grade 2	Grade 3	Grade 4
ICE score ^m	7-9	3-6	0-2	0 (patient is unarousable and unable to perform ICE)
Depressed level of consciousness ⁿ	Awakens spontaneously	Awakens to voice	Awakens only to tactile stimulus	Patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse. Stupor or coma
Seizure	N/A	N/A	Any clinical seizure focal or generalized that resolves rapidly or nonconvulsive seizures on EEG that resolve with intervention	Life-threatening prolonged seizure (>5 min); or repetitive clinical or electrical seizures without return to baseline in between
Motor findings	N/A	N/A	N/A	Deep focal motor weakness such as hemiparesis or paraparesis
Elevated ICP/ cerebral edema	N/A	N/A	Focal/local edema on neuroimaging ^o	Diffuse cerebral edema on neuroimaging; Decerebrate or decorticate posturing; or Cranial nerve VI palsy; or Papilledema; or Cushing’s triad

^dWith permission from Elsevier: Lee DW, Santomaso BD, Locke, FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018;18:31691-4. DOI: <https://doi.org/10.1016/j.bbmt.2018.12.758>. This article is published under the terms of the [Creative Commons Attribution-NonCommercial-No Derivatives License \(CC BY NC ND\)](#).

^l Other signs and symptoms such as headache, tremor, myoclonus, asterixis, and hallucinations may occur and could be attributable to immune effector-cell engaging therapies. Although they are not included in this grading scale, careful attention and directed therapy may be warranted.

^m A patient with an ICE score of 0 may be classified as grade 3 ICANS if awake with global aphasia, but a patient with an ICE score of 0 may be classified as grade 4 ICANS if unarousable.

ⁿ Depressed level of consciousness should be attributable to no other cause (eg, no sedating medication).

^o Intracranial hemorrhage with or without associated edema is not considered a neurotoxicity feature and is excluded from ICANS grading. It may be graded according to CTCAE v5.0.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[See Treatment on CART-5](#)

CAR T-CELL-RELATED NEUROTOXICITY TREATMENT

Assessment and Supportive Care Recommendations (all grades)

- Neurologic assessment and grading at least twice a day to include cognitive assessment and motor weakness
- MRI of the brain with and without contrast (or brain CT if MRI is not feasible) for ≥ grade 2 neurotoxicity
- Neurology consultation at first sign of neurotoxicity
- Conduct electroencephalogram (EEG) for seizure activity for ≥ grade 2 neurotoxicity
- Aspiration precautions; IV hydration
- Use caution when prescribing medications that can cause central nervous system (CNS) depression (aside from those needed for seizure prophylaxis/treatment)

Treatment by Grade	No Concurrent CRS	Additional Therapy if Concurrent CRS
Grade 1	<ul style="list-style-type: none"> • Supportive care 	Tocilizumab 8 mg/kg IV over 1 h (not to exceed 800 mg/dose) ^q
Grade 2^p	<ul style="list-style-type: none"> • Supportive care • Dexamethasone 10 mg IV x 1. Can repeat every 6 hours or methylprednisolone 1 mg/kg IV every 12 h if symptoms worsen. 	Anti-IL-6 therapy as per Grade 1 ^q Consider transferring patient to ICU if neurotoxicity associated with grade ≥2 CRS
Grade 3^p	<ul style="list-style-type: none"> • ICU care is recommended. • Dexamethasone 10 mg IV every 6 h or methylprednisolone, 1 mg/kg IV every 12 hⁱ • Consider repeat neuroimaging (CT or MRI) every 2–3 days if patient has persistent grade ≥3 neurotoxicity. 	Anti-IL-6 therapy as per Grade 1 ^q
Grade 4^p	<ul style="list-style-type: none"> • ICU care, consider mechanical ventilation for airway protection. • High-dose corticosteroids^{i,k} • Consider repeat neuroimaging (CT or MRI) every 2–3 days if patient has persistent grade ≥3 neurotoxicity. • Treat convulsive status epilepticus per institutional guidelines. 	Anti-IL-6 therapy as per Grade 1 ^q

ⁱ Antifungal prophylaxis should be strongly considered in patients receiving steroids for the treatment of CRS and/or neurotoxicity.

^k For example, methylprednisolone IV 1000 mg/day for 3 days, followed by rapid taper at 250 mg every 12 h for 2 days, 125 mg every 12 h for 2 days, and 60 mg every 12 h for 2 days.

^p Diagnostic lumbar puncture for grade 3-4 neurotoxicity; consider for grade 2.

^q Repeat tocilizumab every 8 hours as needed if not responsive to IV fluids or increasing supplemental oxygen. Limit to a maximum of 3 doses in a 24-hour period; maximum total of 4 doses.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



Discussion

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

NCCN Categories of Preference

Preferred intervention: Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.

Other recommended intervention: Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes.

Useful in certain circumstances: Other interventions that may be used for selected patient populations (defined with recommendation).

All recommendations are considered appropriate.

Table of Contents

Overview.....	MS-3	Managing irAEs in Special Patient Populations.....	MS-13
Literature Search Criteria and Guidelines Update Methodology	MS-3	 Patients with Prior irAEs or Pre-existing Autoimmune Conditions	MS-13
The Role of the Immune System in Cancer.....	MS-3	 Organ Transplant Recipients.....	MS-15
 Evolution of Cancer Immunotherapy.....	MS-4	Specific irAE Management.....	MS-16
Immune Checkpoint Inhibitors	MS-5	 Infusion-Related Reactions	MS-16
 Mechanism of Action.....	MS-5	 Dermatologic Toxicity	MS-17
 CTLA-4 Inhibitors	MS-5	 Gastrointestinal (GI) Toxicity	MS-18
 PD-1/PD-L1 Inhibitors	MS-5	 Hepatic Toxicity	MS-19
 ICI-mediated Immune Dysfunction.....	MS-6	 Pancreatic Toxicity	MS-20
 Incidence and Prevalence of irAEs.....	MS-6	 Endocrine Toxicity	MS-21
 Single-Agent Therapy	MS-7	 Pulmonary Toxicity	MS-24
 Combination Therapy	MS-8	 Renal Toxicity	MS-26
 ICI Therapy-Related Fatal irAEs.....	MS-9	 Ocular Toxicity.....	MS-27
 IrAEs as a Biomarker of Treatment Response	MS-10	 Nervous System Toxicity	MS-28
Management of ICI-Related Toxicity.....	MS-10	 Cardiovascular Toxicity	MS-30
 General Principles of Immunosuppression	MS-10	 Musculoskeletal Toxicity.....	MS-32
 Immunomodulators	MS-11	CAR T-Cell Therapy	MS-33
 Considerations for Patients on Immunosuppressants	MS-12	References	MS-34
 Impact of Immunosuppressive Agents on Immunotherapy Efficacy..	MS-12		

Overview

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy.

The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO consisting of medical oncologists and hematologic oncologists with expertise in a wide array of disease sites, as well as experts from the fields of dermatology, gastroenterology, neurooncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several NCCN Panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC.^{1,2}

The initial publication of these guidelines in 2018 focused on managing toxicity related to immune checkpoint inhibitor (ICI) therapy. In 2019, the NCCN Guidelines were expanded to address the management of toxicities related to chimeric antigen receptor (CAR) T-cell therapy. These guidelines will be updated at least annually by the collaborative efforts of the panel members based on their clinical experience and available scientific evidence.

Literature Search Criteria and Guidelines Update Methodology

Prior to the development of this inaugural version of the NCCN Guidelines® for Management of Immunotherapy-Related Toxicities, a search of the PubMed database was performed to obtain key literature on ICI-related toxicity in patients with cancer. The PubMed database

was chosen, as it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.

The search results were narrowed by selecting studies in humans published in English and their potential relevance was examined. The data from key PubMed articles identified by the panel for review during the NCCN Guidelines update meeting as well as articles from additional sources deemed as relevant to these guidelines and discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). Recommendations for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available at www.NCCN.org.

The Role of the Immune System in Cancer

Dynamic interactions take place between the immune system and cancer cells, whereby immune cells can detect genetic and cellular abnormalities present on cancer cells. Various mechanisms are in place to closely regulate the activation and function of immune system effectors. However, malignant cells can also modulate immune cell activity, thus evading recognition and destruction by the immune system. This section provides a brief overview of the relationship between the immune system and tumors, and how immunotherapy targets effector cells in the immune system to activate and enhance the antitumor response.

Immunosurveillance refers to the process by which the immune system can screen for, recognize, and respond to foreign pathogens or abnormal (ie, precancerous, cancerous) cells within the body. The theory of cancer immunosurveillance has been incorporated into the larger concept of cancer immunoediting, which details several phases

of the interaction between cancer and the immune system: elimination, equilibrium, and escape. In the elimination phase, a strong response to an immunogenic tumor leads to successful elimination of tumor cells. When the immune system is unable to completely eliminate the tumor, a phase of equilibrium occurs whereby the tumor remains present without progression or metastasis. Persistent equilibrium can lead to the selection of cells that have mutated to resist or avoid the antitumor immune response. This is described as the escape phase, when tumor cells “escape” the antitumor immune response, leading to tumor growth and progression to cancer.³⁻⁷

Conditions or events that compromise the immune system can lead to cancer cells escaping immunosurveillance.^{4,8,9} Once cancer cells have escaped immunosurveillance and have begun to proliferate, their genetic and phenotypic plasticity enable them to develop additional mechanisms by which the tumor can evade, thwart, or even exploit the immune system.^{4,8,9}

The immune system is capable of mobilizing immune effector cells in response to cancer cells. Immunotherapies harness the immune system to attack and destroy tumors by regulating molecules involved in immune cell activation. In doing so, immunotherapy seeks to activate or reactivate the antitumor immune response to overcome or circumvent the immune evasion or “escape” mechanisms employed by cancer cells and tumors.

Evolution of Cancer Immunotherapy

Initial approaches to immunotherapy for cancer are focused on enhancing the immune system’s antitumor response by targeting cytokines and other molecules responsible for regulating immune cell activity. Some examples of earlier-generation cancer immunotherapy include interleukin-2 (IL-2) and interferon (IFN) alfa-2b, which have been used to treat malignancies such as melanoma and renal cell

carcinoma (RCC). However, a low therapeutic index and suboptimal efficacy limit the use and impact of these agents.^{10,11} Lenalidomide and pomalidomide, immunomodulatory agents used for treating multiple myeloma, represent another prior approach to cancer immunotherapy.^{12,13} These agents have a complex mechanism of action that results in the costimulation of T cells and NK (natural killer) cells, increased IL-2 and IFN gamma production, and decreased IL-6 and tumor necrosis factor (TNF)-alpha levels, among other effects.¹²⁻¹⁴ However, the landscape of cancer care has undergone a dramatic shift with the recent approval of a new generation of cancer immunotherapies during the past 8 years.

Notable new treatments that have recently received FDA approval include ICIs and CAR T-cell therapies. ICIs comprise a novel class of agents that target immune cell “checkpoints,” such as programmed cell death-1 (PD-1; eg, nivolumab, pembrolizumab^{15,16}) and PD-1 ligand (PD-L1; eg, atezolizumab, avelumab, durvalumab¹⁷⁻¹⁹), as well as cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4; eg, ipilimumab,²⁰ tremelimumab [under investigation]). Indications for ICIs have expanded dramatically and now include patients with lung (non-small cell and small cell cancers), head and neck, bladder, kidney, gastric, ovarian, and liver cancers, as well as melanoma, Hodgkin lymphoma, Merkel cell carcinoma, and tumors deficient in DNA mismatch repair mechanisms. ICIs, which were initially indicated for pretreated advanced disease, have moved into earlier treatment settings.¹⁵

The most recent addition to the cancer immunotherapy armamentarium is CAR T-cell therapy. Current approaches involve CD-19–directed genetic engineering of autologous T cells to enable the patient’s immune system to recognize and kill tumor cells. Currently approved CAR T-cell therapies include axicabtagene ciloleucel for diffuse large B-cell lymphomas (DLBCLs) and tisagenlecleucel for B-cell precursor acute lymphoblastic leukemia (ALL) and DLBCL.^{21,22}

Immune Checkpoint Inhibitors

Some of the most effective immunotherapies to date target immune checkpoints exploited by cancers to decrease immune activity. This section will provide a general overview of the mechanism of action of ICIs and discuss what is known regarding ICI-mediated immune dysfunction. For a discussion of the efficacy data for ICIs, please see the NCCN Guidelines for Treatment of Cancer by Site at www.NCCN.org.

Mechanism of Action

T-cell activation is an essential component of antitumor immunity, requiring costimulation through more than one mechanism. Binding of antigen-specific T-cell receptor (TCR) to major histocompatibility complex (MHC) on antigen-presenting cells (APCs) must be accompanied by costimulatory signals. CD28 is a well-characterized costimulatory factor expressed on T cells. Adequate CD28 binding to B7 family of costimulatory factors (CD80 [B7-1] or CD86 [B7-2]) on APCs is required for T-cell proliferation and full activation. The presence of growth factors such as IL-2 promotes T-cell differentiation and survival.^{23,24}

Since unopposed immune activation can lead to a number of tissue-damaging consequences, the immune system has evolved to have complex self-regulatory mechanisms to control or dampen immune responses. This immunologic tolerance is maintained through a variety of mechanisms that include regulatory immune cells, immunosuppressive cytokines and chemokines, and immune checkpoint signaling. Immune checkpoint proteins such as CTLA-4 and PD-1 are closely regulated by immune cells to modulate T-cell activity. When bound by endogenous ligands, these receptors initiate a signaling cascade that suppresses T-cell activation, limiting the immune response. Cancer cells coopt the various mechanisms of immune

tolerance, including immune checkpoints to evade recognition by the immune system. Antibodies have been designed to bind these receptors to prevent receptor-ligand interaction, thus removing inhibition of T-cell activation. In doing so, the inhibitory interactions between tumor cells and infiltrating T cells are blocked, reversing T-cell tolerance. This process “releases the brake” on the immune response, promoting the immune system to mount an antitumor response.²⁵⁻³⁴

CTLA-4 Inhibitors

CTLA-4 is expressed by CD4+ (helper), CD8+ (cytotoxic) T cells, as well as regulatory T cells (Tregs). CTLA-4 functions as an early inhibitory signal during the priming phase for T-cell activation, typically within the lymph nodes. CTLA-4 cell surface expression is upregulated by several factors including TCR activation and certain cytokines. Early studies identified CTLA-4 as a negative regulator of T-cell activation through its high-affinity binding to costimulatory factors of the B7 family (ie, CD80 and CD86) at the surface of APCs. CTLA-4 outcompetes CD28 for binding to costimulatory factors on APCs, acting as a brake on this mechanism for T-cell activation by reducing IL-2 production and T-cell proliferation and survival. The relative degree of signaling through CD28/B7 versus CD28/CTLA-4 determines activation versus anergy of T cells.^{23,24,35-38} Subsequent studies revealed the potential role of CTLA-4 blockade in the antitumor response.³⁹ CTLA-4 blockade results in greater numbers of effector T-cell clones becoming active and proliferating while reducing the immunosuppressive activity of Tregs.^{24,40,41}

PD-1/PD-L1 Inhibitors

PD-1 receptor is present on the cell surface of various immune cells such as T cells, B cells, and NK cells. Its ligands, PD-L1 and PD-L2, have differential tissue expression. PD-L1 is expressed by a wide variety of tissues types, including tumor cells, whereas PD-L2 expression is mainly restricted to hematopoietic cells. PD-1 signaling

exerts an inhibitory effect during the effector phase through inhibition of previously activated T cells primarily in the peripheral tissues. It decreases T-cell proliferation through reduced production of IFN-gamma, TNF alpha, and IL-2. In addition to blocking tumor cell apoptosis, PD-1 interaction with PD-L1/2 can lead to the progressive loss of T-cell functions (ie, T-cell exhaustion) and drive the conversion of T effector cells to Treg cells with immunosuppressive properties.^{24,42-47} Studies have implicated PD-1 signaling in the antitumor response.⁴⁸ Blockade of the PD-1/PD-L1 interaction can lead to the reactivation of T-cell populations that have become exhausted following prolonged antigen exposure, such as quiescent antitumor T cells.^{24,43,49}

ICI-mediated Immune Dysfunction

The pharmacodynamics and pharmacokinetics of ICI immunotherapy differ greatly from that of cytotoxic chemotherapy or targeted anti-cancer therapy.⁵⁰ Similarly, anti-CTLA-4 and anti-PD-1/PD-L1 immunotherapies are associated with toxicity profiles that are distinct from those observed with conventional anti-cancer therapies, though their presentation may at times be similar.⁵¹⁻⁵⁷ Whereas traditional cytotoxic chemotherapy often results in acute-onset emetic and myelosuppressive effects, irAEs tend to be relatively delayed-onset and inflammatory or autoimmune in nature.⁵⁸⁻⁶¹

Although the pathophysiology of ICI-related irAEs is not yet fully elucidated, knowledge regarding the role of immune checkpoint pathways in autoimmune disease provides some clues. Many autoimmune diseases are related to failure of T-cell tolerance and uncontrolled activation of immune effector cells. Alterations in the genes encoding immune checkpoint proteins have been implicated in autoimmune disease. CTLA-4 and PD-1 polymorphisms have been linked to human autoimmune diseases including Celiac disease, diabetes mellitus, lupus, rheumatoid arthritis, and autoimmune thyroid disease. The spectra of irAEs associated with blockade of

immune checkpoints falls in line with the phenotypes observed as a result of mutations in the genes encoding CTLA-4 and PD-1 and has considerable overlap across the various ICIs.⁶²⁻⁶⁵

The precise pathophysiology of ICI-mediated irAEs is currently unknown. Translational research provides some evidence that irAEs may result from some combination of autoreactive T cells, autoantibodies, and/or proinflammatory cytokines (eg, interleukin-17).^{64,66} One potential mechanism is T-cell activity directed at antigens present in both tumor cells and healthy tissue.^{67,68} Inflammation in otherwise normal tissues could result from elevated levels of inflammatory cytokines as a downstream effect of T-cell activation.⁶⁹⁻⁷² Additionally, direct binding of immune checkpoint antibodies to targets expressed in normal tissues (eg, CTLA expression in the pituitary) could lead to complement-mediated inflammation.^{73,74} Finally, immunotherapy might increase the levels of preexisting autoreactive antibodies.⁷⁵

Early- and later-onset irAEs may result from distinct mechanisms that have yet to be elucidated. Typical earlier-onset, common irAEs appear to involve generalized epithelial inflammation and may be observed in the form of rash, colitis, and pneumonitis. These irAEs typically involve recruitment of neutrophils into normal tissues. Later-onset irAEs, which are typically less common, can include neurologic events and hypophysitis, among others. These tend to be more localized, organ-specific reactions. Research is ongoing into the specific mechanisms underlying irAEs associated with specific ICIs.

Incidence and Prevalence of irAEs

The incidence and prevalence of ICI-related toxicity is still being fully elucidated; much of the existing figures are based on trials of ipilimumab, pembrolizumab, and nivolumab. Comprehensive irAE data on newer agents are still being collected and analyzed. Due to the nature of irAEs and inconsistent reporting, it is likely that reported

rates underestimate the actual incidence of these events. The reported incidence of any-grade irAEs associated with single-agent ICI treatment ranges widely across agents and trials, from approximately 15% to 90%.^{1,76} Severe irAEs requiring immunosuppression and hold or discontinuation of treatment are estimated between 0.5% and 13% for monotherapy.⁷⁶ Analysis of pooled trial data found that 43% of patients discontinued combination therapy (nivolumab/ipilimumab) due to AEs, with gastrointestinal (GI) events being the most commonly reported reason for discontinuation.⁷⁷ ICI immunotherapies have been associated with rare AEs that are still in the process of being identified and studied at high-volume centers.

Single-Agent Therapy

CTLA-4

A 2015 meta-analysis by Bertrand, et al examined data from 1265 patients across 22 clinical trials of anti-CTLA-4 antibodies (ipilimumab [n = 1132] and tremelimumab [n = 133]), reporting an overall incidence of 72% for any-grade irAEs and 24% for high-grade irAEs.⁷⁸ The most commonly observed AEs were dermatologic and GI, followed by endocrine and hepatic events. A randomized, double-blind, phase III trial in patients with unresectable or metastatic melanoma revealed a dose-dependent effect in treatment-related AEs for patients receiving ipilimumab at a dose of 3 mg/kg (n = 362) or 10 mg/kg (n = 364).⁷⁹ High-grade irAEs were reported in 18% and 30% of the 3 mg/kg and 10 mg/kg treatment groups, with 2 and 4 treatment-related deaths, respectively. The most common high-grade AEs, including diarrhea, colitis, elevated liver enzymes, and hypophysitis, were all more common at the higher dose of ipilimumab.⁷⁹ Adjuvant use of ipilimumab (10 mg/kg) for resected stage III melanoma appears to be associated with a higher incidence of AEs. Based on phase III data in patients receiving adjuvant ipilimumab (n = 475), the incidence of high-grade irAEs was 41.6% with 5 fatalities (1.1%).^{80,81}

PD-1/PD-L1

For PD-1/PD-L1 inhibitors, the reported overall incidence of any-grade irAEs was up to 30% based on patients in phase III trials.^{1,82-84} To date, the incidence of high-grade AEs associated with PD-1/PD-L1 inhibitors appears to be somewhat less dose-dependent than ipilimumab and to vary by disease site.⁷⁶ In a recent meta-analysis of anti-PD-1/PD-L1 agents, any-grade and severe-grade irAEs occurred in about 26.8% and 6.1% of patients, respectively.⁸⁵ Rates of high-grade irAEs were similar across pembrolizumab, nivolumab, and atezolizumab, ranging from 5% to 8%.⁸⁵

De Velasco and colleagues recently reported on the incidence of the most common ICI-associated irAEs in a meta-analysis of 21 randomized phase II/III trials conducted from 1996 to 2016, which included a total of 6528 patients who received monotherapy (atezolizumab, n = 751; ipilimumab, n = 721; nivolumab, n = 1534; pembrolizumab, n = 1522) and 4926 patients in placebo or standard therapy control arms using chemotherapy or biologic agents.⁸⁶ Due to inconsistent recognition and reporting of less-common irAEs in the clinical trial data, this meta-analysis was limited to examination of 5 common and well-documented types of irAEs: colitis, liver toxicity (AST elevation), rash, hypothyroidism, and pneumonitis. When compared to patients in trial control arms, patients receiving ICIs were found to be at greater risk for any-grade immune-related colitis, AST elevation, rash, hypothyroidism, and pneumonitis. Within this cohort, across all ICIs, the incidence of grade 3/4 events was 1.5% for colitis, 1.5% for liver toxicity, 1.1% for rash, 0.3% for hypothyroidism, and 1.1% for pneumonitis. High-grade colitis and rash were significantly more common among patients on ipilimumab than in those receiving PD-1/PD-L1 inhibitor.⁸⁶ In a separate review of the data, Kumar and colleagues also compared the risk of developing certain irAEs with different classes of ICIs.⁷⁶ While ipilimumab was associated with higher rates of colitis, pruritus, rash, and hypophysitis, PD-1/PD-L1 inhibitors resulted in a higher risk

for developing vitiligo (typically observed in patients with melanoma), thyroid dysfunction, hepatotoxicity, and pneumonitis.⁷⁶

De Velasco, et al compared the risk of developing specific irAEs by tumor type (melanoma, lung, and other), reporting no significant differences for all-grade or high-grade irAEs.⁸⁶ Khoja, et al also conducted a systematic review of irAEs by ICI class and tumor type in 6869 patients from 48 trials between 2003 and 2015,⁸⁷ with probable considerable overlap in patient population from the De Velasco study. Although most findings were similar, Khoja and colleagues' findings deviated slightly when analyzing irAE incidence according to tumor histology in patients treated with PD-1 inhibitors. They found that patients with melanoma experienced higher incidence of GI and skin irAEs but a lower incidence of pneumonitis compared with NSCLC. Patients with melanoma experienced arthritis and myalgia more commonly than those with RCC, but patients with RCC experienced higher frequency of pneumonitis and dyspnea. However, comparisons of irAE incidence across disease type were not adjusted for patient factors such as smoking history and age. Similar comparisons were not possible for CTLA-4 blockade since the majority of available data was on patients with melanoma.⁸⁷

The safety data for PD-L1 inhibitors are still maturing and data collection is ongoing. Comparison of irAE incidence for PD-1 versus PD-L1 inhibitors have been calculated primarily from data published on patients with non-small cell lung cancer (NSCLC). A 2018 meta-analysis compared the data on toxicity profiles of PD-1 and PD-L1 inhibitors from 23 studies that occurred between 2013 and 2016 (PD-1: n = 3284; PD-L1: n = 2460).⁸⁸ A near-significant trend revealed irAEs to be more common with PD-1 versus PD-L1 blockade (16% vs. 11%; $P = .07$). However, the incidence of severe irAEs was not significantly different between PD-L1 and PD-1 inhibitors, (5% vs. 3%, $P = 0.4$). Pneumonitis occurred twice as often with PD-1 inhibitors (4% vs. 2%; $P = .01$) and

hypothyroidism was also more common with PD-1 inhibitors (6.7% vs. 4.2%; $P = .07$).⁸⁸ Similar findings were reported in a 2017 meta-analysis of data on pneumonitis incidence with PD-1 inhibitors (12 trials, n = 3232) and PD-L1 inhibitors (7 trials, n = 1806).⁸⁹ For PD-1 versus PD-L1 inhibitors, the incidence for any-grade pneumonitis was 3.6% versus 1.3% ($P = .001$) and 1.1% versus 0.4% for high-grade pneumonitis ($P = .02$).⁸⁹

Combination Therapy

Numerous ongoing studies are examining regimens that include ICIs given in combination with another ICI, chemotherapy, or targeted agent. While combination regimens offer the potential for enhanced efficacy, in general, observed toxicity with ICI-based combination regimens is greater than that for ICI monotherapy. Combined PD-1 plus CTLA-4 blockade triggers substantially more irAEs than anti-PD-1 agents alone, with high-grade events reported for 55% to 60% of individuals receiving combination therapy versus 10% to 20% of individuals receiving anti-PD-1 monotherapy.⁹⁰⁻⁹² Studies have begun to investigate the extent to which combination therapies pose clinical safety and tolerability challenges, and whether these challenges will limit their usefulness as anticancer therapy.⁹³⁻⁹⁶

The only current FDA-approved regimen using combined ICI therapy is nivolumab plus ipilimumab for treating advanced melanoma, RCC, or microsatellite-unstable tumors.^{16,20} Nivolumab plus ipilimumab resulted in enhanced survival outcomes compared with ipilimumab monotherapy in advanced melanoma.^{92,97} In the phase III CheckMate 067 trial of nivolumab plus ipilimumab versus ipilimumab or nivolumab monotherapy (n = 945, randomized in a 1:1:1 ratio), treatment-related AEs occurred in 96% of patients receiving combination therapy and 86% of those treated with monotherapy. Although no unique toxicities were identified in patients receiving ICI combination therapy, the incidence of high-grade irAEs for combination therapy (59%) was

more than twice the incidence for single-agent nivolumab (21%) and ipilimumab (28%). The percentages of patients discontinuing treatment due to any-grade treatment-related AEs were 39%, 12%, and 16% for patients receiving combination therapy, nivolumab, and ipilimumab, respectively. Preliminary findings suggest that early discontinuation due to irAEs (after a median of 3 doses) may not compromise the survival benefit, as evidenced by a 3-year survival rate of 67%.⁹²

The KEYNOTE-029 trial began to investigate whether standard-dose pembrolizumab in combination with reduced-dose ipilimumab may be more tolerable than full-dose ICI combinations.⁹⁸ Dose-modified nivolumab plus ipilimumab regimens are also under investigation for NSCLC and small cell lung cancer (SCLC),^{99,100} and nivolumab plus ipilimumab is recommended by the NCCN Guidelines for Small Cell Lung Cancer.

Safety data have also been published for early-phase investigations of ICI therapy in combination with additional targeted agents or chemotherapeutics.¹⁰¹⁻¹⁰³ Immune checkpoint blockade given in combination with radiation therapy is also the subject of investigation.^{104,105}

ICI Therapy-Related Fatal irAEs

A recently published systematic review and meta-analysis examined fatal irAEs from ICI therapy using data from multiple sources.⁹¹ Meta-analysis of data from 112 published trials (n = 19,217) compared the rate of fatal irAEs by agent. Similar rates of fatal irAEs were reported for anti-PD-1 (0.36%) and anti-PD-L1 agents (0.38%), with significantly higher rates of fatal irAEs reported for anti-CTLA-4 monotherapy (1.08%) and anti-PD-1/PD-L1 + anti-CTLA-4 combination regimens (1.23%). For ipilimumab monotherapy, significantly fewer fatal irAEs occurred at the 3 mg/kg dose than 10 mg/kg dose. However, when used

in combination with anti-PD-1 therapy, no significant difference in fatal irAE rate was observed for ipilimumab at 1mg/kg versus 3 mg/kg dose.⁹¹

Examination of 613 cases of fatal ICI-related irAEs reported in the WHO pharmacovigilance database revealed that certain ICI agents were associated with a different spectrum of fatal irAEs.⁹¹ The majority of fatal irAEs associated with ipilimumab monotherapy were due to colitis (70%), with smaller proportions of hepatitis and pneumonitis-related deaths. However, fatal irAEs with anti-PD-1/PD-L1 therapy were distributed more broadly: pneumonitis (35%), hepatitis (22%), colitis (17%), neurologic events (15%), and myocarditis (8%). Among the fatal irAEs reported for combination regimens (ipilimumab plus anti-PD-1/PD-L1), colitis was most common (37%), followed by myocarditis (25%), hepatitis (22%), pneumonitis (14%), and myositis (13%). When fatality rates were assessed across different types of irAEs, myocarditis was associated with the highest risk of death (52/131 cases, 39.7%). Fatality rates for patients with hepatitis, pneumonitis, nephritis, and neurologic events ranged between 10% and 17%, while ≤5% of hypophysitis, adrenal insufficiency, and colitis cases proved fatal.⁹¹

Finally, temporal patterns of fatal irAEs were examined using combined pharmacovigilance case reports and multicenter retrospective data review.⁹¹ For irAEs that eventually proved fatal, symptom presentation occurred a median of 40 days after onset of monotherapy with ipilimumab or an anti-PD-1/PD-L1 agent, and 14.5 days after initiation of combination regimens. Median time to death after initiation of ipilimumab monotherapy, anti-PD-1/PD-L1 monotherapy, or combination regimen was 64, 43, and 35 days, respectively.⁹¹

irAEs as a Biomarker of Treatment Response

Investigators have begun to examine whether developing certain ICI-mediated irAEs may be linked to improved treatment response and survival outcomes. An overview of the preliminary findings related to irAEs and treatment outcomes is provided below. Further research into this phenomenon is needed to explore potential patterns.

Historically, induction of cutaneous irAEs was suggested as a positive prognostic factor in patients with melanoma who received various types of immunotherapy.¹⁰⁶ A retrospective review found that cutaneous irAEs, particularly vitiligo, may be associated with improved treatment response with pembrolizumab.¹⁰⁷⁻¹⁰⁹ In patients with melanoma who received nivolumab, rash and vitiligo were both associated with improved overall survival (OS).¹¹⁰ The potential relationship between development of GI irAEs and survival outcomes has also been investigated. A retrospective analysis of 327 patients found an association between GI irAEs and OS, with diarrhea being an independent predictor of OS regardless of whether immunosuppressive therapy was required to manage this irAE.¹¹¹

In a prospective cohort of 524 patients receiving ICI therapy, patients who developed rheumatologic irAEs had a higher tumor response rate compared with patients who experienced no irAEs (85.7% vs. 35.3%; $P < .0001$).¹¹² Additionally, early data suggest a possible association between the development of neurologic irAEs and favorable disease response. Durable disease response has been reported in the setting of neurologic irAEs despite early discontinuation of ICI.¹¹³

However, in a retrospective review of 298 patients who received ipilimumab for metastatic melanoma, the occurrence of any-grade irAEs was not associated with OS or time to treatment failure (TTF).¹¹⁴ The authors also found no association between systemic corticosteroid therapy to manage irAEs and OS or TTF. Along similar lines,

investigators have also questioned the impact of early discontinuation of ICI due to toxicity on antitumor efficacy and safety. Schadendorf, et al examined pooled data from randomized phase II/III trials in which patients received combination nivolumab plus ipilimumab therapy ($n = 409$).⁷⁷ Therapy was discontinued due to AEs in 176 patients, including 96 patients who discontinued therapy during the induction phase (in which the majority of high-grade AEs occurred). Overall response rate (ORR) was 58.3% for patients who discontinued therapy due to AEs during induction, versus 50.2% for those who did not discontinue therapy. Although similar, median OS was not reached for either group.⁷⁷

Management of ICI-Related Toxicity

The primary facets of irAE management include recognition and grading of toxicity, immunosuppression, and individualized modification to ICI administration. Early recognition of symptoms and prompt intervention are key goals for the management of immunotherapy-related toxicity. Significant irAEs often necessitate holding immunotherapy, with permanent discontinuation of the class of agent associated with the toxicity in the setting of certain severe irAEs.

General Principles of Immunosuppression

Corticosteroids are the mainstay of treatment for most high-grade irAEs. Importantly, short-term use of corticosteroids to treat irAEs has not been shown to reduce anti-tumor efficacy. Appropriate duration and careful taper of corticosteroid therapy is important to prevent the recurrence of irAEs. Severe or steroid-refractory irAEs may require administration of additional immunosuppressive agents. For patients with severe irAEs not responsive to steroids within 48 to 72 hours, initiation of an additional immunosuppressant agent may be warranted in consultation with the relevant medical specialist. Close monitoring and follow-up

should be performed to assess for response to corticosteroids and other immunosuppressants in the setting of ICI-related toxicity.

Tailored recommendations regarding the use of non-steroid immunosuppressants can be found in the individual irAE treatment algorithms and corresponding discussion sections. Selected endocrine irAEs may be treated with hormonal supplementation without the need for immunosuppression.

Immunomodulators

In these guidelines, recommendation for use of specific immunomodulating agents to manage irAEs are typically extrapolated from evidence for treating autoimmune conditions of the relevant organ system(s). Several commonly used immunosuppressants for managing steroid-refractory or severe irAEs are discussed below.

TNF inhibitors are a class of drugs widely used to block the inflammatory effects of TNF in autoimmune diseases.¹¹⁵ Infliximab is a monoclonal anti-TNF- α antibody used for treating various autoimmune diseases, including Crohn's disease, ulcerative colitis, rheumatoid and psoriatic arthritis, and psoriasis.¹¹⁵⁻¹¹⁷ Infliximab blocks the interaction of TNF α with its receptors, inhibiting induction of pro-inflammatory cytokines (IL-1, IL-6) and modulating the activity of immune effectors such as leukocytes, neutrophils, and eosinophils.^{117,118} Infliximab has become a commonly used agent for treating steroid-refractory irAEs that develop during ICI therapy.^{64,119} For patients with severe irAEs not responsive to steroids within 48 to 72 hours, early initiation of anti-TNF α therapy (ie, at 72 hours) may be warranted in consultation with the relevant medical specialist. Duration of therapy with TNF-alpha blockers for irAEs is not clearly defined, but is typically a single dose. A second dose of anti-TNF α therapy may be required, and can be administered 2 weeks after initial dose of infliximab. Anti-TNF α agents (eg, infliximab)

are particularly effective in management of immune-related colitis and inflammatory arthritis (IA).

Vedolizumab is an integrin antagonist that binds to $\alpha 4\beta 7$ integrin, blocking its interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1), inhibiting the migration of T cells across the endothelium into inflamed GI tissues. Vedolizumab is currently indicated for treating GI inflammation due to ulcerative colitis and Crohn's disease.^{120,121} Case reports have described the use of vedolizumab for treating ICI-induced enterocolitis.^{121,122} Vedolizumab may provide more specific immune suppression for the inflamed GI mucosa, hence theoretically sparing systemic immune suppression and anti-tumor immune responses.

Mycophenolate-containing medicines are immunosuppressive agents used for preventing organ rejection after transplant (ie, kidney, heart, liver). It is available as mycophenolic acid (MPA) or as mycophenolate mofetil (MMF), a prodrug of MPA.^{123,124} These agents have multiple immunosuppressive actions, which result in decreased B- and T-cell proliferation, T-cell apoptosis, and suppression of dendritic cells and IL-1.^{125,126} Published studies also support the clinical efficacy of these mycophenolate in various inflammatory or autoimmune conditions, such as autoimmune hepatitis, myositis, bullous disease, interstitial lung disease, and lupus nephritis, among others.¹²⁷⁻¹³² Retrospective analyses and case reports describe the use of mycophenolate in the management of steroid-refractory irAEs, including those involving the liver, kidney, pancreas, and eyes.^{90,133-136}

Intravenous immunoglobulin (IVIG) has been used to suppress a wide array of autoimmune and chronic inflammatory conditions.^{137,138} It is comprised of pooled IgG immunoglobulins harvested from the plasma of healthy blood donors and prepared for intravenous (IV) administration. The immunomodulatory mechanisms of IVIG are not fully understood, but it is known to modulate the activity and effector functions of B

and T lymphocytes, impacting antigen presentation, pathogenic autoantibodies, complement system, and cytokines.¹³⁸⁻¹⁴⁰ Efficacy has been demonstrated in neurologic inflammatory or autoimmune conditions such as Guillain-Barré syndrome (GBS), myasthenia gravis, neuropathies, rheumatologic conditions, blistering disorders, immune hematologic conditions, and many others.^{141,142}

Plasmapheresis is a type of therapy that may be indicated when a substance in the plasma, such as immunoglobulin, becomes acutely toxic, as can occur during certain autoimmune reactions. During plasmapheresis, the blood contents are separated extracorporeally, resulting in removal of the plasma and subsequent therapeutic plasma exchange via infusion. Indications for which this procedure is a first-line therapy include neurologic conditions such as myasthenia gravis and GBS, but it is also indicated for various other autoimmune conditions.¹⁴³ Plasmapheresis (and IVIG) is often indicated as a second-line therapy for managing neurologic irAEs after limited or non-response to initial high-dose corticosteroid.¹⁴⁴ However, success in treating severe and often rapidly progressive neurologic irAEs has been mixed.¹⁴⁴⁻¹⁴⁶

Additional agents that have been used less frequently as part of advanced lines of immunosuppressive therapy include rituximab, tacrolimus, tocilizumab, cyclosporine, cyclophosphamide, methotrexate, and antirheumatic agents (eg, sulfasalazine, leflunomide).

Considerations for Patients on Immunosuppressants

Additional supportive care measures are needed for patients receiving an immunosuppressive regimen. Hyperglycemia, gastritis, opportunistic bacterial or fungal infections, and osteoporosis can occur with a longer-term systemic corticosteroid.¹⁴⁷⁻¹⁵² The panel recommends blood glucose monitoring and various prophylactic measures. For patients at higher risk of developing gastritis (ie, those taking nonsteroidal anti-inflammatory drugs [NSAIDs] or anticoagulants), histamine 2

(H2) blockers or proton pump inhibitors can be given during steroid therapy. Consider prophylactic antimicrobial and antifungal agents. Prophylaxis against pneumocystis jiroveci pneumonia (PJP) should be considered in patients receiving a prednisone equivalent of ≥ 20 mg/day for 4 or more weeks, with general prophylaxis against fungal infections (ie, fluconazole) for patients receiving a prednisone equivalent of ≥ 20 mg/day for 6 or more weeks. Consider prophylaxis against zoster reactivation. Lastly, vitamin D and calcium supplementation is recommended to reduce the risk of osteoporosis.

Anti-TNF- α therapy may pose a risk of reactivating viral infections such as viral hepatitis or tuberculosis (TB).¹⁵³⁻¹⁵⁶ The panel recommends testing for hepatitis B and C virus prior to TNF inhibition, and carriers should be monitored during and for several months after immunosuppressive therapy. Additionally, testing for latent/active TB is recommended prior to initiation of infliximab therapy; IFN-gamma release assays are preferred. However, TB testing should not delay initiation of anti-TNF α agents for the management of acute severe or refractory irAEs.

Impact of Immunosuppressive Agents on Immunotherapy Efficacy

Although no prospective data exist, retrospective data generally suggest that immunosuppressive therapy initiated after onset of irAEs does not appear to decrease ICI efficacy. Results were recently published from a pooled analysis of 4 studies enrolling 576 patients who received nivolumab for advanced melanoma.¹⁵⁷ When adjusting for the number of nivolumab doses, ORR was higher among patients who experienced all-grade irAEs compared with those who did not. Among the 474 phase III trial participants, 114 (24%) received systemic corticosteroids for managing irAEs. ORR was not significantly different between patients who required corticosteroids and those who did not.¹⁵⁷ Similar findings were reported by an earlier retrospective analysis of 298 patients with metastatic melanoma who were treated with ipilimumab.¹¹⁴ Within this

cohort, 103 (35%) required corticosteroid therapy to manage irAEs, and 29 of these patients (10%) also required anti-TNF alpha therapy to address unresolved symptoms. OS and TTF were not impacted by the development of irAEs or the need for corticosteroid therapy to manage them.¹¹⁴ Similarly, among a pooled group of 409 patients who received nivolumab plus ipilimumab combination therapy as part of CheckMate 067 and 069, ORR was not reduced among patients who required corticosteroid therapy to manage irAEs relative to the rest of the cohort.^{77,158}

Investigators have also analyzed whether immunosuppression via TNF antagonist had a negative impact on combination ICI therapy response. Based on retrospective analysis of data from CheckMate 067 and 069, using infliximab to manage colitis did not appear to alter the kinetics of tumor response or durability.⁷⁷ Another analysis of pooled data from these trials demonstrated similar survival outcomes between patients with GI irAEs who received corticosteroid therapy ± infliximab and patients with GI irAEs who did not receive immunosuppressive agents.¹⁵⁸

Due to clinical trial exclusion criteria, less is known about the impact of immunosuppressants on ICI efficacy when given prior to ICI therapy. A recent retrospective study identified 90 individuals who were on baseline corticosteroid therapy (≥10 prednisone equivalent daily) from a cohort of 640 patients with NSCLC on anti-PD-1/PD-L1 monotherapy. Baseline corticosteroid therapy was associated with poorer outcomes from ICI therapy, as indicated by decreased ORR, progression-free survival (PFS), and OS.¹⁵⁹ Additional research will be needed to better understand the potential impact of corticosteroid exposure prior to or during ICI therapy initiation, especially as it pertains to premedication with corticosteroid prior to ICI infusion.

Managing irAEs in Special Patient Populations

Patients with Prior irAEs or Pre-existing Autoimmune Conditions

In patients with pre-existing autoimmune disease, exacerbation of autoimmunity is a concern with the administration of immune-activating agents. Similarly, ICI therapy must be approached cautiously among patients who have experienced a prior irAE while receiving immunotherapy. Data on the toxicity of ICIs in patients with preexisting autoimmune disease or irAEs is generally lacking due to exclusion of these populations from clinical trials leading to FDA approval. Based on limited data from smaller retrospective studies, ICIs appear to be similarly effective in these patient groups with response rates of 20% to 40%.¹⁶⁰⁻¹⁶² Based on the available data, most autoimmune disease flares and irAEs in this patient population have been managed with corticosteroid or additional immunosuppressive therapy; however, fatal AEs have been reported.¹⁶³ Preliminary data on safety and toxicity are described below.

In the largest series to date, ipilimumab therapy was provided to a cohort of 30 patients with advanced melanoma and pre-existing autoimmune disorders including inflammatory bowel disease (n = 6), rheumatoid arthritis (n = 6), psoriasis (n = 5), systemic lupus erythematosus (n = 2), multiple sclerosis (n = 2), autoimmune thyroiditis (n = 2), and various others.¹⁶² Thirteen of 30 patients were taking immunosuppressive therapy to manage their conditions. While on ipilimumab, 27% of patients experienced exacerbation of their autoimmune condition, typically in the form of recurrent or enhanced preexisting symptoms. Most were managed successfully using corticosteroid, with 2 patients requiring infliximab. Ten patients (33%) experienced conventional high-grade irAEs considered unrelated to their baseline autoimmune condition (including one fatality due to colitis in a patient with skin-limited psoriasis). Three patients experienced concurrent autoimmune condition flares and conventional

irAEs requiring high-dose corticosteroid. However, half of the cohort experienced no irAEs or autoimmune condition flare.¹⁶²

Studies have also examined the effects of PD-1 inhibitors for advanced melanoma in patients with pre-existing autoimmune disease.^{160,161}

Among a subset of 19 patients with prior autoimmune disease, PD-1 inhibition led to autoimmune flare in 42%, and onset of a new irAE in 16%.¹⁶⁰ In a separate study of 52 patients with significant autoimmune conditions (eg, rheumatoid arthritis, polymyalgia rheumatica, Sjögren's syndrome, immune thrombocytopenic purpura, psoriasis), 38% had an autoimmune condition flare requiring immunosuppression, and 29% developed a new irAE.¹⁶¹ Interestingly, no members of that cohort with GI or neurologic autoimmune conditions (n = 11) experienced a flare.¹⁶¹ In both studies of PD-1 inhibitors, most flares of preexisting autoimmune conditions were adequately managed using immunosuppressive and symptomatic therapy.^{160,161} However, onset of new irAEs led to discontinuation of PD-1 inhibitor in about 10% of patients in one study.¹⁶¹

Reviews of the data have also probed the impact of PD-1 inhibitor therapy for treating melanoma in patients who developed prior treatment-related irAEs during ipilimumab monotherapy or combination CTLA-4/PD-1 blockade.^{160,161,164} Among the 22 patients with ipilimumab-related irAEs described by Gutzmer et al, treatment with a PD-1 inhibitor led to a flare of the prior irAE in 4.5% of patients, while 23% developed a new irAE. In another study of 67 patients with prior ipilimumab-related irAEs requiring immunosuppression, flare was reported in 3% of patients, and 34% developed new irAEs.¹⁶¹

Nivolumab or pembrolizumab monotherapy was resumed in a cohort of 80 patients who had previously discontinued combination ICI therapy due to irAEs.¹⁶⁴ Upon resumption of PD-1 inhibitor, 14 patients (18%) experienced a recurrence of the same irAE and 17 patients (21%)

experienced clinically significant “distinct” or de novo irAEs. Half of the cohort (n = 40) experienced any-grade irAE, with high-grade toxicity in 18% (n = 14). Twenty-four patients (30%) discontinued PD-1 monotherapy due to irAE. Colitis and neurologic toxicities were found to be least likely to recur, whereas hepatitis, pancreatitis, nephritis, and pneumonitis recurred more commonly. Symptomatic hypophysitis and rash were assessed as intermediate risk for recurrence; however, 1 fatality occurred due to recurrent and worsening rash and bullous disease. Due to the relatively high rate of severe but distinct irAEs that were observed during anti-PD-1 agent rechallenge (21%), the authors posited two potential explanations. First, patients could be predisposed to subsequent toxicity due to immune priming by ICI combination therapy, and second, delayed presentation of irAEs due to combination therapy-related toxicity could have occurred.¹⁶⁴ Additional research is needed to understand the safety of ICI therapy in this population and others at a potentially greater risk for developing irAEs.

NCCN Recommendations

Optimization of immunosuppression for pre-existing autoimmune conditions and close cooperation with pertinent subspecialists is recommended. These guidelines suggest a goal of immunosuppressive regimen allowing for prednisone dose of <10 mg daily (or equivalent) prior to initiating cancer immunotherapy. However, patients with autoimmune neurologic conditions or life-threatening autoimmune disorders are unlikely to be suitable candidates for ICI immunotherapy. Additionally, ICI therapy may not be appropriate for patients whose autoimmune conditions are inadequately controlled using immunosuppressive medications, or for those who require high doses of immunosuppressive agents to manage their condition.

Caution should be exercised when considering resumption of ICI therapy for patients who have experienced a previous treatment-related irAE. A key consideration is the patient's tumor response. In patients

with responding or stable disease, it may be prudent to continue close surveillance and to re-introduce ICI therapy if the patient develops evidence of progression of cancer. As appropriate, consult with organ-specific specialists prior to resumption. With some exceptions, resumption of ICI therapy after a grade 2 irAE can be considered once signs and symptoms have resolved to grade 1 or below. Perform close follow-up to monitor for any signs or symptoms of irAE recurrence. If toxicity returns upon ICI rechallenge, permanently discontinue that class of ICI.

In the setting of most severe (and some moderate) irAEs, permanent discontinuation of that given class of immunotherapy is typically warranted. For example, if a patient experiences grade 3 or 4 toxicity from an ipilimumab-containing regimen, consideration may be given to later therapy with anti-PD-1/PD-L1 monotherapy upon full resolution of any earlier toxicity.

Organ Transplant Recipients

Concerns regarding graft rejection in transplant recipients has led to the exclusion of this patient population from many clinical trials of ICI therapy.¹⁶⁵ Safety and efficacy data on ICI therapy in patients who have received a prior organ transplant are limited to a small number of case reports. Safe ipilimumab use has been reported in several patients who received kidney or liver transplants.¹⁶⁵⁻¹⁶⁸ A 2017 review of 12 case reports on ICI use in transplant recipients identified 4 patients who experienced kidney graft rejection after combination CTLA-4/PD-1 blockade or anti-PD-1 monotherapy.¹⁶⁵ PD-1 inhibition appears to be more commonly associated with graft rejection, suggesting that this pathway may play a more critical role in allograft immune tolerance.^{165,169} Other factors to consider in organ transplant recipients who may be candidates for ICI therapy may include elapsed time between transplant and initiation of immunotherapy, the strength of maintenance

immunosuppressive therapy required to prevent graft rejection, and the immunogenicity of the transplanted organ.^{165,166}

Research is underway to explore alternative immunosuppressive regimens in an effort to reduce allograft rejection during ICI therapy.^{166,169} The safety and utility of immunotherapy is also being investigated in patients with multiple myeloma who may be unable to mount an adequate immune response. In KEYNOTE 183 and KEYNOTE 185, more deaths were observed for treatment arms in which pembrolizumab was added to lenalidomide/dexamethasone or pomalidomide/dexamethasone.¹⁷⁰

NCCN Recommendations

Consideration of ICI therapy in organ transplant recipients is very complex and requires multidisciplinary involvement. Graft failure while on ICI immunotherapy has been reported, and transplant organ loss may be an outcome of treatment. Patients with solid organ transplantation who have a viable option for alternative therapy if graft rejection occurs (ie, kidney and dialysis) may be candidates for immunotherapy, particularly if there is no prior evidence of graft rejection and patients are on a stable maintenance immunosuppression regimen. The possible consequences of ICI therapy should be discussed with the patient and organ transplant team and there should be a plan in place to seamlessly manage the patient if graft loss occurs. Although patients with prior allogeneic stem cell transplant may be candidates for immunotherapy, there is an increased risk of transplant-related complications, including potentially fatal graft-versus-host disease (GVHD). Careful discussion with the patient and stem cell transplant physicians should precede initiation of immunotherapy.

Specific irAE Management

In general, close consultation with disease-specific subspecialists is encouraged during irAE management. Referral to a tertiary care center may be required for management of complex cases or multi-system irAEs. Due to the kinetics of the immune response, the onset of irAEs can occur at any point during treatment or even after completion of therapy.^{171,172} irAE rebound during steroid taper has also been reported. The typical timing and presentation of specific irAEs are discussed below. Please see the corresponding algorithm pages in the guidelines for detailed recommendations on assessing and treating particular irAEs by grade/severity.

Caution and careful judgment are required when considering whether to resume immunotherapy following significant toxicity. Clinicians should assess patient's tumor status prior to rechallenge. If an objective response (complete or partial) to ICI therapy was achieved, resumption of immunotherapy may not be advisable due to risk of toxicity recurrence. The NCCN Panel recommends that clinicians discuss the risks/benefits of restarting immunotherapy with the patient.

Infusion-Related Reactions

Infusion reactions have been reported most commonly with the PD-L1 inhibitor avelumab. Pooled safety data on avelumab reported that 25% of patients experienced any-grade infusion reactions (439/1738) with high-grade events in 0.7% (12/1738); the majority occurred during the first infusion, with nearly all reactions occurring within the first 4 treatment cycles.^{17,173} Premedication appeared to decrease the rate of severe infusion-related reactions (IRRs).¹⁷³ The U.S. prescribing instructions for avelumab include acetaminophen and diphenhydramine prior to infusion during the first 4 treatment cycles.¹⁷

Most infusion reactions associated with ICIs are mild and associated with low-grade fever, chills, headache, or nausea. Severe or high-

grade reactions occurred in <1% of patients across all other ICIs. Incidence of any-grade infusion reactions for the remaining ICIs include atezolizumab at 1.3%, durvalumab at 2.2%, <10% for PD-1 inhibitors, and <1% for ipilimumab monotherapy.^{1,15,16,18-20}

NCCN Recommendations

The panel refers clinicians to the prescribing information for each individual immunotherapy agent for recommendations regarding premedication to prevent infusion reactions. In the absence of specific indications such as prior IRR or concurrent chemotherapy, routine premedication with corticosteroids prior to receiving ICI therapy is not recommended given the potential mitigation of immunotherapeutic effectiveness in the prophylactic setting.

In patients having a possible IRR, perform a physical examination, monitor vital signs, monitor pulse oximetry, and perform an ECG if the patient is experiencing chest pain or sustained tachycardia. Symptoms of IRRs can include fever, chills, rigors; urticaria/pruritus; angioedema; flushing; headache; hypertension or hypotension; and/or shortness of breath, cough, or wheezing. Hypoxemia, dizziness/syncope, sweating, and arthralgia or myalgia may also occur.

Mild (G1) reactions are typically transient and do not require immunotherapy infusion interruption or other intervention. For moderate (G2) reactions, hold or slow the rate of infusion and treat per institutional guidelines. Antihistamines, acetaminophen, NSAIDs, narcotics, or IV fluids may be required. Moderate reactions typically respond promptly to symptomatic treatment and require medication for ≤24 hours. Consider premedication with acetaminophen and diphenhydramine with future infusions. For severe (G3/4) IRRs, treat urgently according to institutional guidelines. Permanently discontinue the immune checkpoint drug(s) associated with the toxicity. Severe reactions are often more prolonged with limited responsiveness to intervention or infusion

interruption. Symptoms can reoccur following initial improvement. Inpatient care and urgent intervention may be needed to prevent life-threatening consequences.

Dermatologic Toxicity

Dermatologic toxicities are the most prevalent irAEs associated with ICI therapy. Inflammatory skin conditions typically present within the first 2 cycles of treatment (ie, within several weeks).^{51,83,86,174,175} Ipilimumab has been consistently associated with higher rates of all-grade dermatologic irAEs than PD-1/PD-L1 inhibitors; reported incidences of all grade dermatologic toxicity range from 37%–70% for ipilimumab and 17%–40% for PD-1/PD-L1 inhibitors. The rates of high-grade dermatologic irAEs are similar across ICI classes and range from 1%–3% for ipilimumab and PD-1/PD-L1 inhibitors.^{2,76,83,176} Generally, regimens combining CTLA-4 blockade with an anti-PD-1/PD-L1 agent led to more frequent, severe, and earlier presentation of dermatologic toxicity.¹⁷⁷

Maculopapular rash, with or without pruritus, is the most common presentation. Vitiligo is also a fairly common observation in patients with melanoma on PD-1 inhibitors, typically presenting later in the course of treatment. Observed inflammatory skin conditions reported with ICI therapy include eczematous, lichenoid, and psoriasiform manifestations, as well as bullous dermatitis.^{51,174,177,178} Alopecia and hair repigmentation have also been reported.^{177,179,180} The majority of dermatologic irAEs are low grade and manageable with appropriate care without requiring interruption of ICI. However, rare cases of severe cutaneous reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported.^{178,181,182} Although serious conditions typically required hospitalization, resolution was achievable via systemic immunosuppressive therapy and ICI discontinuation.

NCCN Recommendations

To assess potential dermatologic irAEs, the guidelines recommend total body skin exam, including mucosa, and patient history of any prior inflammatory dermatologic disease. Routine examination of skin and mucosa is recommended for patients with a history of immune-related skin disorders. Clinicians should monitor the lesion type and affected body surface area (BSA); photographic documentation may be helpful. Biopsy can be considered for rash with unusual features. Treatment recommendations are subdivided by presentation into maculopapular rash, pruritus, and bullous dermatitis (blistering disorders). In general, short-term use of higher potency topical corticosteroids (eg, Class 2 or 3) is preferred over longer-term use of a lower-potency agent.

Maculopapular rash is characterized by the presence of macules (flat) and papules (elevated). Also known as morbilliform rash, it is one of the most common cutaneous AEs, frequently affecting the upper trunk, spreading centripetally, and may be associated with pruritus. Oral antihistamine and topical emollient are recommended. Mild (G1) maculopapular rash should be treated with moderate-potency topical corticosteroid while ICI therapy continues. For moderate rash (G2), treatment with high-potency topical corticosteroids and/or 0.5–1 mg/kg/day prednisone is indicated. Consider holding immunotherapy. For severe rash (G3/4), hold immunotherapy and treat with high-potency topical corticosteroids and 0.5–1 mg/kg/day prednisone (with dose increase up to 2 mg/kg/day if no improvement). Urgent dermatology consultation is recommended; consider inpatient care. Following immunotherapy hold, consider resuming once symptoms have resolved to ≤ G1 and only topical interventions are indicated.

Pruritus is an intense itching sensation that may occur with or without rash. Mild pruritus (G1) can be treated with oral antihistamines and moderate-potency topical corticosteroid while immunotherapy is continued. Consult dermatology and continue immunotherapy

with intensified antipruritic therapy for moderate pruritus (G2). Immunotherapy hold can be considered in select cases. Oral antihistamines are recommended in addition to high-potency topical steroid. For severe pruritus, hold immunotherapy and obtain urgent dermatology consultation. In addition to antihistamines, oral or IV prednisone/methylprednisolone (0.5–1 mg/kg/day) should be administered. Consider a GABA antagonist such as gabapentin or pregabalin, and aprepitant or omalizumab for refractory cases. Following immunotherapy hold, consider resuming once symptoms have resolved to ≤ G1 and only topical intervention is required.

Bullous dermatitis and other forms of blistering skin reactions are characterized by skin inflammation and fluid-filled bullae. For mild to moderate bullous dermatitis, hold immunotherapy until resolution. High-potency topical corticosteroid (G1) or 0.5–1 mg/kg/day prednisone/methylprednisolone (G2) is indicated. For severe or life-threatening bullous dermatitis and all cases of SJS/TEN, hospitalization and permanent discontinuation of immunotherapy are required. Seek urgent consultation from dermatology, ophthalmology, and urology. Methylprednisolone/prednisone should be initiated at 1–2 mg/kg/day.

In cases for which systemic corticosteroid is indicated, treatment should be continued until symptoms improve to ≤ G1, followed by dose taper over 4 to 6 weeks.

Gastrointestinal (GI) Toxicity

GI irAEs may present as diarrhea or symptoms of colitis, which include watery diarrhea, cramping, and urgency. Diarrhea and colitis are the second-most commonly reported AEs with ICIs, and symptoms typically develop within 6 to 8 weeks of starting treatment.^{183,184} GI irAEs have been reported more frequently with anti-CTLA-4 monotherapy than with PD-1/PD-L1 inhibitors. In studies of CTLA-4 blockade, diarrhea has been reported in up to half of patients, with incidence typically reported

between 30% and 40%.^{76,185} The highest rates of ICI-mediated GI irAEs have been observed with the addition of a PD-1/PD-L1 inhibitor to CTLA-4 blockade.¹⁸⁶⁻¹⁸⁸ Retrospective case reviews suggest that symptom grade may not correlate with colitis severity as observed by endoscopy and histology.^{111,189}

Systematic reviews and meta-analyses have examined the incidence of specific GI irAEs in patients with solid tumors who received ICI therapy. A meta-analysis of 34 studies enrolling 8863 patients with solid tumors examined the incidence of GI irAEs with various ICIs.¹⁸⁸ The highest rates of GI irAEs were observed in patients receiving combination ipilimumab plus nivolumab, with all-grade colitis, severe colitis, and severe diarrhea reported in 13.6%, 9.4%, and 9.2% of patients, respectively. Incidence of irAEs with ipilimumab monotherapy was 9.1% for all-grade colitis, 6.8% for severe colitis, and 7.9% for severe diarrhea. Monotherapy with a PD-1/PD-L1 inhibitor had the lowest GI irAE incidence, with 1.3% for all-grade colitis, 0.9% for severe colitis, and 1.2% for severe diarrhea. No significant differences in GI irAE incidence were observed by tumor type (eg, melanoma, NSCLC, RCC).¹⁸⁸ Another meta-analysis compared the pooled incidence of diarrhea and colitis for different checkpoint inhibitors in patients with melanoma (CTLA-4: n = 3116; PD-1 inhibitors: n = 1537). PD-1 inhibitors were associated with a lower relative risk of all-grade diarrhea and colitis compared with anti-CTLA-4 agents, while combination therapy was associated with a higher relative risk of diarrhea and colitis than monotherapy. Rates of discontinuation were higher among patients taking anti-CTLA-4 agents.¹⁸⁷

Corticosteroids are typically the first line of treatment for GI irAEs. In retrospective reviews of patients with ICI-related enterocolitis, symptoms resolved with corticosteroid treatment in approximately 40% to 60% of individuals.^{184,189,190} However, a recent retrospective analysis of patients found higher infection rates among patients treated with

long-duration steroids (>30 days). Long-duration corticosteroid without infliximab was associated with increased infection risk compared to short-duration steroid plus infliximab, suggesting that earlier non-steroid immunosuppressive therapy may confer better outcomes.¹¹¹

Endoscopy revealed colonic ulcerations more commonly in steroid-refractory cases.^{184,189,190} Case studies report on the successful use of infliximab for treating severe, steroid-refractory colitis associated with ipilimumab.¹⁹⁰⁻¹⁹² Case series and reports have also documented successful treatment of ICI-mediated, steroid-dependent, or steroid-refractory enterocolitis with vedolizumab.^{121,193} Vedolizumab may be effective in the setting of infliximab-resistant inflammation of the small intestine and colon.¹²²

NCCN Recommendations

Determine the patient's baseline bowel habits. Blood in the stools and/or fever should prompt a more thorough workup for infection and for other causes of GI bleeding, including peptic ulcer disease (PUD) and malignant bleeding. For patients presenting with mild diarrhea (G1), close monitoring is recommended with progressive symptoms indicating further workup. Loperamide or diphenoxylate/atropine and hydration are recommended, and consider holding immunotherapy. Moderate (G2) or severe (G3/4) diarrhea and colitis require stool evaluation to rule out infectious etiology. Consider abdominal/pelvic CT with contrast and GI consultation for further evaluation (ie, colonoscopy or flexible sigmoidoscopy ± esophagogastroduodenoscopy [EGD] with biopsy). Therapy for irAE can be initiated while awaiting test results.

For moderate diarrhea/colitis (G2), hold immunotherapy and administer prednisone/methylprednisolone (1 mg/kg/day). If no improvement is noted within 2 to 3 days, increase corticosteroid dose to 2 mg/kg/day and consider adding infliximab. Consider inpatient care if needed to provide adequate supportive care for severe colitis (G3/4). Administer IV

methylprednisolone, 2 mg/kg/day. If no response is detected in 2 days, continue steroids and consider adding infliximab. Consider vedolizumab for infliximab-refractory diarrhea and colitis or cases for which infliximab is contraindicated.

For patients taking ipilimumab, the panel recommends permanent discontinuation if a serious or life-threatening GI irAE occurs. For patients receiving PD-1/PD-L1 inhibitors, therapy should be held for G2/3 irAEs, with consideration of rechallenge upon resolution of symptoms below G1. For rare circumstances in which the patient cannot completely taper off corticosteroids, immunotherapy may be resumed while the patient is still on ≤10 mg prednisone (or equivalent) daily. Permanently discontinue the immunotherapy agent(s) responsible for the toxicity after G4 irAEs. If a systemic corticosteroid is given, treatment should be continued until symptoms improve to ≤ G1, followed by dose taper over 4 to 6 weeks. Convert from IV methylprednisolone to oral prednisone when appropriate.

Hepatic Toxicity

Although immune-related hepatotoxicity occurs at a lower rate than diarrhea/colitis, it is a well-documented ICI-mediated irAE that is typically mild but can be severe or even fatal in rare cases.⁶⁵ Asymptomatic elevations in aspartate transaminase (AST) and alanine transaminase (ALT) are the most commonly observed hepatic AEs.^{57,176} The pooled incidence of immune-related hepatotoxicity is estimated at 3% to 9% for ipilimumab and between 0.7% and 1.8% for PD-1/PD-L1 inhibitors.¹⁹⁴ Combination therapy is associated with a considerably higher incidence of hepatotoxicity with 29% and 17% experiencing any-grade and high-grade hepatotoxicity, respectively.^{194,195} Median time of onset is typically 5 to 6 weeks from start of treatment but irAEs can occur months later.^{194,196-198} Autoimmune hepatitis and drug-induced hepatitis can present in a similar fashion and be difficult to distinguish, but can often be differentiated by distinct histologic features

and imaging.^{199,200} A recent study characterized the distinct histologic patterns associated with hepatitis mediated by CTLA-4 versus PD-1/PD-L1 blockade.¹⁹⁶

Corticosteroids are the most common method of treatment in most studies of ICI-mediated hepatotoxicity.^{194,196,197} In several cases, re-initiation of steroids after taper was needed based on worsening liver values.¹⁹⁷ Mycophenolate has been used to treat severe persistent hepatitis despite corticosteroid therapy.^{136,194,201,202} Another study reported the use of cyclosporine as an additional immunosuppressant in the setting of steroid-refractory hepatotoxicity.¹⁹⁷ Infliximab is not recommended given concerns for liver toxicity, although it has not been tested in this setting. Case report data also suggest that tacrolimus may be effective for treating refractory ICI-related hepatitis.^{203,204}

NCCN Recommendations

Liver damage may be indicated by elevated levels of the liver enzymes ALT and AST (ie, transaminitis). Patients experiencing hepatic irAEs may present with varying grades of transaminitis. The panel recommends ruling out other potential factors such as viral etiology, disease-related hepatic dysfunction, or drug-induced enzyme elevations. Specialist consultation should be considered and efforts should be made to limit or discontinue any hepatotoxic medications. Assess acetaminophen, dietary supplement, and alcohol use.

Treatment recommendations are separated based on the co-occurrence of elevated bilirubin. Management of transaminitis without elevated bilirubin is by grade, based on the degree to which enzymes exceed the upper limit of normal [ULN]. For mild transaminitis (G1), immunotherapy can be continued with increased frequency of transaminase and bilirubin monitoring. Consider holding immunotherapy for concerning laboratory value trends. Hold immunotherapy for moderate transaminitis (G2) and monitor liver function tests (LFTs)

every 3 to 5 days and consider prednisone 0.5–1 mg/kg/day. Severe or life-threatening transaminitis (G3/4) requires permanent discontinuation of ICI therapy, hepatology consult, and LFT monitoring every 1 to 2 days. Provide inpatient care for G4 transaminitis and consider hospitalization for G3. Liver biopsy can be considered if there are no contraindications. Initiate prednisone at 1–2 mg/kg/day (G3) or 2 mg/kg/day (G4). For patients with persistent severe hepatitis despite high-dose corticosteroid for 3 days, consider adding MMF. Infliximab is not currently recommended for use in patients with hepatitis.

For ≥ G2 transaminitis with bilirubin levels above 1.5 ULN (excluding patients with Gilbert's syndrome), management is similar to that for high-grade hepatitis without bilirubin elevation. Permanently discontinue immunotherapy and initiate prednisone at 2 mg/kg/day. Monitor LFTs daily and consult with hepatology. Mycophenolate can be considered in addition to steroid for refractory cases after 3 days.

For all hepatitis cases requiring corticosteroid, initiate tapering when liver enzymes show sustained improvement or return to ≤ G1. Continue to taper dose over at least 1 month with re-escalation as needed for rebounding enzyme levels. In the setting of G2 hepatitis without elevated bilirubin, clinicians can consider resuming immunotherapy once liver enzymes return to baseline and prednisone (or equivalent) has been tapered to ≤10 mg daily. Do not rechallenge following high-grade (G3/4) irAEs.

Pancreatic Toxicity

Amylase and/or lipase elevations, although typically asymptomatic, can occur with ICI therapy. The potential significance of asymptomatic elevations remains unclear, but discontinuation of therapy is not usually recommended based on these findings alone.^{76,176,205} Although rare, acute pancreatitis has been observed in patients taking ICIs,^{176,199,206} and radiologic features of immune-related pancreatitis have been

described.²⁰⁷ Cases of recurrent pancreatitis have been reported upon resumption of PD-1 inhibitors following a hold for initial irAE.¹⁶⁴ Toxic effects on the endocrine pancreas, such as hyperglycemia and diabetes, are addressed in the larger context of the endocrine system in the next section.

NCCN Recommendations

Baseline/routine amylase/lipase assessments and pancreatic imaging do not need to be performed outside of clinical suspicion of pancreatitis. For persistent moderate/severe elevations in amylase and/or lipase, the panel recommends evaluation for pancreatitis to include clinical assessment and imaging. Imaging may include abdominal CT with contrast or magnetic resonance cholangiopancreatography (MRCP). Other potential causes for elevated pancreatic enzymes should be considered. For moderate/severe elevations in amylase and/or lipase, consider continuing immunotherapy if no evidence of pancreatitis is found.

Provide standard medical care for signs and symptoms of acute pancreatitis, including hospital admission, aggressive fluid resuscitation, and pain control. Gastroenterology consultation and immunosuppression are warranted if clinical assessment and/or imaging findings support moderate/severe acute pancreatitis. For moderate (G2) pancreatitis, hold immunotherapy and initiate methylprednisolone/prednisone at 0.5 to 1 mg/kg/day. Permanently discontinue ICI therapy for severe (G3/4) pancreatitis and administer corticosteroid at 1–2 mg/kg/day.

In cases for which systemic corticosteroid is indicated, treatment should be continued until symptoms improve to ≤ G1, followed by dose taper over 4 to 6 weeks. If there is no evidence clinical/radiologic evidence of pancreatitis and amylase/lipase levels improve, clinicians can consider resuming immunotherapy after a hold for a symptomatic G2 irAE.

Consider consulting with a pancreatic specialist regarding rechallenge. Resumption of immunotherapy is not recommended after G3/4 pancreatitis.

Endocrine Toxicity

ICI-related endocrine gland autoimmunity has resulted in dysfunction of the thyroid, pituitary, adrenal glands, and pancreas. Manifestations of immune-mediated endocrine gland dysfunction include hypothyroidism, hyperthyroidism, hypophysitis, type I diabetes, and primary adrenal insufficiency. The mechanisms of ICI-mediated endocrinopathies have been reviewed by Sznol, et al and Byun, et al.^{208,209} Because many symptoms of endocrine toxicity could be related to other acute illnesses or underlying malignancy, diagnosis can be challenging. Additionally, clinicians have to differentiate whether the source of endocrine dysfunction is central (ie, pituitary) or primary (eg, adrenal or thyroid) in order to tailor management appropriately.^{208,209} Due to this potential complexity, endocrinology specialists play an important role in the management of these irAEs, particularly for severe or complex cases. Alessandrino, et al have reviewed imaging features of endocrine irAEs at presentation and after treatment to assist in making a differential diagnosis.²¹⁰

Different patterns of endocrine dysfunction have been observed with various ICI regimens. Hypophysitis is characteristic of ipilimumab, while thyroid dysfunction is seen more commonly with PD-1/PD-L1 inhibitors. Other types of endocrine irAEs such as primary adrenal insufficiency and type I diabetes are considerably more rare. Overall, combination ICI therapy was associated with highest incidence of endocrinopathy.^{1,208,209,211} Median time to onset of moderate to severe endocrinopathy has ranged between 1.75 and 5 months for ipilimumab. Median time to onset of endocrinopathy with PD-1 inhibitor monotherapy ranged from 1.4 to 4.9 months.^{183,209}

A 2018 meta-analysis examined the incidence of endocrine dysfunction across 38 randomized trials enrolling 7551 patients who received monotherapy with PD-1 inhibitor, PD-L1 inhibitor, or CTLA-4 inhibitor; or combination anti-PD-1/CTLA-4 therapy.²¹¹ The estimated incidence of hypothyroidism was 3.8% with ipilimumab and up to 13.2% for combination therapy. Compared with ipilimumab, PD-1 inhibitors were associated with a significantly greater risk of hypothyroidism (OR, 1.89; 95% CI, 1.17–3.05; $P = .03$). Interestingly, the risk of hyperthyroidism was higher with PD-1 versus PD-L1 inhibitors (OR, 5.36; 95% CI, 2.04–14.08; $P = .002$). Overall, the observed incidence of hypophysitis was 6.4% for combination therapy; 3.2% for CTLA-4 inhibitors; 0.4% for PD-1 inhibitors; and below 0.1% for PD-L1 inhibitors. Compared to PD-1 monotherapy, hypophysitis was a more common occurrence during ipilimumab monotherapy (OR, 0.29; 95% CI, 0.18–0.49; $P < .001$) and combination therapy (OR, 2.2; 95% CI, 1.39–3.60; $P = .001$). The rarer nature of primary adrenal insufficiency and diabetes precluded statistical comparison of endocrine irAE incidence between different ICI regimens.²¹¹

A retrospective review identified 27 cases of new-onset insulin-dependent diabetes from a population of 2960 patients that received ICI therapy over 6 years at 2 academic medical centers (0.9% prevalence).²¹² All patients who developed or experienced a worsening of diabetes (ie, becoming insulin dependent) had received anti-PD-1/PD-L1 therapy. Median time to onset was 20 weeks after the first ICI cycle; 59% presented with ketoacidosis, 42% had evidence of pancreatitis, and 40% had one or more positive autoantibodies on testing. Additional concurrent irAEs were present among 70% of the individuals with ICI-related diabetes, many of whom experienced other endocrine AEs. Seventy-six percent of the individuals who developed ICI-related diabetes had the HLA-DR4 genotype, a significantly higher frequency than that reported for the general population, suggesting a

possible high-risk allele for the development of this irAE.²¹² However, further research will be needed.

ICI-mediated endocrine toxicity often results in permanent organ damage and typically requires life-long hormonal supplementation.^{209,213-215} To date, evidence does not suggest that high-dose corticosteroid therapy mitigates organ damage in most cases of ICI-mediated endocrinopathy; however, corticosteroids may help to mitigate symptoms of acute inflammation in the setting of hypophysitis, adrenalitis, or in some cases, thyrotoxicosis. Experts generally do not recommend corticosteroid therapy for managing hypothyroidism or type I diabetes.^{208,209,213,215,216}

NCCN Recommendations

Thyroid Dysfunction

Thyroid function should be assessed by monitoring the levels of thyroid-stimulating hormone (TSH) and free thyroxine (T4). In the setting of thyroid abnormalities, routine monitoring is recommended every 4 to 6 weeks. This interval can be extended to every 12 to 18 weeks in patients who have normal thyroid function or who continue to be asymptomatic. Evaluation of total T3 is recommended in the setting of abnormal findings.

For asymptomatic or subclinical hypothyroidism, defined as elevated TSH with normal free T4, continue routine monitoring and proceed with immunotherapy. Levothyroxine can be considered for TSH levels above 10 mIU/L. Primary hypothyroidism is characterized by elevated TSH levels (>10 mIU/L) and low free T4 with clinical symptoms. Provide thyroid supplementation and consider endocrine consultation. Prior to starting thyroid replacement therapy, concomitant adrenal insufficiency should be ruled out by testing AM cortisol levels. Low or suppressed TSH with inappropriately low free T4 may present as a sequela of hypophysitis, in which other pituitary axes may be affected. Follow free

T4 for thyroid replacement in the setting of hypophysitis-induced loss of TSH production.

Although rare, thyroiditis (often a painless, transient inflammatory process) can occur with ICI therapy. Thyrotoxicosis, observed as low or suppressed TSH (<0.01 mIU/L) with high free T4 and/or total triiodothyronine (T3), may be symptomatic in the setting of high free T4. If symptomatic (eg, palpitations, anxiety, insomnia), consider endocrine consultation and propranolol to manage symptoms until resolution. Thyrotoxicosis often evolves to hypothyroidism. Repeat thyroid function testing should be performed in 4 to 6 weeks. Findings of persistent suppressed TSH with high free T4/total T3 should be followed by additional testing for true hyperthyroidism and Graves' disease-like etiology. Hypothyroidism usually ensues after an occurrence of ICI-induced thyrotoxicosis. If TSH becomes significantly elevated (>10 mIU/L), thyroid supplementation should be initiated.

Immunotherapy may be continued in the setting of hypothyroidism or thyrotoxicosis. When appropriate, levothyroxine is given for thyroid hormone supplementation at approximately 1.6 mcg/kg with the intent of getting TSH levels to reference range or age-appropriate values. Levothyroxine dose can be reduced by 10% to avoid hyperthyroidism in patient populations that may be sensitive to thyroid supplementation (ie, elderly or patients with comorbidities). The guidelines recommend TSH and T4 monitoring every 4 to 6 weeks during immunotherapy, with follow-up every 12 week thereafter, as indicated.

Hypophysitis

Acute symptoms of hypophysitis can include headache, photophobia, dizziness, nausea/emesis, fevers, anorexia, visual field cuts, or severe fatigue. Chronic symptoms can include fatigue and weight loss. Workup for hypophysitis should include assessment of adrenocorticotrophic hormone (ACTH), AM cortisol, follicle-stimulating hormone (FSH),

luteinizing hormone (LH), TSH, free T4, testosterone in men, and estrogen in premenopausal women. Test results indicative of hypophysitis may show low levels of the following: ACTH, AM cortisol, sodium, potassium, testosterone, and DHEA-S. If the patient is symptomatic, a brain MRI with pituitary/sellar cuts is recommended.

Consider consulting endocrinology if a diagnosis of hypophysitis is made. For acute, symptomatic hypophysitis (headache and symptoms that are caused by acute swelling of the pituitary), hold immunotherapy and initiate methylprednisolone/prednisone at 1–2 mg/kg/day until acute symptoms resolve, typically 1 to 2 weeks. Then taper steroids rapidly to physiologic replacement levels upon improvement. Consider resumption of ICI therapy once symptoms related to mass effect have resolved.

The more common presentation for hypophysitis features deficiency of TSH/ACTH and/or gonad-stimulating hormones, but without symptomatic pituitary swelling. Patients may manifest a variety of symptoms related to deficiency of endogenous thyroid hormone, cortisol, or gonadal hormones. Immunotherapy can be continued while endocrine therapy is titrated to appropriate physiologic levels.

Physiologic hormone replacement will likely be required indefinitely (typically life-long), and should include steroid replacement, levothyroxine if accompanied by central hypothyroidism, and testosterone supplementation in males. Provide patient education regarding stress doses of hydrocortisone in the event of infection, trauma, or other medical event. Patients should wear a medical alert bracelet.

Primary Adrenal Insufficiency

Workup for primary adrenal insufficiency should include serum cortisol, as well as a comprehensive metabolic panel (CMP) and renin levels. Follow-up evaluation for abnormal findings should include ACTH, LH, FSH, and testosterone. Hallmarks of adrenal damage include low AM cortisol (<5) with ACTH above the reference range, with or without abnormal electrolytes and symptoms. Other abnormalities may include hypotension, orthostatic hypotension, low sodium, and high potassium.

Endocrinology should be consulted for these patients, with specialist evaluation prior to any surgery or procedure. Hold immunotherapy. If patients are hemodynamically unstable, inpatient care and high-dose/ stress-dose corticosteroids are recommended. Patients with severe symptoms including hypotension may require additional fluids. It is important to initiate corticosteroid replacement prior to other hormone replacement to avoid adrenal crisis. Steroid replacement will include hydrocortisone or prednisone, plus mineralocorticoid replacement (fludrocortisone). Immunotherapy can be resumed once endocrine replacement therapy has been established.

Physiologic hormone replacement will likely be required indefinitely (typically life-long). The goal for physiologic steroid replacement is to identify the lowest steroid dose needed to prevent symptoms of adrenal insufficiency. Provide patient education regarding stress doses of hydrocortisone in case of infection, trauma, or other medical event. Patients should wear a medical alert bracelet.

Hyperglycemia/Diabetes

Fasting glucose is preferred to assess potential hyperglycemia. Note that high-dose corticosteroids can induce or exacerbate hyperglycemia. Consider endocrinology referral and appropriate management if patients are symptomatic or hyperglycemia remains persistently uncontrolled. Management is guided by patient history of type II diabetes mellitus

(T2DM), glucose levels, and concern for diabetic ketoacidosis (DKA). Symptoms of DKA may include excessive thirst, frequent urination, general weakness, vomiting, confusion, abdominal pain, dry skin, dry mouth, increased heart rate, and fruity odor on the breath.

For patients with new-onset hyperglycemia less than 200 mg/dL, and/or a history of T2DM with low suspicion for DKA, the observed hyperglycemia may be corticosteroid-related or due to preexisting diabetes. Immunotherapy can be continued with serial blood glucose monitoring at each dose. Diet and lifestyle modifications are recommended as needed along with medical therapy per institutional guidelines.

Further workup is warranted for findings of 1) new-onset hyperglycemia >200 mg/dL; 2) random blood glucose >250 mg/dL; or 3) history of T2DM with glucose levels >250 m/dL. If any of the previous findings are noted, consider new-onset type I diabetes mellitus (T1DM) and evaluate for DKA. ICI-related development of T1DM is rare (1%–2%) but can be life-threatening if insulin therapy is not provided. Management and monitoring should be directed by endocrinology team. DKA requires hospitalization and immunotherapy hold. Management of DKA varies by institution and may include (but is not limited to) IV fluids with or without potassium supplementation, IV insulin, and hourly testing of glucose, serum ketones, blood pH, and anion gap. Corticosteroid therapy is not recommended for treating T1DM as there is insufficient evidence to suggest that it effectively reverses ICI-related T1DM, and it may further complicate glycemic control.

Pulmonary Toxicity

Pneumonitis has been associated with ICI therapy. Generally, rates of any-grade pneumonitis for PD-1/PD-L1 monotherapy have been reported at or below 5% for all-grade, and around 1% for high-grade pneumonitis.^{217,218} Unlike the pattern with most other irAEs, ipilimumab

monotherapy has a lower incidence of pneumonitis compared with PD-1/PD-L1 inhibitors, with reported rates of less than 1%.^{219,220} Observed rates for combination immunotherapy (PD-1/PD-L1 inhibitor plus anti-CTLA-4) are higher than for monotherapy with other ICIs.^{217,218,221} Although wide-ranging, median time to irAE onset from start of treatment has been reported at 2.5 months, with generally earlier onset for combination versus monotherapy.^{217,221}

A 2016 meta-analysis of 20 clinical trials of PD-1 inhibitors that enrolled 4496 patients with melanoma, lung, or renal cancer revealed an overall incidence of all-grade and high-grade pneumonitis of 2.7% and 0.8%, with a higher incidence in NSCLC than melanoma.²¹⁸ Incidence was higher for combination therapy than for monotherapy (all-grade 6.6% vs. 1.6%, $P < .001$; high-grade 1.5% vs. 0.2%, $P = .001$).

A pooled analysis of 916 patients analyzed pneumonitis among patients who received PD-1/PD-L1 inhibitors with or without anti-CTLA-4 therapy. Incidence of pneumonitis for PD-1/PD-L1 inhibitor monotherapy versus combination therapy (PD-1/PD-L1 inhibitor + CTLA-4 inhibitor) was 3% versus 10%, respectively ($P = .001$). No significant differences were observed in rates of pneumonitis between PD-1 and PD-L1 inhibitors. A similar incidence of pneumonitis was observed among the largest disease cohorts, melanoma and NSCLC, for both monotherapy and combination therapy. Of the patients diagnosed with pneumonitis in this study, most low-grade cases were treated in the outpatient setting, but 19% of patients with G2 pneumonitis and all patients \geq G3 required inpatient care. All mild pneumonitis (G1) cases were managed using ICI dose holds or oral corticosteroid, while all moderate and severe cases received oral or IV corticosteroid. Among patients with G3 or higher pneumonitis, 42% required additional immunosuppression with infliximab alone or infliximab with cyclophosphamide.²¹⁷

NCCN Recommendations

These guidelines characterize mild pneumonitis (G1) as asymptomatic, confined to less than 25% of the lung parenchyma or a single lobe. Moderate pneumonitis (G2) is characterized by the presence of new or worsening symptoms including shortness of breath, cough, chest pain, and fever. Severe pneumonitis (G3) involves all lobes of the lung or greater than 50% of the lung parenchyma. The symptoms typically limit self-care activities of daily living (ADLs). Life-threatening (G4) pneumonitis involves serious respiratory compromise.

Baseline pulmonary function should be determined by measuring oxygen saturation (at rest and with ambulation), and pulmonary function tests are recommended for high-risk patients. Repeat oxygen saturation tests as symptoms indicate and evaluate for pneumonitis via chest CT. Pneumonitis can present as focal or diffuse inflammation of the lung parenchyma and is typically identified on CT imaging as ground-glass opacities. For mild to moderate pneumonitis (G1), consider holding immunotherapy and obtain chest CT, with repeat imaging in 4 weeks or sooner if clinically indicated for worsening symptoms. For mild pneumonitis, reassess in 1 to 2 weeks, including physical exam and pulse oximetry at rest and with ambulation. For moderate pneumonitis (G2), consult pulmonology and order infectious workup to include nasal swab for potential viral pathogens as well as sputum, blood, and urine cultures. The panel recommends infectious evaluation with institutional immunocompromised panel. Bronchoscopy with bronchoalveolar lavage (BAL) can be used to rule out infection and malignant lung infiltration. Consider chest CT with repeat imaging in 3 to 4 weeks. Consider empiric antibiotics if infection has not yet been fully excluded and begin methylprednisone/prednisolone at 1–2 mg/kg/day. Monitor every 3 to 7 days with physical examination and pulse oximetry. Treat with corticosteroid until symptoms improve to \leq G1 and then taper over 4 to 6 weeks. The panel recommends treating per the algorithm for severe

(G3) pneumonitis if no improvement is seen after 48 to 72 hours of corticosteroid therapy.

Permanently discontinue immunotherapy for all cases of severe or life-threatening pneumonitis. Inpatient care is required. Complete infectious workup and bronchoscopy with BAL as per the G2 algorithm and consult with pulmonology and infectious disease specialists. Consider empiric antibiotics if infection has not yet been fully excluded and begin methylprednisone/prednisolone at 1–2 mg/kg/day. Assess response within 48 hours and plan a slow corticosteroid taper over ≥ 6 weeks. If no improvement is observed after 48 hours of treatment, consider additional immunosuppression with any of the following agents: infliximab, MMF, or IVIG.

Resumption of immunotherapy following mild pneumonitis can be considered upon radiographic evidence of improvement. Following G2 irAE, rechallenge can be considered upon resolution of pneumonitis to \leq G1 and no requirement for steroid.

Renal Toxicity

Based on initial studies, the estimated incidence of all-grade renal toxicity is approximately 2% for monotherapy, and up to 4.9% for ICI combination therapy.^{195,222} Based on a review of phase II and III clinical trials of ICIs enrolling 3695 patients, the incidence of high-grade renal toxicity was 0.6%.²²² However, reviews of emerging data suggest that incidence of renal toxicity could be considerably higher.^{223,224} For ipilimumab, time to onset of renal toxicity has been reported to be around 6 to 12 weeks for ipilimumab, but 3 to 12 months for PD-1 inhibitors.²²⁵

In the largest case series to date, time to onset of renal toxicity was around 3 months from initiation of ICI therapy, but varied from 3 weeks to approximately 8 months.²²² Within the cohort of 13 patients, kidney injury was preceded by an extrarenal irAE in 7 patients and pyuria (>5

white blood cells [WBC] per high-power field [HPF]) was present in 8 of 13 patients. Pathology revealed acute tubulointerstitial nephritis in 12 of 13 patients. Among the 10 patients who were treated with corticosteroid, 9 patients showed recovery of renal function (complete recovery in 2, partial recovery in 7). Four patients required hemodialysis, and 2 remained dialysis-dependent.²²² Other case reports/series have discussed similar approaches to diagnosis and management of ICI-related nephritis.²²⁶⁻²²⁸ Notably, there is conflicting evidence surrounding the efficacy of corticosteroid therapy for treating acute interstitial nephritis linked to non-ICI-related causes.^{229,230}

NCCN Recommendations

Elevated serum creatinine could indicate a developing renal irAE. Signs of acute renal failure may include azotemia, creatinine elevation, and ability to maintain acid/base or electrolyte balance, and changes in urine output. Mild renal irAEs (G1) are categorized by serum creatinine levels 1.5 to 2 times above baseline or an increase in ≥ 0.3 mg/dL. Creatinine levels of 2 to 3 times above baseline are considered moderate renal irAEs (G2). With severe irAEs (G3), creatinine levels may be in excess of 3 times above baseline, or >4.0 mg/dL. Creatinine levels >6 times above baseline indicate life-threatening renal issues (G4) and necessitate dialysis.

Upon development of signs of acute renal damage, the panel recommends conducting a medication review and limiting/discontinuing any nephrotoxic medications (eg, NSAIDs). Dose adjust remaining medications to creatinine clearance. Evaluate for and rule out other potential alternative etiologies for abnormal findings, testing as indicated for potential prerenal and postrenal causes (eg, contrast-enhanced imaging). Distinguish cell infiltrate from immune-complex-mediated injury. Possible considerations should include cardiomyopathy, heart failure, pulmonary hypertension, kidney stones/obstruction, hypovolemia due to a primary GI issue, diuretics, and infection. Protein-to-creatinine

ratio in spot urine samples can be used to assess proteinuria, with follow-up testing for findings of proteinuria above 3 g/24-hour (ie, ANA, RF, ANCA, anti-dsDNA, serum C3 and C4, CH50).

For mild to moderate renal irAEs (G1), follow creatinine and urine protein every 3 to 7 days. Consider holding immunotherapy for G1 renal dysfunction, and hold immunotherapy dose in the setting of moderate renal irAEs (G2). If other causes are ruled out, administer prednisone 0.5–1 mg/kg/day. Increase dose to 1–2 mg/kg/day of methylprednisone/prednisolone for persistent G2 issues beyond 1 week. After G1/2 irAEs, once symptoms resolve to \leq G1, consider resuming immunotherapy concomitant with corticosteroid.

Permanently discontinue immunotherapy if severe/life-threatening renal irAEs occur. Consider inpatient care, consult nephrology and consider renal biopsy, and initiate methylprednisone/prednisolone at 1–2 mg/kg/day. For persistent findings above G2 after 1 week of steroid therapy, consider adding one of the following agents: azathioprine, monthly cyclophosphamide, cyclosporine, infliximab, or mycophenolate.

When corticosteroid therapy is used to manage renal irAEs, continue until improvement to \leq G1, then taper over 4 to 6 weeks.

Ocular Toxicity

Ophthalmic irAEs are categorized by the affected area of the eye, into ocular inflammation (eg, uveitis, episcleritis, blepharitis, peripheral ulcerative keratitis), orbital inflammation/orbitopathy (eg, idiopathic or thyroid-induced orbitopathy), retinal/choroidal disease (eg, retinopathy or choroidal neovascularization), and optic neuropathy.²³¹⁻²³³ Dry eye and uveitis have been the most commonly reported ocular ICI-associated events, with a reported incidence between 1% and 24%.²³³⁻²³⁵ Based on case series and reports, mild ophthalmic irAEs have generally been managed successfully using a topical steroid, whereas more severe conditions have required systemic corticosteroid therapy

and discontinuation of ICI therapy.^{232,233,236,237} Close cooperation with ophthalmologic specialists is critical for prompt diagnosis and optimal treatment.^{232,235}

NCCN Recommendations

Signs or symptoms such as blurred/distorted vision, changes in color vision, blind spots, photophobia, eye pain, eyelid swelling, and proptosis may indicate the development of an ocular irAE such as uveitis, episcleritis, or blepharitis. Episcleritis can be associated with red/purple discoloration of the eye, and uveitis may present with eye redness. Grading for uveitis is broken out by mild uveitis (G1), anterior uveitis (G2), posterior or panuveitis (G3), and uveitis causing vision of 20/200 or worse (G4). Episcleritis is graded as mild (G1), associated with vision of 20/40 or better (G2), associated with vision of 20/40 or worse (G3), or associated with vision of 20/200 or worse (G4).

For mild uveitis, episcleritis, or blepharitis, continue immunotherapy, provide artificial tears, and refer to ophthalmology. Avoid eye irritants such as contact lenses and cosmetics. Hold immunotherapy for G2 ocular irAEs and seek urgent ophthalmology consultation. Permanently discontinue immunotherapy for any G3 or G4 ocular irAEs and obtain emergent ophthalmology consultation. Treatment for moderate to severe irAEs should be guided by ophthalmology and will likely include ophthalmic and systemic prednisone/methylprednisone. For ophthalmic conditions refractory to high-dose systemic corticosteroid, consider adding infliximab or an antimetabolic agent (eg, methotrexate).

Corticosteroid treatment should be continued until resolution to \leq G1, followed by dose taper over 4 to 6 weeks. For G2 ocular irAEs, the panel suggests consideration of resuming immunotherapy in consultation with ophthalmology upon resolution of the irAE to \leq G1. Rechallenge is contraindicated after high-grade irAEs.

Nervous System Toxicity

ICI-mediated neurologic toxicity spans a broad spectrum of conditions related to autoimmunity within the central and/or peripheral nervous systems. Some neurologic irAEs can be quite challenging to diagnose due to nonspecific symptoms, variability in presentation, and the wide range of differential diagnoses to consider.^{144,146,238} Documented cases of neurologic irAEs include numerous conditions such as myasthenia gravis, GBS-like syndrome, central and/or peripheral neuropathy, aseptic meningitis, encephalitis, and transverse myelitis. With some exceptions (eg, peripheral neuropathies), irAEs of the nervous system are higher grade events by default. Fatalities have been reported in patients receiving ICI who developed severe neurologic irAEs such as immune-mediated encephalitis, myasthenia gravis/myasthenic syndromes, and acute immune demyelinating polyneuropathy.^{144,145,238-242} The neurologic irAEs that most commonly resulted in fatality were encephalitis and myasthenia gravis.⁹¹

A systematic review of the literature examined data on neurologic AEs from case reports and prospective ICI trials (59 trials, n = 9208).²⁴³ The overall incidence of neurologic irAEs was 3.8% for CTLA-4 inhibitors, 6% with PD-1 inhibitors, and 12% for combination therapy. Headache, encephalopathy, and meningitis were the most commonly reported events; the majority of events were lower grade.²⁴³ Generally, reviews report a ≤1% incidence of high-grade neurologic irAEs across various ICI regimens.^{146,241,243} Another study probed a pharmaceutical Global Pharmacovigilance and Epidemiology database for neurologic irAEs reported in patients with advanced melanoma receiving nivolumab with or without ipilimumab (12 trials, n = 3763).¹⁴⁶ Out of 3763 patients, 35 (0.93%) experienced 43 serious neurologic irAEs over an 8-year period, with neuropathy being the most commonly reported event. Resolution of irAE(s) was documented in 75% of patients (26 of 35).

Literature and database reviews generally report a median time to onset of neurologic irAEs of about 6 weeks.^{144,146,243} Corticosteroid therapy is usually employed as the first line of treatment for neurologic irAEs; high-dose IV corticosteroids and ICI discontinuation was employed in the setting of higher-grade events.^{144,146} Prompt treatment is critical for reducing long-term morbidity and mortality.^{113,144,146,238,241} Median time to irAE resolution has been reported at just under 8 weeks.¹⁴⁶ Of note, unlike canonical cases of GBS, ICI-mediated development of GBS-like syndrome has been successfully managed using corticosteroid therapy.²⁴³

Additional lines of immunosuppressive therapy are often required for cases of rapidly progressive or steroid-refractory neurologic irAEs. Autoimmune encephalitis and other neurologic irAEs have been managed with agents such as IVIG, plasmapheresis, rituximab, and cyclosporine, leading to partial or full recovery.^{144,146,240} However, for several reported cases of myasthenic syndrome, encephalitis, or demyelinating polyneuropathy, irAEs proved fatal despite treatment with multiple lines of immunosuppressant (including plasmapheresis, IVIG, tacrolimus, and/or MMF).^{144,145} At present, there are no definitive outcomes data to guide decisions regarding immune-modulating treatments, and clinicians have relied on data from neurologic irAE case reports, management of other autoimmune neurologic disorders, and individual patient characteristics (ie, the presence of irAEs affecting other organ systems).¹⁴⁴

NCCN Recommendations

Myasthenia Gravis

If myasthenia gravis is suspected, obtain neurology consultation. Assessment should include pulmonary function testing, electromyography (EMG) and nerve conduction study, as well as consideration of brain and/or spine MRI if symptoms are suggestive

of malignant CNS involvement. Laboratory testing should include acetylcholine receptor and muscle-specific tyrosine kinase antibodies, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), creatinine phosphokinase, and aldolase for possible superimposed myositis. If the patient has respiratory insufficiency or elevated CPK, perform cardiac examination to include ECG, troponin, and transthoracic echocardiogram for possible concomitant myocarditis.

Hold immunotherapy for moderate symptoms (G2) with some interference in ADLs. Administer pyridostigmine and gradually increase to a maximum of 120 mg orally four times/day as tolerated and based on symptoms. Consider low-dose oral prednisone at 20 mg daily and gradually increase to a target dose of 1 mg/kg/day (not to exceed 100 mg daily). Taper these agents based on symptom improvement. Consider resuming immunotherapy based on steroid responsiveness. Severe cases (G3/4) warrant permanent discontinuation of immunotherapy, hospitalization, and neurology consultation with daily neurologic evaluation and frequent pulmonary function testing. Start methylprednisolone 1–2 mg/kg/day. For patients with refractory, severe, or worsening symptoms, initiate plasmapheresis or IVIG. Medications that can worsen this condition, such as beta-blockers, ciprofloxacin, and IV magnesium, should be avoided.

Guillain-Barré Syndrome (GBS)

Inpatient care with access to intensive care–level monitoring is recommended; consult neurology. Recommended testing includes spinal MRI, lumbar puncture, serum antibody testing for GBS variants, and pulmonary function testing. Permanently discontinue immunotherapy for all cases of GBS and provide inpatient care with capability for rapid transfer to ICU-level monitoring. Initiate IVIG or plasmapheresis in addition to pulse dose methylprednisolone (1 g/d for 5 days). Conduct frequent neurologic examinations and pulmonary

function testing. Monitor for concurrent autonomic dysfunction and provide non-opioid analgesic for management of neuropathic pain.

Unlike classical GBS, in immune-mediated GBS, cerebrospinal fluid (CSF) findings often include elevated protein and WBC count. Although corticosteroid is not typically indicated in idiopathic GBS, a trial is reasonable if the suspected cause is ICI therapy. Slow steroid taper is recommended once symptoms resolve. Immunotherapy rechallenge is not recommended.

Peripheral Neuropathy

Evaluate for other potential causes when assessing mild to moderate peripheral neuropathy. Potential factors include medication, infection, metabolic or endocrine disorders, vascular or autoimmune disease, and trauma, among other potential causes. Any cranial nerve involvement should be treated as a G2 irAE. Gastrointestinal tract paresis due to myenteric neuritis is a rare toxicity associated with ICI therapy.²⁴⁴ The presentation may be fulminant with profound ileus. Early institution of high-dose steroids in concert with multidisciplinary management is recommended.

In the setting of peripheral neuropathy, obtain neuraxial imaging as recommended by neurology. For mild cases, consider holding immunotherapy and continue to monitor symptoms for any new interference with ADLs due to pain, weakness, difficulty walking, ataxia, or autonomic changes. Hold immunotherapy for moderate cases (G2) and observe closely. If symptoms progress, initiate methylprednisolone/prednisone at 0.5–1 mg/kg/day and administer gabapentin, pregabalin, or duloxetine for pain. Increase dose to 2 to 4 mg/kg/day if further progression. Severe peripheral neuropathy (G3/4) is not necessarily GBS, but management can be similar. Gabapentin, pregabalin, or duloxetine can be administered for neuropathic pain.

Aseptic Meningitis

When assessing immunotherapy patients for meningitis, exclude potential infectious causes and consider neurology consultation. The panel recommends brain MRI (with and without contrast) to include the pituitary gland. ACTH and AM cortisol can be used to rule out adrenal insufficiency. Lumbar puncture may be helpful in making a differential diagnosis. Relevant measures include opening pressure, CSF cell counts, protein glucose, gram stain, and culture for infectious organisms. Findings may include elevated WBC count with normal glucose, culture, and gram stain. Reactive lymphocytes or histiocytes may be observed on cytology. Based on these results, conduct polymerase chain reaction (PCR) for herpes simplex virus or other suspected viral infections.

If severity is mild to moderate, hold immunotherapy. If severe (G3/4), provide inpatient care and permanently discontinue immunotherapy. IV acyclovir can be considered until PCR results are obtained. Once infectious etiology has been ruled out, closely monitor or initiate corticosteroid therapy at 0.5–1 mg/kg/day. Provide methylprednisolone dose of 1–2 mg/kg/day for moderate to severe symptoms. Taper corticosteroid rapidly once symptoms resolve. Consider resuming immunotherapy following mild to moderate aseptic meningitis only if symptoms have completely resolved.

Encephalitis

Infectious causes of encephalitis should be excluded. Consult neurology and perform brain MRI (with and without contrast), lumbar puncture, and electroencephalography (EEG) to rule out seizure activity. Laboratory testing should include CMP, complete blood count (CBC), thyroid panel including thyroid peroxidase (TPO) and thyroglobulin, as well as autoimmune and paraneoplastic panels. Also test ESR, CRP, and antineutrophil cytoplasmic antibody if vasculitis process is suspected. MRI may reveal T2/FLAIR changes typical of what is seen

in autoimmune encephalopathies or limbic encephalitis. CSF may have elevated WBCs with lymphocytic predominance and/or elevated protein.

Hold immunotherapy for mild cases (G1), but permanently discontinue if moderate or severe (G2/3/4) encephalitis occurs. Severe encephalitis warrants inpatient care. A trial of acyclovir can be initiated until CSF PCR results are obtained. Also consider a trial of methylprednisolone 1–2 mg/kg/day. If symptoms are severe/progressive, or if oligoclonal bands are present on CSF, consider pulse-dose corticosteroid (1 g/day for 3–5 days) in addition to IVIG. Consider rituximab if limited or no improvement is seen after 1 to 2 weeks and test results are indicative of autoimmune encephalopathy.

Transverse Myelitis

Consult with neurology. Recommended assessment includes MRI of the brain and spine, lumbar puncture, and evaluation for urinary retention or constipation. Examine CSF for cell counts, protein, glucose, oligoclonal bands, cytology, and onconeural antibodies, and conduct viral PCRs as indicated. Laboratory studies include B₁₂ levels, HIV testing, rapid plasma reagin (RPR), ANA, anti-Ro/La antibodies, TSH, and aquaporin-4 IgG and paraneoplastic panel. Inpatient care is recommended. Discontinue immunotherapy. Provide pulse-dose methylprednisolone (1 g/day for 3–5 days) and strongly consider IVIG or plasmapheresis.

Cardiovascular Toxicity

Cardiac irAEs are potentially fatal ICI-associated toxicities that have been associated with ipilimumab, pembrolizumab, and nivolumab. Case series reveal a variety of potential manifestations of cardiovascular irAEs, including myocarditis, cardiomyopathy, cardiac fibrosis, heart failure, and cardiac arrest.^{67,245,246} Efforts to characterize cardiac irAEs associated with ICI therapy have begun to provide a better understanding of ICI-associated myocarditis. Data collected over 4

years from 8 sites revealed 35 cases of ICI-mediated myocarditis, which were compared to a sample of patients on ICI therapy without myocarditis.²⁴⁶ Prevalence was 1.14% in this patient population with a median onset of 34 days from initiation of treatment. However, recent evidence suggests that ICI-associated cardiovascular toxicity, myocarditis in particular, is more common than initially thought.^{91,246-248}

Recent analysis of the WHO database revealed 101 individual case safety reports of severe myocarditis following initiation of ICI therapy.²⁴⁸ Of these cases, 57% had received anti PD-1 monotherapy, and 27% received combination PD-1/PD-L1 plus CTLA-4 inhibitor. For cases with available dosing information (n = 59), 64% (n = 38) had received only 1 or 2 ICI doses at the time of toxicity onset. Concurrent severe irAEs, most commonly myositis and myasthenia gravis, were reported for 42%. Data on cardiovascular comorbidities were not available, but only 25% were on a cardiovascular or diabetes medication regimen.²⁴⁸

Based on multicenter registry data, myocarditis was observed more often in patients receiving combination ICI therapy and in patients with diabetes.²⁴⁶ Approximately half of the patients diagnosed with myocarditis experienced major adverse cardiac events (MACE), which were defined as “the composite of cardiovascular death, cardiogenic shock, cardiac arrest, and hemodynamically significant complete heart block.”²⁴⁶ Troponin levels of ≥ 1.5 ng/mL were associated with a 4-fold increased risk of MACE (HR, 4.0; 95% CI, 1.5–10.9; $P = .003$). Corticosteroid was administered in 89% of cases, with high-dose steroids resulting in better treatment response. Elevated troponin and higher rates of MACE were observed more commonly among patients who were treated with lower-dose corticosteroid.²⁴⁶

Pre-existing cardiovascular pathology was identified in the majority of patients (5/8) in one case series.²⁴⁵ Co-occurrence with non-cardiac irAEs was also observed in over 50% of patients. Corticosteroids and/

or supportive care measures were helpful to improve symptoms in most cases, although permanent cardiotoxicity and fatalities also occurred despite intervention.²⁴⁵ Myositis and myocarditis were observed to co-occur in a recent study of ICI-related fatalities. Notably, myasthenia gravis also co-occurred in 10% of fatal myocarditis cases.⁹¹ Case reports of ICI-related myocarditis have reported irAE flare during steroid taper or ICI rechallenge.^{249,250} IVIG was successfully used in a case report of smoldering ICI-related myocarditis that initially responded to corticosteroid but flared upon taper.²⁴⁹

NCCN Recommendations

Immediate cardiology consultation and inpatient care is recommended. Assessment should include telemetry monitoring, ECG, and cardiac MRI. Recommended laboratory testing includes cardiac biomarkers (creatinine kinase and troponin) and inflammatory biomarkers (ESR, CRP, and WBC count). Seek to rule out other potential causes via viral titers, echocardiogram, or biopsy in the case of severe symptoms.

In the setting of severe (G3) cardiac irAE, arrhythmia may be accompanied by significant echocardiogram findings without hypotension, and cardiac biomarkers above the ULN. Life-threatening (G4) cardiac irAEs are denoted by arrhythmia, hemodynamic instability, and cardiac biomarkers more than 3 times the ULN. Permanently discontinue immunotherapy for any G3 or G4 cardiovascular irAEs. The panel recommends methylprednisolone pulse dosing (1 g/day for 3–5 days). Treat until cardiac function returns to baseline, then dose taper over 4 to 6 weeks. For life-threatening cases (G4), if no improvement is noted within 24 hours, consider adding infliximab or anti-thymocyte globulin (ATG).

Musculoskeletal Toxicity

Musculoskeletal and rheumatic irAEs include IA, myositis, and myalgias. Myositis is characterized by inflammation involving the skeletal muscles, and myalgia involves marked discomfort originating from a muscle or group of muscles. IA is typically identified as a result of joint pain (arthralgia) and/or swelling and stiffness after inactivity. Although rare, severe myositis can be fatal and has been documented more commonly in patients receiving PD-1/PD-L1 inhibitor.²⁵¹

A recent systematic review of the literature examined rheumatic and musculoskeletal irAEs associated with ICI therapy. Data from 33 clinical trials, 3 observational studies, and 16 case reports/series were included.²⁵¹ Arthralgia and myalgia were the most commonly reported irAEs, with a widely ranging incidence of 1% to 43%. Five of 33 clinical trials reported cases of arthritis development, and case reports have described IA, vasculitis, myositis, and lupus nephritis. Prospective cohort studies and retrospective reviews report the incidence of IA or other rheumatologic irAEs among patients receiving ICIs to be between 1% and 7%.^{112,251-253}

Among a prospective cohort study of 524 patients receiving ICIs, 35 (6.6%) were referred to rheumatology.¹¹² Twenty patients had IA that presented similar to rheumatoid arthritis (n = 7), polymyalgia rheumatica (n = 11), or psoriatic arthritis (n = 2), while the remaining 15 patients were diagnosed with noninflammatory musculoskeletal conditions. Nineteen patients with IA required low to moderate doses of corticosteroid, and methotrexate was administered in 2 patients. Notably, ICI therapy was not discontinued in these cases.

One case series initially reported on 13 patients (5 receiving nivolumab or ipilimumab monotherapy, 8 receiving combination ICI) who developed new rheumatologic symptoms while receiving an ICI at an academic medical center between 2012 and 2016.²⁵⁴ Clinical presentation varied,

with involvement in both large and small joints of the upper and lower extremities. All patients were treated with corticosteroid therapy, demonstrating variable response. The authors later published their findings on the distinct clinical presentation of IA within a cumulative series of 30 patients who received various ICI regimens.²⁵⁵ Patients who received PD-1/PD-L1 inhibitor monotherapy tended to have small joint IA as their sole irAE, whereas patients on a combination regimen (PD-1/CTLA-4 blockade) were more likely to present with knee arthritis, higher levels of CRP, and prior irAE of another type, and display a reactive arthritis-like phenotype. Ten of 30 patients required additional lines of immunosuppressive therapy beyond corticosteroid (ie, methotrexate or TNF blockers).²⁵⁵

Reported cases of IA or other rheumatologic irAEs have generally been responsive to immunosuppressive therapy, with approximately one-quarter to one-third of patients requiring additional lines of therapy beyond corticosteroid.^{112,255,256}

NCCN Recommendations

Inflammatory Arthritis (IA)

When assessing for IA, note the number of joints involved, perform a functional assessment, and obtain imaging as appropriate (eg, x-ray, joint ultrasound, joint MRI). Continue immunotherapy if arthritis is mild and administer NSAIDs or low-dose corticosteroid for refractory symptoms. Intraarticular steroids can be considered depending on joint location and the number of involved joints. For moderately severe arthritis, consider holding immunotherapy and administer prednisone 0.5 mg/kg/day for 4 to 6 weeks. If no improvement is seen within a month, treat per the algorithm for severe IA and seek rheumatology consultation. For severe arthritis that limits instrumental ADLs (with or without irreversible joint damage), hold immunotherapy and prescribe methylprednisolone/prednisone 1 mg/kg/day. If no improvement by

week 2, consult rheumatology for consideration of additional disease modifying anti-rheumatic drugs depending on the clinical phenotype of inflammatory arthritis. Consider the co-existence of other irAEs in which choice of immunosuppression may be relevant; options may include infliximab, methotrexate, tocilizumab, sulfasalazine, azathioprine, leflunomide, and IVIG. Continued lack of improvement warrants rheumatology consultation for consideration of additional disease-modifying anti-rheumatic agents such as sulfasalazine, methotrexate, or leflunomide.

Continue to treat IA with corticosteroid until symptoms improve to a mild level, then taper the dose over 4 to 6 weeks. Perform serial rheumatologic examinations to monitor the patient's condition; if levels were initially elevated, ESR and CRP testing can also be used to monitor treatment response. After an immunotherapy hold, clinicians can consider resuming therapy upon stabilization or adequate management of symptoms. However, severe IA that impairs ADLs and quality of life may require permanent discontinuation of immunotherapy.

Myositis/Myalgia (Muscle Weakness)

Order a CMP and check creatine kinase and aldolase levels during workup for myositis or myalgia. Immunotherapy can continue uninterrupted in the setting of mild pain. Continue serial creatine kinase/aldolase monitoring and treat pain as indicated. For moderate, severe, or life-threatening (ie, myositis only, urgent intervention required) irAEs, obtain muscle MRI and EMG. Administer prednisone 1–2 mg/kg/day and treat pain as appropriate. Hold immunotherapy if creatine kinase/aldolase levels are elevated. Muscle biopsy can be considered for severe or refractory cases. Creatine kinase/aldolase serial monitoring should continue until symptoms resolve or corticosteroid has been discontinued. Corticosteroid treatment should continue until

symptoms are \leq G1, followed by dose taper over 4 to 6 weeks. Consult rheumatology for follow-up as well as neurology for myositis.

CAR T-Cell Therapy

Section under development.

References

1. Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. *J Immunother Cancer* 2017;5:95. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29162153>.
2. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 2018;36:1714-1768. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29442540>.
3. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. *Nat Immunol* 2002;3:991-998. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12407406>.
4. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. *Ann Oncol* 2012;23 Suppl 8:viii6-9. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22918931>.
5. Finn OJ. A Believer's Overview of Cancer Immunosurveillance and Immunotherapy. *J Immunol* 2018;200:385-391. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29311379>.
6. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science* 2011;331:1565-1570. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21436444>.
7. Wilczynski JR, Nowak M. Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors. In: Klink M, ed. *Interaction of Immune and Cancer Cells*. Vienna: Springer Vienna; 2014:143-205.
8. Bhatia A, Kumar Y. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. *Expert Rev Clin Immunol* 2014;10:41-62. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24325346>.
9. Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. *Semin Cancer Biol* 2015;35 Suppl:S185-S198. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25818339>.
10. Trinh VA, Zobniw C, Hwu WJ. The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma. *Expert Opin Drug Saf* 2017;16:933-940. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28627943>.
11. Marabondo S, Kaufman HL. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. *Expert Opin Drug Saf* 2017;16:1347-1357. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28929820>.
12. Holstein SA, McCarthy PL. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. *Drugs* 2017;77:505-520. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28205024>.
13. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. *Leukemia* 2010;24:22-32. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19907437>.
14. Andhavarapu S, Roy V. Immunomodulatory drugs in multiple myeloma. *Expert Rev Hematol* 2013;6:69-82. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23373782>.



15. Prescribing Information: Pembrolizumab Available at: <http://bit.ly/2cTmltE>. Accessed Jul 25, 2017.
16. Prescribing Information: Nivolumab Available at: <http://bit.ly/1V77FcW>. Accessed Jan 23, 2018.
17. Prescribing Information: Avelumab. Available at: https://www.bavencio.com/en_US/document/Prescribing-Information.pdf. Accessed July 25, 2017.
18. Prescribing Information: Atezolizumab. Available at: https://www.gene.com/download/pdf/tecentriq_prescribing.pdf. Accessed Jan 23, 2018.
19. Prescribing Information: Durvalumab. Available at: <https://www.azpicentral.com/imfinzi/imfinzi.pdf#page=1>. Accessed July 25, 2017.
20. Prescribing information: Ipilimumab. Available at: <http://bit.ly/2cTp2AT>. Accessed Jan 23, 2018.
21. Prescribing Information: Tisagenlecleucel Available at: <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/kymriah.pdf>. Accessed Oct 12, 2018
22. Prescribing Information: Axicabtagene ciloleucel. Available at: <https://www.yescarta.com/wp-content/uploads/yescarta-pi.pdf>. Accessed Oct 10, 2018.
23. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. *Annu Rev Immunol* 2001;19:565-594. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11244047>.
24. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. *Am J Clin Oncol* 2016;39:98-106. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26558876>.
25. Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. *J Hematol Oncol* 2018;11:31. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29482595>.
26. Sukari A, Nagasaka M, Al-Hadidi A, Lum LG. Cancer Immunology and Immunotherapy. *Anticancer Res* 2016;36:5593-5606. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27793882>.
27. Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. *Clin Exp Immunol* 2009;157:9-19. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19659765>.
28. Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. *Cancer Res* 2012;72:917-927. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22186141>.
29. Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. *Cancer Immunol Res* 2014;2:846-856. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24872026>.
30. Ostroumov D, Fekete-Drimusz N, Saborowski M, et al. CD4 and CD8 T lymphocyte interplay in controlling tumor growth. *Cell Mol Life Sci* 2018;75:689-713. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29032503>.

31. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. *J Exp Med* 1995;182:459-465. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7543139>.
32. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012;12:252-264. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22437870>.
33. Huard B, Prigent P, Tournier M, et al. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. *Eur J Immunol* 1995;25:2718-2721. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7589152>.
34. Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. *J Clin Invest* 2007;117:3383-3392. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17932562>.
35. Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. *Immunity* 1997;7:885-895. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9430233>.
36. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. *Immunity* 1995;3:541-547. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/7584144>.
37. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. *Nat Rev Immunol* 2011;11:852-863. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22116087>.
38. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. *Science* 1995;270:985-988. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/7481803>.
39. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. *Science* 1996;271:1734-1736. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/8596936>.
40. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. *Immunol Rev* 2008;224:166-182. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18759926>.
41. Walker LSK. EFIS Lecture: Understanding the CTLA-4 checkpoint in the maintenance of immune homeostasis. *Immunol Lett* 2017;184:43-50. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28216262>.
42. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. *Annu Rev Immunol* 2008;26:677-704. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18173375>.
43. Wherry EJ. T cell exhaustion. *Nat Immunol* 2011;12:492-499. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21739672>.
44. Amarnath S, Mangus CW, Wang JC, et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. *Sci Transl Med* 2011;3:111ra120. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22133721>.
45. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. *J Exp Med* 2009;206:3015-3029. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20008522>.

46. Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. *Sci Transl Med* 2013;5:200ra116. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23986400>.
47. Kinter AL, Godbout EJ, McNally JP, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. *J Immunol* 2008;181:6738-6746. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18981091>.
48. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. *Cancer Res* 2005;65:1089-1096. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15705911>.
49. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. *Clin Cancer Res* 2012;18:6580-6587. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23087408>.
50. Lam LH, Lin SD, Sun J. Pharmacokinetics and Pharmacodynamics of Immunotherapy. In: Patel SP, Kurzrock R, eds. *Early Phase Cancer Immunotherapy*. Cham: Springer International Publishing; 2018.
51. Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. *Eur J Cancer* 2016;60:12-25. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27043866>.
52. Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. *Future Oncol* 2015;11:1307-1326. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25798726>.
53. Ciccarese C, Alfieri S, Santoni M, et al. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. *Expert Opin Drug Metab Toxicol* 2016;12:57-75. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26565919>.
54. Eigentler TK, Hassel JC, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. *Cancer Treat Rev* 2016;45:7-18. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26922661>.
55. Kyi C, Postow MA. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. *Immunotherapy* 2016;8:821-837. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27349981>.
56. Marrone KA, Ying W, Naidoo J. Immune-Related Adverse Events From Immune Checkpoint Inhibitors. *Clin Pharmacol Ther* 2016;100:242-251. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27170616>.
57. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. *J Clin Oncol* 2015;33:1974-1982. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25605845>.
58. Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. *Nat Rev Clin Oncol* 2014;11:91-99. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24445516>.
59. Kong YC, Flynn JC. Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. *Front Immunol* 2014;5:206. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24904570>.

60. Ledezma B, Heng A. Real-world impact of education: treating patients with ipilimumab in a community practice setting. *Cancer Manag Res* 2013;6:5-14. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24379698>.
61. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. *Cancer J* 2014;20:119-122. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24667956>.
62. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. *Eur J Cancer* 2016;54:139-148. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26765102>.
63. Lo B, Fritz JM, Su HC, et al. CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. *Blood* 2016;128:1037-1042. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27418640>.
64. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. *N Engl J Med* 2018;378:158-168. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29320654>.
65. Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. *Nat Rev Clin Oncol* 2016;13:473-486. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27141885>.
66. Esfahani K, Miller WH, Jr. Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. *N Engl J Med* 2017;376:1989-1991. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28514612>.
67. Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. *N Engl J Med* 2016;375:1749-1755. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27806233>.
68. Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. *Cancer* 2017;123:2143-2153. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28543699>.
69. Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. *J Immunother Cancer* 2015;3:39. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26380086>.
70. Callahan MK, Yang A, Tandon S, et al. Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis. *Journal of Clinical Oncology* 2011;29:2505-2505. Available at: http://ascopubs.org/doi/abs/10.1200/jco.2011.29.15_suppl.2505.
71. Feng T, Qin H, Wang L, et al. Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 production. *J Immunol* 2011;186:6313-6318. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21531892>.
72. Harbour SN, Maynard CL, Zindl CL, et al. Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. *Proc Natl Acad Sci U S A* 2015;112:7061-7066. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26038559>.

73. Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. *Sci Transl Med* 2014;6:230ra245. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24695685>.
74. Caturegli P, Di Dalmazi G, Lombardi M, et al. Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. *Am J Pathol* 2016;186:3225-3235. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27750046>.
75. Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. *Ann Oncol* 2017;28:583-589. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27998967>.
76. Kumar V, Chaudhary N, Garg M, et al. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. *Front Pharmacol* 2017;8:49. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28228726>.
77. Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. *J Clin Oncol* 2017;35:3807-3814. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28841387>.
78. Bertrand A, Kostine M, Barnette T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. *BMC Med* 2015;13:211. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26337719>.
79. Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncol* 2017;18:611-622. Available at:
80. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. *N Engl J Med* 2016;375:1845-1855. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27717298>.
81. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. *Lancet Oncol* 2015;16:522-530. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25840693>.
82. Maughan BL, Bailey E, Gill DM, Agarwal N. Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers. *Front Oncol* 2017;7:56. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28421161>.
83. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. *Transl Lung Cancer Res* 2015;4:560-575. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26629425>.
84. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012;366:2443-2454. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22658127>.

85. Wang PF, Chen Y, Song SY, et al. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. *Front Pharmacol* 2017;8:730. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29093678>.
86. De Velasco G, Je Y, Bosse D, et al. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. *Cancer Immunol Res* 2017;5:312-318. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28246107>.
87. Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. *Ann Oncol* 2017;28:2377-2385. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28945858>.
88. Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. *Cancer* 2018;124:271-277. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28960263>.
89. Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. *Chest* 2017;152:271-281. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28499515>.
90. Shoushtari AN, Friedman CF, Navid-Azarbaijani P, et al. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. *JAMA Oncol* 2018;4:98-101. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28817755>.
91. Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. *JAMA Oncol* 2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30242316>.
92. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *N Engl J Med* 2017;377:1345-1356. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28889792>.
93. Flynn MJ, Larkin JMG. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. *Expert Opin Pharmacother* 2017;18:1477-1490. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28820000>.
94. Hermel DJ, Ott PA. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. *Cancer Metastasis Rev* 2017;36:43-50. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28181070>.
95. Prieto PA, Reuben A, Cooper ZA, Wargo JA. Targeted Therapies Combined With Immune Checkpoint Therapy. *Cancer J* 2016;22:138-146. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27111910>.
96. Salama AK, Moschos SJ. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. *Ann Oncol* 2017;28:57-74. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28177433>.
97. Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. *Lancet Oncol* 2016;17:1558-1568. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27622997>.

98. Long GV, Atkinson V, Cebon JS, et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. *Lancet Oncol* 2017;18:1202-1210. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28729151>.
99. Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. *Lancet Oncol* 2017;18:31-41. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27932067>.
100. Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncol* 2016;17:883-895. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27269741>.
101. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. *Lancet Oncol* 2016;17:1497-1508. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27745820>.
102. Govindan R, Szczesna A, Ahn MJ, et al. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. *J Clin Oncol* 2017;35:3449-3457. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28854067>.
103. Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. *Front Pharmacol* 2017;8:561. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28878676>.
104. Tallet AV, Dhermain F, Le Rhun E, et al. Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy. *Ann Oncol* 2017;28:2962-2976. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29045524>.
105. Hu ZI, Ho AY, McArthur HL. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. *Int J Radiat Oncol Biol Phys* 2017;99:153-164. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28816141>.
106. Teulings HE, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. *J Clin Oncol* 2015;33:773-781. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25605840>.
107. Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. *JAMA Dermatol* 2015;151:1206-1212. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26222619>.
108. Lo JA, Fisher DE, Flaherty KT. Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. *JAMA Oncol* 2015;1:1340-1341. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26270186>.
109. Hua C, Boussemart L, Mateus C, et al. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. *JAMA Dermatol* 2016;152:45-51. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26501224>.

110. Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. *Clin Cancer Res* 2016;22:886-894. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26446948>.
111. Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. *J Immunother Cancer* 2018;6:37. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29747688>.
112. Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. *Ann Rheum Dis* 2018;77:393-398. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29146737>.
113. Feng S, Coward J, McCaffrey E, et al. Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors. *J Thorac Oncol* 2017;12:1626-1635. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28843363>.
114. Horvat TZ, Adel NG, Dang TO, et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. *J Clin Oncol* 2015;33:3193-3198. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26282644>.
115. Reimold AM. TNFalpha as therapeutic target: new drugs, more applications. *Curr Drug Targets Inflamm Allergy* 2002;1:377-392. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/14561184>.
116. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. *Curr Dir Autoimmun* 2010;11:180-210. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20173395>.
117. Wolfe RM, Ang DC. Biologic Therapies for Autoimmune and Connective Tissue Diseases. *Immunol Allergy Clin North Am* 2017;37:283-299. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28366477>.
118. Prescribing Information: Infliximab. Available at: <http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/REMICADE-pi.pdf>. Accessed April 25, 2018.
119. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. *JAMA Oncol* 2016;2:1346-1353. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27367787>.
120. Prescribing Information: Vedolizumab. Available at: <https://general.takedapharm.com/ENTYVIOPi>. Accessed April 24, 2018.
121. Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. *Cancer Immunol Immunother* 2017;66:581-592. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28204866>.
122. Diana P, Mankongpaisarnrung C, Atkins MB, et al. Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis. *ACG Case Rep J* 2018;5:e17. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29516018>.

123. Prescribing Information: Mycophenolate mofetil. Available at: https://www.gene.com/download/pdf/cellcept_prescribing.pdf. Accessed Jun 12, 2018.
124. Prescribing Information: Mycophenolic acid Available at: <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/myfortic.pdf> Accessed Jun 12, 2018.
125. Karnell JL, Karnell FG, 3rd, Stephens GL, et al. Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation. *J Immunol* 2011;187:3603-3612. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21873529>.
126. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. *Transplantation* 2005;80:S181-190. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16251851>.
127. Henderson L, Masson P, Craig JC, et al. Treatment for lupus nephritis. *Cochrane Database Syst Rev* 2012;12:CD002922. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23235592>.
128. Nousari HC, Sragovich A, Kimyai-Asadi A, et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. *J Am Acad Dermatol* 1999;40:265-268. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10025760>.
129. Eskin-Schwartz M, David M, Mimouni D. Mycophenolate mofetil for the management of autoimmune bullous diseases. *Dermatol Clin* 2011;29:555-559. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21924997>.
130. Ueda T, Sakagami T, Kikuchi T, Takada T. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis. *Respir Investig* 2018;56:14-20. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29325675>.
131. Mieli-Vergani G, Vergani D, Czaja AJ, et al. Autoimmune hepatitis. *Nat Rev Dis Primers* 2018;4:18017. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29644994>.
132. Aggarwal R, Oddis CV. Therapeutic advances in myositis. *Curr Opin Rheumatol* 2012;24:635-641. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22955021>.
133. Daanen RA, Maas RJH, Koornstra RHT, et al. Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report. *J Immunother* 2017;40:345-348. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28961608>.
134. Pushkarevskaya A, Neuberger U, Dimitrakopoulou-Strauss A, et al. Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases. *J Immunother* 2017;40:282-285. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28604554>.
135. Cheng R, Cooper A, Kench J, et al. Ipilimumab-induced toxicities and the gastroenterologist. *J Gastroenterol Hepatol* 2015;30:657-666. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25641691>.
136. Tanaka R, Fujisawa Y, Sae I, et al. Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab. *Jpn J Clin Oncol* 2017;47:175-178. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28173241>.

137. Gurcan HM, Ahmed AR. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. *Ann Pharmacother* 2007;41:812-823. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17440006>.
138. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? *Nat Rev Immunol* 2013;13:176-189. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23411799>.
139. Siberil S, Elluru S, Graff-Dubois S, et al. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. *Ann N Y Acad Sci* 2007;1110:497-506. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17911465>.
140. Bayry J, Misra N, Latry V, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. *Transfus Clin Biol* 2003;10:165-169. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12798851>.
141. Lunemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology--mode of action and clinical efficacy. *Nat Rev Neurol* 2015;11:80-89. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25561275>.
142. Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. *Clin Exp Immunol* 2005;142:1-11. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16178850>.
143. Schwartz J, Padmanabhan A, Aqai N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. *J Clin Apher* 2016;31:149-162. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27322218>.
144. Touat M, Talmasov D, Ricard D, Psimaras D. Neurological toxicities associated with immune-checkpoint inhibitors. *Curr Opin Neurol* 2017;30:659-668. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28938341>.
145. Fellner A, Makranz C, Lotem M, et al. Neurologic complications of immune checkpoint inhibitors. *J Neurooncol* 2018;137:601-609. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29332184>.
146. Larkin J, Chmielowski B, Lao CD, et al. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. *Oncologist* 2017;22:709-718. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28495807>.
147. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. *Arthritis Rheum* 2006;55:420-426. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16739208>.
148. Williams KJ, Grauer DW, Henry DW, Rockey ML. Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors. *J Oncol Pharm Pract* 2017;1078155217744872. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29224458>.
149. Riminton DS, Hartung HP, Reddel SW. Managing the risks of immunosuppression. *Curr Opin Neurol* 2011;24:217-223. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21519254>.
150. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. *Endocr Pract* 2009;15:469-474. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19454391>.

151. Kwon S, Hermayer KL, Hermayer K. Glucocorticoid-induced hyperglycemia. *Am J Med Sci* 2013;345:274-277. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23531958>.
152. Youssef J, Novosad SA, Winthrop KL. Infection Risk and Safety of Corticosteroid Use. *Rheum Dis Clin North Am* 2016;42:157-176, ix-x. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26611557>.
153. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N Engl J Med* 2001;345:1098-1104. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11596589>.
154. Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. *World J Gastroenterol* 2015;21:10274-10289. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26420955>.
155. Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. *World J Gastroenterol* 2011;17:1531-1537. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21472116>.
156. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. *Clin Rheumatol* 2010;29:1021-1029. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20556450>.
157. Weber JS, Hodi FS, Wolchok JD, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. *J Clin Oncol* 2017;35:785-792. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28068177>.
158. Weber JS, Larkin JMG, Schadendorf D, et al. Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL) [abstract]. *Journal of Clinical Oncology* 2017;35:9523-9523. Available at: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9523.
159. Arbour KC, Mezquita L, Long N, et al. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. *J Clin Oncol* 2018;36:2872-2878. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30125216>.
160. Gutzmer R, Koop A, Meier F, et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. *Eur J Cancer* 2017;75:24-32. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28214654>.
161. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. *Ann Oncol* 2017;28:368-376. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27687304>.
162. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. *JAMA Oncol* 2016;2:234-240. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26633184>.
163. Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review. *Ann Intern Med* 2018;168:121-130. Available at:

164. Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. *Ann Oncol* 2018;29:250-255. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29045547>.
165. Kittai AS, Oldham H, Cetnar J, Taylor M. Immune Checkpoint Inhibitors in Organ Transplant Patients. *J Immunother* 2017;40:277-281. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28719552>.
166. Maggiore U, Pascual J. The Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients. *Adv Chronic Kidney Dis* 2016;23:312-316. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27742386>.
167. Morales RE, Shoushtari AN, Walsh MM, et al. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. *J Immunother Cancer* 2015;3:22. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26082835>.
168. Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. *J Clin Oncol* 2014;32:e69-71. Available at:
169. Chae YK, Galvez C, Anker JF, et al. Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients. *Cancer Treat Rev* 2018;63:116-121. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29276997>.
170. Krauss AC, Mulkey F, Shen Y-L, et al. FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response [Anstract]. *Journal of Clinical Oncology* 2018;36:8008-8008. Available at: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.8008.
171. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. *Semin Oncol* 2010;37:499-507. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21074065>.
172. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. *Cancer Treat Rev* 2016;44:51-60. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26874776>.
173. Kelly K, Infante JR, Taylor MH, et al. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. *Cancer* 2018;124:2010-2017. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29469949>.
174. Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. *J Am Acad Dermatol* 2014;71:161-169. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24767731>.
175. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. *J Clin Oncol* 2012;30:2691-2697. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22614989>.
176. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. *Ann Oncol* 2015;26:2375-2391. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26371282>.

177. Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. *Am J Clin Dermatol* 2018;19:345-361. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29256113>.
178. Naidoo J, Schindler K, Querfeld C, et al. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. *Cancer Immunol Res* 2016;4:383-389. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26928461>.
179. Rivera N, Boada A, Bielsa MI, et al. Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer. *JAMA Dermatol* 2017;153:1162-1165. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28700789>.
180. Zarbo A, Belum VR, Sibaud V, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. *Br J Dermatol* 2017;176:1649-1652. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27943234>.
181. Jaber SH, Cowen EW, Haworth LR, et al. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. *Arch Dermatol* 2006;142:166-172. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16490844>.
182. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. *PLoS One* 2013;8:e53745. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23341990>.
183. Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. *Cancer* 2013;119:1675-1682. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23400564>.
184. Wang Y, Abu-Sbeih H, Mao E, et al. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. *Inflamm Bowel Dis* 2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29718308>.
185. Gupta A, De Felice KM, Loftus EV, Jr., Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. *Aliment Pharmacol Ther* 2015;42:406-417. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26079306>.
186. Pernot S, Ramtohl T, Taieb J. Checkpoint inhibitors and gastrointestinal immune-related adverse events. *Curr Opin Oncol* 2016;28:264-268. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27138569>.
187. Tandon P, Bourassa-Blanchette S, Bishay K, et al. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis. *J Immunother* 2018;41:101-108. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29401166>.
188. Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. *Oncoimmunology* 2017;6:e1344805. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29123955>.

189. Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. *ESMO Open* 2018;3:e000278. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29387476>.
190. Jain A, Lipson EJ, Sharfman WH, et al. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. *World J Gastroenterol* 2017;23:2023-2028. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28373768>.
191. Pages C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. *Melanoma Res* 2013;23:227-230. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23458760>.
192. Merrill SP, Reynolds P, Kalra A, et al. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. *Ann Pharmacother* 2014;48:806-810. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24651165>.
193. Hsieh AH, Ferman M, Brown MP, Andrews JM. Vedolizumab: a novel treatment for ipilimumab-induced colitis. *BMJ Case Rep* 2016;2016. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27539137>.
194. Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. *Liver Int* 2018;38:976-987. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29603856>.
195. Sznol M, Ferrucci PF, Hogg D, et al. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. *J Clin Oncol* 2017;35:3815-3822. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28915085>.
196. De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. *J Hepatol* 2018;68:1181-1190. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29427729>.
197. Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management. *Am J Clin Oncol* 2017. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28749795>.
198. Ziemer M, Koukoulioti E, Beyer S, et al. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. *J Hepatol* 2017;66:657-659. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27908801>.
199. Cramer P, Bresalier RS. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. *Curr Gastroenterol Rep* 2017;19:3. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28124291>.
200. Alessandrino F, Tirumani SH, Krajewski KM, et al. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. *Clin Radiol* 2017;72:521-533. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28476244>.
201. Chmiel KD, Suan D, Liddle C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. *J Clin Oncol* 2011;29:e237-240. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21220617>.

202. Tripathi A, Kaymakcalan MD, LeBoeuf NR, Harshman LC. Programmed cell death-1 pathway inhibitors in genitourinary malignancies: specific side-effects and their management. *Curr Opin Urol* 2016;26:548-555. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27517638>.
203. Spankuch I, Gassenmaier M, Tampouri I, et al. Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins. *Eur J Cancer* 2017;81:203-205. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28641200>.
204. Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management. *American Society of Clinical Oncology Educational Book* 2018:13-19. Available at: http://ascopubs.org/doi/abs/10.1200/EDBK_100013.
205. Postow MA. Managing immune checkpoint-blocking antibody side effects. *Am Soc Clin Oncol Educ Book* 2015:76-83. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25993145>.
206. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. *Eur J Cancer* 2016;60:190-209. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27085692>.
207. Widmann G, Nguyen VA, Plaickner J, Jaschke W. Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy. *Curr Radiol Rep* 2016;5:59. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28959504>.
208. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. *Nat Rev Endocrinol* 2017;13:195-207. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28106152>.
209. Sznol M, Postow MA, Davies MJ, et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. *Cancer Treat Rev* 2017;58:70-76. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28689073>.
210. Alessandrino F, Shah HJ, Ramaiya NH. Multimodality imaging of endocrine immune related adverse events: a primer for radiologists. *Clin Imaging* 2018;50:96-103. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29348053>.
211. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. *JAMA Oncol* 2018;4:173-182. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28973656>.
212. Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. *Diabetes* 2018;67:1471-1480. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29937434>.
213. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. *J Clin Endocrinol Metab* 2014;99:4078-4085. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25078147>.
214. Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. *Endocr Relat Cancer* 2014;21:371-381. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24610577>.

215. Torino F, Corsello SM, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. *Curr Opin Oncol* 2016;28:278-287. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27136136>.
216. Min L, Hodi FS, Giobbie-Hurder A, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. *Clin Cancer Res* 2015;21:749-755. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25538262>.
217. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. *J Clin Oncol* 2017;35:709-717. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27646942>.
218. Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. *JAMA Oncol* 2016;2:1607-1616. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27540850>.
219. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711-723. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20525992>.
220. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. *Lancet Oncol* 2010;11:155-164. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20004617>.
221. Chuzi S, Tavora F, Cruz M, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. *Cancer Manag Res* 2017;9:207-213. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28652812>.
222. Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. *Kidney Int* 2016;90:638-647. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27282937>.
223. Wanchoo R, Karam S, Uppal NN, et al. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. *Am J Nephrol* 2017;45:160-169. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28076863>.
224. Jhaveri KD, Perazella MA. Adverse Events Associated with Immune Checkpoint Blockade. *N Engl J Med* 2018;378:1163. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29565518>.
225. Jhaveri KD, Wanchoo R, Sakhiya V, et al. Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. *Kidney Int Rep* 2017;2:108-123. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29318210>.
226. Belliere J, Meyer N, Mazieres J, et al. Acute interstitial nephritis related to immune checkpoint inhibitors. *Br J Cancer* 2016;115:1457-1461. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27832664>.
227. Shirali AC, Perazella MA, Gettinger S. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. *Am J Kidney Dis* 2016;68:287-291. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27113507>.

228. Murakami N, Borges TJ, Yamashita M, Riella LV. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. *Clin Kidney J* 2016;9:411-417. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27274826>.

229. Clarkson MR, Giblin L, O'Connell FP, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. *Nephrol Dial Transplant* 2004;19:2778-2783. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15340098>.

230. Gonzalez E, Gutierrez E, Galeano C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. *Kidney Int* 2008;73:940-946. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18185501>.

231. Haanen J, Carbone F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2017;28:iv119-iv142. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28881921>.

232. Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. *Curr Opin Oncol* 2016;28:288-294. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27136135>.

233. Dalvin LA, Shields CL, Orloff M, et al. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. *Retina* 2018;38:1063-1078. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29689030>.

234. Abdel-Rahman O, Oweira H, Petrusch U, et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. *Expert Rev Anticancer Ther* 2017;17:387-394. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28277102>.

235. Conrady CD, Laroche M, Pecun P, et al. Checkpoint inhibitor-induced uveitis: a case series. *Graefes Arch Clin Exp Ophthalmol* 2018;256:187-191. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29080102>.

236. Sosa A, Lopez Cadena E, Simon Olive C, et al. Clinical assessment of immune-related adverse events. *Ther Adv Med Oncol* 2018;10:1758835918764628. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29623110>.

237. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. *Eur J Cancer* 2016;60:210-225. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27084345>.

238. Kao JC, Liao B, Markovic SN, et al. Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies. *JAMA Neurol* 2017;74:1216-1222. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28873125>.

239. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med* 2015;373:23-34. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26027431>.

240. Williams TJ, Benavides DR, Patrice KA, et al. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. *JAMA Neurol* 2016;73:928-933. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27271951>.

241. Mancone S, Lycan T, Ahmed T, et al. Severe neurologic complications of immune checkpoint inhibitors: a single-center review. *J Neurol* 2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29761297>.

242. Makarios D, Horwood K, Coward JIG. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors. *Eur J Cancer* 2017;82:128-136. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28666240>.
243. Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. *Eur J Cancer* 2017;73:1-8. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28064139>.
244. Appelbaum J, Wells D, Hiatt JB, et al. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. *J Immunother Cancer* 2018;6:82. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30170630>.
245. Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. *J Immunother Cancer* 2016;4:50. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27532025>.
246. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. *J Am Coll Cardiol* 2018;71:1755-1764. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29567210>.
247. Varricchi G, Marone G, Mercurio V, et al. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. *Curr Med Chem* 2018;25:1327-1339. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28403786>.
248. Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. *Lancet* 2018;391:933. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29536852>.
249. Norwood TG, Westbrook BC, Johnson DB, et al. Smoldering myocarditis following immune checkpoint blockade. *J Immunother Cancer* 2017;5:91. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29157297>.
250. Tajmir-Riahi A, Bergmann T, Schmid M, et al. Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy. *J Immunother* 2018;41:35-38. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29077601>.
251. Cappelli LC, Gutierrez AK, Bingham CO, 3rd, Shah AA. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. *Arthritis Care Res (Hoboken)* 2017;69:1751-1763. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27998041>.
252. Naidoo J, Cappelli LC, Forde PM, et al. Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. *Oncologist* 2017;22:627-630. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28576858>.
253. Lidar M, Giat E, Garelick D, et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. *Autoimmun Rev* 2018;17:284-289. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29341936>.
254. Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. *Ann Rheum Dis* 2017;76:43-50. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27307501>.



255. Cappelli LC, Brahmer JR, Forde PM, et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. *Semin Arthritis Rheum* 2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29573850>.

256. Belkhir R, Burel SL, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. *Ann Rheum Dis* 2017;76:1747-1750. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28600350>.